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III. Lay Summary 
 
The mammalian immune system contains various types of white blood cells 
that protect the body from invading microbes. A key cell type required for 
effective immune responses is the T cell. T cells can be further classified into 
‘helper’ T cells and ‘cytotoxic’ T cells. While helper T cells coordinate the 
immune response by secreting immunomodulatory molecules, cytotoxic T 
cells have the capacity to kill virus-infected or cancerous cells. Strict regulation 
of T cell responses is crucial to protect the body from infectious diseases and 
cancer, while simultaneously avoiding autoimmunity and allergy, which are 
caused by inappropriate immune cell activation. In order to understand how T 
cells function, we must study the molecular mechanisms that regulate T cell 
activation and differentiation into effector cells. 
 
In this study we focused on the role of cytotoxic T cells. Cytotoxic T cells are 
activated by binding small fragments of microbes called ‘antigens’ that are 
present on the surface of infected cells. Binding of the T cell receptor (TCR) to 
its specific antigen in appropriate conditions activates the cell through 
intracellular signalling pathways. Small signalling molecules in the cell 
propagate in signalling cascades that result in altered gene expression. Two 
key steps are required for gene expression. First, DNA is transcribed into 
messenger RNA (mRNA) which is a template from which proteins can be 
made. The second step is the translation of mRNA into protein by cellular 
machines called ribosomes. Gene expression can be regulated either at the 
level of gene transcription, or at the level of mRNA translation. A type of RNA 
called microRNA can regulate mRNA translation. microRNAs can bind their 
target mRNAs and promote their destruction, thus stopping their translation 
into proteins. Hundreds of different microRNAs exist, each specifically 
targeting a set of mRNAs. 
 
We aimed to study the role of microRNAs in cytotoxic T cell activation. We first 
identified the most abundant microRNAs from non-activated and activated T 
cells and found that these were largely different. To further understand 
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microRNA function in activated T cells, we measured changes in the 
abundance of microRNA-associated proteins. microRNAs bind their target 
mRNAs in a protein complex called the RNA-induced silencing complex 
(RISC). T cell activation has been shown to cause changes in the protein 
composition of RISC. Specifically, T cell activation induces the formation of a 
large protein complex called high molecular weight (HMW) RISC which is not 
found in non-activated cells. microRNAs in this complex have been suggested 
to be particularly potent at inhibiting their target mRNAs. We isolated RNAs 
that were bound to the HMW RISC and from this identified a microRNA named 
miR-7, the role of which we further studied in cytotoxic T cells. Blocking the 
function of this microRNA in T cells caused changes in cell activation and 
expansion, suggesting it may be important for regulating T cell responses. To 
understand microRNA function, we must know which mRNAs they bind to. In 
order to find microRNA targets, we used a biochemical method called CLASH 
(cross-linking, ligation and sequencing of hybrids). This method can be used 
to determine which mRNAs a particular microRNA binds to and targets for 
degradation. From the CLASH datasets obtained from cytotoxic T cells, we 
identified some potential novel mRNA targets for several different microRNAs. 
 
microRNAs are known to play an important role in immune cell function and 
regulate many aspects of T cell immunity. Furthermore, dysregulation of 
microRNAs can be seen in many human diseases, including autoimmune 
diseases and cancer. Therefore, potential novel therapeutic strategies could 
be based on promoting or inhibiting specific microRNAs. Expanding our 
knowledge on how microRNAs function in T cells will be crucial to developing 




IV. Scientific abstract 
 
microRNAs (miRNAs) are short (~22 nucleotide long) single-stranded non-
coding RNAs that regulate gene expression post-transcriptionally in the RNA-
induced silencing complex (RISC). miRNAs play an important role in immune 
cell function and affect many aspects of T cell immunity. Activation of naive T 
cells induces dramatic changes in the expression of miRNAs and RISC-
associated proteins. We studied these changes in expression of miRNAs in 
CD8+ T cells using the OT-I transgenic T-cell receptor (TCR) mouse model, in 
which all T cells are CD8+ and respond to ovalbumin peptides. Upon in 
vitro activation, we saw dynamic changes in the expression of individual 
miRNAs, which were influenced by whether the T cells responded to high or 
low affinity peptides and whether they were differentiating to effector or 
memory cells.  
 
It was recently shown that in naive T cells, miRNAs are predominantly found 
in a low molecular weight (LMW) RISC composed of Argonaute (Ago)-proteins 
and miRNAs. Upon activation of T cells, biologically active miRNAs interacting 
with their target messenger RNAs (mRNAs) were shown to redistribute to a 
high molecular weight (HMW) RISC, which additionally contains RNA 
metabolism factors and Ago-interacting proteins such as GW182. We followed 
the development of HMW and LMW complexes in activated CD8+ T cells in 
order to determine their role and to identify the miRNAs and their targets 
present in both.  
 
We confirmed that GW182 protein was induced upon CD8+ T cell activation 
and associated with Ago-2, forming HMW complexes. To study the distribution 
of miRNAs between HMW and LMW RISC, we undertook small RNA 
sequencing of the associated miRNAs. From these data we identified specific 
miRNAs that were enriched in HMW RISC in activated CD8+ T cells. We also 
found that miRNA abundance did not always reflect its association with HMW 
RISC. Lastly, to discover miRNA targets, we used a novel method called cross-
linking, ligation and sequencing of hybrids (CLASH), which directly identifies 
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miRNAs and their targets by immunoprecipitation of RISC and RNA 
sequencing. From these data we found potential novel targets for key miRNAs 
in CD8+ T cells. 
 
Expanding our knowledge of the role of miRNAs in T cell activation beyond 
observations of miRNA expression changes, by focusing on biologically active 
miRNAs and their targets in HMW RISC will deepen our understanding of the 
mechanism of action of miRNAs as well as the signalling pathways 
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CHAPTER 1: Introduction 
 
1.1 Function of T cells in the immune system 
 
1.1.1 The immune response 
 
Immune responses in vertebrates are orchestrated by the innate and adaptive 
immune systems. The innate immune system forms a first line of defence 
consisting of physical immune barriers and secretions, inflammatory signals 
and innate immune cells. The innate response is immediate and provides rapid 
protection against infection. Innate immune cells include cells derived from the 
common myeloid progenitor, such as granulocytes, mast cells, macrophages 
and dendritic cells, and Natural Killer (NK) cells that are derived from the 
common lymphoid progenitor (Turvey and Broide, 2010, Janeway 2012). 
These cells have important roles in killing invading pathogens and alerting the 
body to the presence of invaders through secretion of inflammatory signals. 
Granulocytes, which include neutrophils, eosinophils and basophils, contain 
granules of cytotoxic molecules and enzymes, the contents of which can be 
released upon activation.  Phagocytic cells, such as macrophages and 
neutrophils, can engulf and destroy pathogens. Dendritic cells are phagocytic 
as well: uptake of pathogens results in maturation into antigen-presenting cells 
(APCs) that can activate cells of the adaptive immune system. NK cells can 
recognise abnormal cells, such as virus-infected or tumorous cells and kill 
these with lytic granules.  
 
The adaptive immune response takes longer to develop but is adapted to 
combat specific infections. The adaptive immune system is composed of T and 
B lymphocytes which have specific antigen-recognition receptors on their 
surface. The B cell receptor (BCR) and T cell receptor (TCR) are similar in 
their basic structure and consist of constant regions and variable regions at 
the antigen-binding site. The BCR recognises antigen directly whereas the 
TCR recognises antigen fragments that are presented on Major 
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Histocompatibility Complex (MHC) molecules on the surface of other cells 
(Rudolph, Stanfield and Wilson, 2006). MHC Class I molecules, that are 
expressed on all nucleated cells in the body, display peptides from all proteins 
produced in the cell. MHC Class II molecules are only expressed on 
specialised APCs which include dendritic cells, B cells and macrophages. T 
cells can be divided into CD4+ ‘helper’ T (Th) cells and CD8+ ‘cytotoxic’ T cells. 
CD4+ T cells recognise antigen presented on MHC Class II molecules, 
whereas CD8+ T cells require MHC Class I.  
 
The adaptive immune response first begins with uptake of antigen by dendritic 
cells that travel to secondary lymphoid organs and present antigen to CD4+ T 
cells. T cells require three signals for activation (Curtsinger et al., 1999). Firstly, 
they must recognise their cognate antigen through their TCR, which binds 
peptides that are presented on MHC proteins. Secondly, T cell activation is 
regulated through co-stimulatory receptors such as CD27, CD28, 4-1BB, 
CD40 and OX40 (Jenkins and Johnson, 1993; Kaech and Cui, 2012). 
Activated dendritic cells are able to provide co-stimulatory signals to T cells. 
Finally, T cells require cytokines and inflammatory signals to fully differentiate 
into functional effector cells (Curtsinger et al., 1999). Pro-inflammatory 
cytokines cause upregulation of cytokine and co-stimulatory receptors on T 
cells. The combined duration and strength of these signals will predict the fate 
of the cell. TCR stimulation alone is insufficient to promote cell activation and 
proliferation, and co-stimulation and cytokine signals are required for a full 
response.  Presentation of antigen in the absence of co-stimulation can lead 
to cell tolerance instead of activation (Schwartz, 2003). 
 
1.1.2 Adaptive immune cell subsets 
 
Following activation by an activated dendritic cell, a naive CD4+ T cell will 
differentiate into an effector Th cell. Th cells coordinate the adaptive immune 
response by interacting with multiple immune cell types, influencing their 
subsequent activation and differentiation. Naive CD8+ T cells require additional 
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co-stimulation from APCs, which can be provided by CD4+ T cells interacting 
with the same APC (Wodarz and Jansen, 2001). B cell activation relies on 
direct co-stimulation from an activated CD4+ T cell, to which the B cell presents 
antigen (Parker DC, 1993). ‘Signature’ cytokine profiles and master 
transcription factors characterise subtypes of Th cells, which include Th1, Th2, 
Th17, Th9, Th22, follicular helper Tfh and regulatory Treg cells (Raphael et al., 
2015). Each of these subtypes is specialised in combatting different types of 
infection by secreting cytokines and recruiting and activating appropriate 
immune cells, whereas Tregs have an important role in preventing immune 
pathology.  It has recently become apparent that this classification is an 
oversimplification, and the transcriptional landscape of Th cells is more 
complex and plasticity is common between the subtypes (Wang, Collins and 
Kuchroo, 2015; Hirahara and Nakayama, 2016). Tfh cells are of crucial 
importance in providing help to B cells, which following activation differentiate 
into antibody-secreting plasma cells. Some activated B cells migrate together 
with Tfh cells into lymphoid follicles where they form germinal centres in which 
they undergo affinity maturation and antibody class-switching before 
differentiating into plasma cells (Victora and Nussenzweig, 2012). 
 
CD8+ T cells have the capacity to differentiate into cytotoxic T lymphocytes 
(CTLs) upon activation. CTLs secrete cytokines such as Interferon gamma 
(IFNγ) and Tumour necrosis factor alpha (TNFα) and produce cytotoxic 
effector molecules such as perforin and granzymes that can lyse target cell 
membranes causing cell death (Kaech and Cui, 2012). CTLs recognise 
antigen presented on MHC Class I on the surface of abnormal cells, such as 




1.2 T cell activation 
  
1.2.1 Initiation of TCR signalling 
 
T cells are activated by binding peptide:MHC complexes (pMHC) with their 
TCRs (Davis et al., 2002). Several non-exclusive models exist to explain how 
TCR signalling is initiated (Courtney, Lo and Weiss, 2018). Mechanosensory 
models suggest that a conformational change in the TCR initiates signalling, 
by facilitating the phosphorylation of TCR-associated immunoreceptor 
tyrosine-base activation motifs (ITAMs) (Basu and Huse, 2015). The structural 
understanding of such conformational change is however unclear. The kinetic 
segregation model suggests that the spatial reorganisation of signalling 
molecules on the cell surface leads to the segregation of the TCR signalosome 
from negative regulators, allowing signalling to take place (Davis and van der 
Merwe, 2006). According to the serial engagement model, multiple TCRs are 
required to be sequentially engaged to accumulate sufficient signalling 
(Valitutti et al., 1995; Valitutti and Lanzavecchia, 1997).  
 
1.2.2 TCR signal propagation 
 
The TCR signalosome is composed of numerous molecules that can have 
positive or negative effects on TCR signal propagation, with a complex network 
of intersecting signalling pathways (Acuto, Bartolo and Michel, 2008; Brownlie 
and Zamoyska, 2013). The TCR is associated with its co-receptors CD3, and 
CD4 or CD8, which aid with binding pMHC and signal propagation (Davis et 
al., 2002). The CD3 co-receptor is composed of CD3γ, CD3δ and two CD3ε 
chains and forms a complex with the TCRαβ chains and the intracellular TRC-
associated ζ chains. However, the TCR-CD3 complex does not have intrinsic 
enzymatic activity and instead relies on the SRC-family kinases Lck and Fyn 
to initiate the TCR signalling cascade (Salmond et al., 2009). Lck is found 
associated with the CD4 and CD8 co-receptors, and when activated can 
phosphorylate ITAMs in CD3 chains and the associated ζ chains (Veillette et 
al., 1988; Shaw et al., 1990). Lck activity is controlled by the differential 
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phosphorylation of inhibitory and activating tyrosine residues (Couture et al., 
1996). The stand-by model suggests that Lck is found in a constitutively active 
form, and signalling is initiated not by changes in Lck enzymatic activity, but 
rather its distribution in the cell or availability of its target ITAMs (Nika et al., 
2010). Recent data however suggest that de novo phosphorylation of Lck may 
also be required (Philipsen et al., 2017).  
 
Phosphorylated CD3 chain ITAMs become docking sites to other signalling 
molecules such as the Zeta-chain associated protein kinase (ZAP)-70 which 
is also phosphorylated by Lck (Pelosi et al., 1999). ZAP-70 subsequently 
phosphorylates Linker for activation of T cells (LAT), an important scaffold 
protein that recruits key enzymes and adapter proteins leading to downstream 
signal diversification and amplification. The LAT signalling complex is essential 
to T-cell signal propagation and contains various signalling molecules that 
influence one another and cooperate through multiple protein interactions 
(Balagopalan, Coussens and Sherman, 2010; Samelson et al., 2015). The 
activation of phospholipase C-gamma (PLCγ1) requires interaction with LAT 
and phosphorylation by Itk. PLCγ1 catalyses the formation of IP3 (inositol 
1,4,5-trisphosphate) and DAG (diacylglycerol) from PIP2 (phosphatidylinositol 
4,5-bisphosphate). DAG activates the Ras signalling pathway and PKC 
(Protein kinase C), whereas IP3 production leads to release of intracellular 
Ca2+ stores. These signalling pathways eventually lead to activation of key 
transcription factors such as NFAT, NF-κB and AP-1 (Balagopalan, Coussens 
and Sherman, 2010).  
 
The GRB2 (Growth factor receptor bound protein 2) family members GRB2, 
GADS and GRAP also bind LAT. GRB2 plays a role in the activation of the 
Ras pathway through recruitment of SOS1. GADS links SLP-76 to the 
complex, which in turn recruits multiple effector proteins, including VAV, NCK, 
ITK, ADAP, and Phosphoinositide 3 kinase (PI3K) (Balagopalan, Coussens 
and Sherman, 2010). VAV activates Rho-family G-proteins and cooperates 
with NCK and WASp to induce cytoskeletal changes in activated cells. ITK 
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plays a crucial role in the phosphorylation and activation of PLCγ1. ADAP 
regulates cell adhesion and integrin function in activated T cells. PI3K 
catalyses the formation of PIP3 from PIP2 which contributes to activation of the 
mechanistic target of rapamycin (mTOR). Therefore, the effects of LAT 
associated signalling molecules on the cell are wide-spread and lead to 
activation of transcription factors and changes in the cytoskeleton and cell 
adhesion (Fig.1.1).  
 
Further signalling through co-stimulatory receptors such as CD28 increases 
and supports these functions. CD28 binding to its ligands CD80 and CD86 
induces cell proliferation, survival and IL-2 production in response to low 
concentrations of antigen that would not elicit a response in its absence 
(Boomer and Green, 2010). Signalling through co-stimulatory receptors is also 
important for promoting the sustained activation of mTOR through activation 
of the PI3K-AKT pathway. mTOR is a threonine/serine kinase, that plays an 
important role in regulating cell proliferation, metabolism, and T cell fate 
decisions. mTOR can form two different protein complexes, MTORC1 and 
MTORC2, both of which are activated following TCR signalling through 
multiple pathways that integrate input signals from co-stimulatory receptors, 





Figure 1.1 TCR signalling pathway 
A simplified figure depicting the TCR signalling pathway in CD8+ T cells. 
Antigen is presented on MHC Class I to the TCR. Lck, which interacts with the 
CD8 co-receptor, phosphorylates ITAMs in CD3 chains and the associated ζ 
chains. ZAP-70 binds to the ITAMs and is also phosphorylated by Lck. ZAP-
70 can then phosphorylate LAT and SLP-76. This leads to recruitment of 
multiple effector molecules such as GRB2 family proteins, ADAP, VAV, NCK, 
PLCγ1 and ITK. ITK phosphorylates PLCγ1 which catalyses production of 
DAG and IP3 from PIP2, leading to the induction of key transcription factors 
AP-1, NF-κβ and NFAT that regulate cell proliferation and differentiation. 
ADAP initiates an integrin signalling pathway leading to changes in cell 
adhesion, and VAV and NCK induce a pathway leading to cytoskeletal 





1.3 Immune tolerance and regulation of TCR signalling 
 
It is crucial that lymphocyte activation is tightly regulated in order to avoid 
autoimmunity and other immunological disorders. The activation of 
autoreactive immune cells can lead to the development of autoimmune 
diseases such as multiple sclerosis, type I diabetes, psoriasis and systemic 
lupus erythematous (SLE). Failure of immune checkpoints can also result in 
unregulated proliferation and expansion of immune cells, leading to lymphoma 
or leukaemia (Goodnow, 2007; Brownlie and Zamoyska, 2013). In a healthy 
body, many immune checkpoints exist to prevent the maturation and activation 
of self-reactive cells. T cells require multiple signals for full activation, with 
insufficient signals such as TCR stimulation in the absence of co-stimulatory 
signals, can lead to cell death or anergy (Schwartz, 2003). Many negative 
feedback loops also control the extent of TCR signalling (Gaud, Lesourne and 
Love, 2018). Furthermore, Tregs limit the extent of immune responses in the 
periphery and can dampen the response (Dario A. A. Vignali, 2008).  
 
1.3.1 Self-reactivity and T cell development 
 
T cell autoreactivity is regulated on many levels starting with development in 
the thymus, where cells undergo positive and negative selection leading to the 
release of a select repertoire of T cells. T cell progenitors are produced in the 
bone marrow, from where they migrate to the thymus to undergo maturation. 
In the thymus, the T cells undergo recombination of their variable (V), diversity 
(D) and joining (J) gene segments to form their TCR α and β chains, which are 
expressed alongside the co-receptors CD4 and CD8 (Schatz and Ji, 2011). 
The functionality of the newly expressed αβTCR is then tested during positive 
selection for binding pMHC presented by cortical thymic epithelial cells. Cells 
that express TCRs that do not mediate positive selection (nearly 90%) are 
subject to ‘death by neglect’. Next, the cells undergo negative selection to 
eliminate cells that are strongly autoreactive. Medullary thymic epithelial cells 
express a range of otherwise tissue-restricted antigens; strong binding to these 
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leads to cell death or in the case of CD4+ T cells can lead to deviation into 
Foxp3+ Tregs. (Miosge and Zamoyska, 2007; Klein et al., 2014) 
 
Thymic positive selection requires weak interactions with self-antigen to 
ensure functionality of the TCR, meaning that T cells are inherently self-
reactive. Even in the periphery T cells homeostasis relies on weak interactions 
with self-pMHC alongside cytokine signals (Tanchot, Lemonnier and 
Perarnau, 1997; Seddon and Zamoyska, 2003). Therefore, the TCR must be 
able to differentiate between self-pMHC complexes and foreign peptide, to 
prevent autoimmunity. The kinetic proofreading model postulates that for 
signalling to occur, a significant threshold must be crossed in a chain of events 
before TCR-pMHC dissociation. Several intermediate rate-limiting steps are 
required between ligand recognition and signal transmission, such as 
recruitment of active Lck to the TCR by the CD4 and CD8 co-receptors, and 
phosphorylation the TCR complex and ZAP-70. This allows discrimination 
between high and low affinity agonists. (Mckeithan, 1995; Stepanek et al., 
2014). TCR signalling also appears to be subject to stage-specific tuning, 
allowing the signalling threshold to be adjusted for positive selection to take 
place during T cell development, but to allow mature naive T cells to weakly 
bind self-pMHC for homeostatic proliferation and maintenance (Surh and 
Sprent, 2008; Cho and Sprent, 2018). Pre-selection thymocytes have been 
shown to be more responsive to low affinity agonists than mature cells (Davey 
et al., 1998). Positive selection leads to the selection of responsive, proficient 
cells that also respond well to foreign peptide (Mandl et al., 2013). The 
expression of the transmembrane receptor CD5, the level of which is 
determined during thymic development, correlates with high affinity to self-
pMHC, but is also linked to high responsiveness to foreign peptide (Azzam et 




1.3.2 Regulation of TCR signalling 
 
TCR signalling is regulated through a vast range of control mechanisms and 
feedback loops (Gaud, Lesourne and Love, 2018).  Protein tyrosine 
phosphorylation is a key property of TCR signalling and cell activation, thus 
interfering with it is an important regulatory mechanism. Negative regulators of 
TCR signalling include inhibitory protein tyrosine kinases such as Csk, and 
protein tyrosine phosphatases, which include cytoplasmic phosphatases such 
as SHP-1 and PTPN22, and receptor-like phosphatases like CD45 (Veillette, 
Latour and Davidson, 2002; Hermiston, Xu and Weiss, 2003; Pao et al., 2007). 
Lipid phosphatases including SHIP1, SHIP2 and PTEN are also important. 
Following TCR signalling, negative feedback mechanisms are rapidly 
activated to control extent of signalling. Phosphatases are recruited to the TCR 
to regulate signalling by dephosphorylating key signalling molecules. For 
example, PTPN22 has been shown to limit signalling through the TCR in 
response to weak agonists, without compromising responses to strong 
agonists (Salmond et al., 2014). The scaffold molecule LAT not only promotes 
TCR signal propagation, but also controls the formation of a negative signalling 
complex (Dong et al., 2006). Sustained signalling through the TCR also leads 
to the upregulation of co-inhibitory receptors such as CTLA4 and PD-1. These 
inhibitory receptors function by sequestering ligands that bind co-stimulatory 
receptors, and by recruiting phosphatases or other molecules that negatively 
regulate TCR signalling (Thaventhiran, 2013). For example, CTLA-4 competes 
with CD28 for co-stimulatory signals and can also bind the tyrosine 
phosphatase SHP-1. 
 
1.4 Effector and memory T cell differentiation 
 
1.4.1 T cell fate decisions 
 
An important quality of all lymphocytes is the capability to persist to form a 
long-lasting memory cell population that protects from subsequent infection. 
While some T cells differentiate into short-lived effector cells, others become 
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memory cells. These have traditionally been differentiated by markers such as 
KLRG1 that is characteristic of short-lived effector cells, and IL-7R that is 
expressed by memory cells (Kaech et al., 2003). It is commonly accepted that 
every cell has the potential to either become an effector or a memory cell, and 
this is determined by a number of signals received by the cells during or after 
activation (Stemberger et al., 2007). The point at which cell fate is decided is 
controversial. It has been suggested that asymmetric cell division leads to a 
‘pre-effector’ and a ‘pre-memory’ daughter cell after the first cell division 
following activation (Chang et al., 2007). The opposing line of thought suggests 
that the divide occurs later, with an initial homogeneous pool of cells and 
gradual acquisition of short-lived effector or memory cell functions. In either 
case differentiation into effector and memory cells is likely to be influenced by 
the strength and duration of the initial TCR signal and co-stimulatory signals, 
as well as the microenvironment during activation and migration into tissues, 
such as exposure to cytokines, chemokines, nutrients and oxygen (Kaech and 
Cui, 2012). 
 
1.4.2 Memory cell subsets 
 
T cell memory was previously thought to be divided into ‘central memory’ 
(Tcm) and ‘effector memory’ (Tem), differentiated by the expression of homing 
receptors to secondary lymphoid organs by the former, or the absence from 
lymphoid organs and the capacity to rapidly produce effector molecules by the 
latter (Sallusto, Geginat and Lanzavecchia, 2004). It is however becoming 
increasingly clear that memory cells exist as more of a continuum and cannot 
be neatly divided into subgroups (Jameson and Masopust, 2018). Both Tcm 
and Tem are migratory cells, whereas another more recently discovered group 
of cells is non-migratory and resides in nonlymphoid tissues, named ‘resident 
memory’ (Trm) (Masopust et al., 2001). These cells were initially thought to be 
part of the Tem population, due to shared characteristics like low expression 
of lymph node homing receptors CCR7 and CD62L and rapid execution of 
effector functions, but are now known to be a distinct population crucial for 
12 
 
protective immunity at barrier sites (Schenkel and Masopust, 2014). The 
circulating Tem pool is heterogeneous as well,  and several populations of cells 
can be differentiated based on the expression of transcription factors and 
chemokine receptors such as CX3CR1 and CXCR3 (Gerlach et al., 2016). The 
importance and durability of these different types of memory cells is not fully 
understood. It is generally thought that CD8+ memory does not require 
continued exposure to antigen, but cells rely on cytokines such as IL-7 and IL-
15 (Surh and Sprent, 2008). This however may hold more true for some types 
of memory cells than others, and in vivo re-exposure to antigen upon 
secondary or tertiary challenge could be an important factor in memory cell 
maintenance (Jameson and Masopust, 2018).  
 
1.4.3 Molecular control of memory cell differentiation 
 
Pairs of transcription factors are thought to control CD8+ T cell differentiation. 
For example T-bet, and the related transcription factor Eomesodermin 
(Eomes) both play important roles in effector and memory cell differentiation 
(Pearce et al., 2003; Sullivan et al., 2003). The two transcription factors have 
partially redundant roles in supporting acquisition of effector cell functions, but 
their ratio may affect effector/memory cell differentiation. T-bet expression is 
induced rapidly by TCR signalling and IL-12, with Eomes expression induced 
slightly later by IL-2 with a further increase in memory cells. The exposure to 
inflammatory signals, such as IL-12, were shown to cause a gradient in T-bet 
expression, with high expressing cells becoming short-lived effector cells 
(Joshi et al., 2007). Contrarily, Eomes expression has been shown to be 
repressed by IL-12 and instead was shown to increase in memory cells, with 
Eomes-deficient cells defective in long-term survival (Takemoto et al., 2006; 
Banerjee et al., 2010). Other pairs of transcription factor which regulate CD8+ 
T cell differentiation include Id2 an Id3, and the pair Bcl-6 and Blimp1. Some 
of these transcription factors are expressed by many different types of cells 
and so the epigenetic landscape may be crucial in determining which genes 
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are rapidly accessible and transcribed after activation of specific transcription 
factors. 
  
Cell metabolism is another important determinant of effector versus memory 
cell differentiation. Activated T cells must support an increase in protein, 
nucleic acid and phospholipid synthesis, and consequently upregulate amino 
acid, glucose and transferrin receptors and switch from oxidative 
phosphorylation to anaerobic glycolysis (Finlay and Cantrell, 2011). Memory 
cells resemble naive cells in their metabolism but are more poised to faster 
acquire effector-cell like metabolic profiles upon re-activation. The two mTOR 
complexes have recently been shown to differentially regulate CD8+ T cell 
metabolism and memory formation. Several early studies showed that 
inhibiting the mTOR pathway with rapamycin enhanced memory cell 
differentiation, partly by affecting levels of T-bet and Eomes (Araki et al., 2009; 
Rao et al., 2010). More recently, mTORC1 was shown to promote glycolysis 
and efficient effector cell development from both naive and antigen-
experienced cells and inhibited memory formation, whereas mTORC2 
enhanced generation of memory (Pollizzi et al., 2015). 
 
1.5 microRNAs and the RNA-induced silencing complex 
 
1.5.1 miRNA biogenesis and function 
 
microRNAs (miRNAs) are short, 22-nucleotide non-coding RNAs that mediate 
gene silencing by binding their target messenger RNAs (mRNAs), and 
subsequently promoting their degradation and/or translational repression. 
miRNAs have been shown to be important for almost every process in the 
body, from development and cell differentiation to normal organ function and 
homeostasis. Deletion of the miRNA processing enzyme Dicer is 
embryonically lethal in mice (Bernstein et al., 2003). Immune cells are also 
subject to regulation by miRNAs, and miRNA expression is crucial to the 
normal functioning of the immune system. Deregulation of miRNAs is 
associated with many pathologies, including cancer, inflammatory disorders 
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and autoimmunity (Lin and Gregory, 2015; Garo and Murugaiyan, 2016). 
Consequently, there is potential for miRNAs to be used as biomarkers or 
therapeutic targets (Luck, Muljo and Collins, 2015; Simpson and Ansel, 2015). 
 
miRNAs are transcribed as a primary miRNA (pri-miRNA) duplex. A pri-miRNA 
can consist of a single miRNA or a cluster of miRNAs that are transcribed 
together. The pri-miRNA is processed by the enzymes Drosha and DGCR8 
into a pre-miRNA, which is exported to the cytoplasm and cleaved by Dicer 
into a mature miRNA. In the cytoplasm, one of the strands of the mature 
miRNA is discarded (passenger strand), whereas the other (guide strand) is 
loaded on Argonaute (Ago) to form the RNA induced silencing complex (RISC) 
(Fig.1.2) (O’Connell et al., 2010; Mehta and Baltimore, 2016). It is in this 
complex that miRNAs interact with their target mRNAs. This binding is 
mediated by the miRNA seed site, corresponding to nucleotides 2-7 of the 5’ 
end. miRNA target sites are complementary to the miRNA seed and are 
usually found in the 3’ untranslated region (3’UTR) of the target mRNA. A 
single miRNA can have the potential to target hundreds of genes, even though 
their effect is usually mild (Selbach et al., 2008). Similarly, one gene can be 
targeted by multiple miRNAs. miRNAs can be grouped into families that have 
identical or similar seed sites, often resulting in repression of the same group 
of target genes. Cooperation of repression can occur with binding to multiple 
adjacent target sites on a single gene (Na and Kim, 2013; Mehta and 






Figure 1.2 miRNA biogenesis pathway 
After transcription of pri-miRNAs, these are first processed by Drosha and 
DGCR8 to pre-miRNA which is exported to the cytoplasm. It is then cleaved 





1.5.2 Ago function and interactions 
 
miRNAs bind to their target mRNAs in the Ago-containing RISC. Ago proteins 
mediate miRNA target repression directly or through recruitment of other 
mRNA binding silencing proteins. Four homologues of the Ago protein exist in 
mammals: Ago 1-4, of which Ago-2 is unique in its ability to directly cleave 
target mRNAs. Ago proteins alone weight approximately 95kDa and can form 
small (250-350kDa), medium (600-700kDa) or high (>900kDa) molecular 
weight complexes by associating with gene silencing proteins (e.g. Dicer, 
GW182, TRBP), DEAD-box containing proteins (e.g. RNA helicase A), mRNA 
binding proteins (e.g. poly-A binding proteins), proteins involved in RNA 
metabolism and ribosomes (Höck et al., 2007; Landthaler et al., 2008).  
 
One of the key interactors of Ago is GW182, which has been shown to be 
required for the miRNA silencing effect (Behm-Ansmant et al., 2006; Eulalio, 
Huntzinger and Izaurralde, 2008). Through its N-terminal G (glycine) W 
(tryptophan)-repeats, GW182 binds to Ago PIWI domain, whereas through its 
C-terminus it recruits silencing effector proteins (Lazzaretti, Tournier and 
Izaurralde, 2009; Lian et al., 2009). These mRNA binding proteins include 
poly(A) binding proteins (PABPs), deadenylases and decapping proteins, 
which together mediate target gene repression (Fig.1.3). CCR4:NOT 
deadenylase and DCP1:DCP2 decapping complexes were both shown to be 
required for target mRNA degradation (Behm-Ansmant et al., 2006). GW182 
also plays a role in promoting miRNA stability (Yao et al., 2012). miRNA 
binding increases the affinity of Ago to GW182, promoting the interaction of 
the two proteins (Elkayam et al., 2017). GW182 may bind multiple Ago 
proteins, and potentially cause translational repression of miRNA target sites 






Figure 1.3 RISC and mRNA repression 
A representation of RISC and associated proteins causing target mRNA 
repression. Ago-bound miRNAs bind their target mRNAs through 
complementarity in the miRNA seed and mRNA 3’UTR. Ago is bound by 
GW182, which recruits effector molecules such as PABPs, deadenylases (e.g. 
CCR4:NOT complex) and decapping proteins (e.g. DCP1:DCP2 complex) that 
bind the mRNA and cause its translational inhibition and/or degradation. 
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1.6 miRNA function in T cells 
 
 
1.6.1 Importance of miRNAs for T cell development and function 
 
miRNAs are known to regulate most aspects of T cell biology, from T cell 
development to cell activation, differentiation and effector and memory cell 
formation. Deletion of the miRNA biogenesis enzyme Dicer in the T cell lineage 
causes severe defects in T cell development and greatly reduces mature cell 
numbers in the periphery (Muljo et al., 2005). The resulting CD4+ T cells are 
defective in their response to stimulus, characterised by poor proliferation and 
aberrant cell differentiation and cytokine production (Muljo et al., 2005). Dicer 
depletion also causes defects in Tregs, leading to immune pathology (Cobb et 
al., 2006). In CD8+ T cells,  Dicer depletion causes stronger T cell activation in 
vitro and higher expression of the cytotoxic effector molecule perforin in CTLs 
(Zhang and Bevan, 2010; Trifari et al., 2013). The cells initially proliferate 
more, but cell survival was reduced after two days. In vivo, the cells fail to 
expand and survive, partly due to failure to downregulate CD69 following 
activation to migrate from lymph nodes into tissues (Zhang and Bevan, 2010). 
Naive cells have no detectable phenotype, with comparable expression of 
markers such as CD44 and CD62L (Zhang and Bevan, 2010). Depletion of 
Ago-2 in T cells does not compromise cell development or homeostasis in the 
periphery. The proliferation of CD4+ Ago-2 deficient cells was not affected, 
however as for the Dicer deficient CD4+ T cells, cell differentiation and cytokine 
production was aberrant (Bronevetsky et al., 2013).  
 
1.6.2 Regulation of miRNA expression and function in T cells through 
transcriptional regulation and editing of miRNAs and targets 
 
Globally, miRNA expression is downregulated upon T cell activation. Naive 
and memory cells generally express higher levels of miRNAs compared to 
effector T cells (Wu et al., 2007). In CD4+ T cells, in vitro stimulation with anti-
CD3/CD28 was shown to cause downregulation of most miRNAs as early as 
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4 h after stimulation (Bronevetsky et al., 2013). miRNA expression is regulated 
transcriptionally, in a similar way to protein-coding genes. In CD4+ T cells, 
activation caused strong or moderate transcriptional induction, or 
downregulation of specific miRNAs (Bronevetsky et al., 2013).  
 
RNA editing can also affect miRNA function: modifications at the 5’ end can 
alter the miRNA seed, whereas editing of the 3’ end more commonly affects 
miRNA stability and turnover. Variants of the mature miRNA are named 
isomirs, and can differ in their sequence or length (Ameres and Zamore, 2013). 
Isomirs can arise from differential cleavage, RNA editing or non-template 
nucleotide addition (Gebert and MacRae, 2019).  Pri-miRNAs and pre-miRNAs 
can be targeted by adenosine deaminase acting on RNA (ADAR) or cytidine 
deaminase acting on RNA (CDAR) proteins, which catalyse the conversion of 
adenosine to inosine, or cytidine to uracil, respectively. These modifications 
can alter the cleavage and export of the miRNA precursors, or cause changes 
in the miRNA seed. Alternative cleavage by Dicer and Drosha can also result 
in formation of isomirs. In CD8+ T cells, alternative processing by Drosha has 
been demonstrated for miR-142 and miR-342 (Wu et al., 2009). The shift in 
Drosha processing generated three different pre-miRNAs from the single miR-
142 pri-miRNA. The three miR-142 variants differed in their seed sequence, 
and most of the predicted targets were different. Interestingly, one variant 
seemed to be dominant in thymocytes, and another in mature naive CD8+ T 
cells. Finally, mature miRNAs can be edited through non-template nucleotide 
addition, such as 3’ adenylation or 3’ uridylation. Terminal uridylyltransferase 
4 (TUT4) mediated uridylation has been shown to cause miRNA 
downregulation during CD4+ T cell activation (Gutiérrez-Vázquez et al., 2017). 
The 3’ uridylation was observed in naive cells, and following activation the 3’ 
uridylated miRNAs were degraded, alongside downregulation of the TUT4 
enzyme. 
 
miRNA function can also be regulated through their target sites. Formation of 
mRNA 3’ UTR isoforms or altering of the 3’ UTR can add or remove miRNA 
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target sites. In CD4+ T cells, activation induced shortening of the 3’ UTR of 
mRNAs was shown to decrease miRNA mediated regulation of some 
transcripts (Sandberg et al., 2008). High target concentration may result in 
weaker miRNA activity. Large availability of targets can lead to diminished 
effect on each individual target (Arvey et al., 2010). By calculating a cellular 
target-to-miRNA ratio, a trend was found between weaker miRNA activity and 
higher target concentration (Mullokandov et al., 2012). On the other hand, a 
different study however found that overexpression of a mRNA with miRNA 
target sites caused increased RISC association of the miRNA (Flores et al., 
2014).  
 
1.6.3 Regulation of Ago and RISC formation during T cell activation 
 
miRNA accumulation can also be controlled at the level of the proteins involved 
in miRNA biogenesis and function, such as Dicer, Drosha, Ago and GW182. 
Strong inflammatory signals were shown to downregulate Dicer in CTLs (Trifari 
et al., 2013). This did not however have a major effect on miRNA expression, 
with only a slight decrease in some lowly expressed miRNAs in the 
inflammatory conditions. Global downregulation of Ago proteins has been 
suggested to contribute to miRNA downregulation during CD4+ T cell 
activation.  Ago proteins were shown to be ubiquitinylated during activation, 
and the amount of Ago was limiting to for CD4+ T cell miRNA expression, with 
Ago-2 deficient cells expressing less miRNA (Bronevetsky et al., 2013). Ago 
degradation was therefore suggested to contribute to the global miRNA 
downregulation, leading to fast miRNA turnover and remodelling of the miRNA 
repertoire (Bronevetsky and Ansel, 2013).   
 
Additionally, Ago modifications such as phosphorylation may influence its 
function and interaction with other proteins. Target engagement was shown to 
induce phosphorylation of Ago-2 on S824-834, followed by rapid 
dephosphorylation. Phosphorylation inhibited target mRNA binding, perhaps 
limiting the length of Ago-target interaction and allowing rapid turnover and 
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efficient suppression of targets (Golden et al., 2017). Ago-2 phosphorylation 
on S387 by Akt was shown to promote interaction with LIMD1, which in turn 
lead to interaction with GW182 (Horman et al., 2013; Bridge et al., 2017). In 
actively proliferating cells such as cancer cells or activated T cells, Ago is 
mainly found in a high molecular weight (HMW) RISC, interacting with GW182 
and other proteins (Olejniczak et al., 2013). In T cells, the PI3K-Akt-mTOR 
pathway has been shown to promote expression of GW182 and the formation 
of HMW RISC in activated T cells. In naive T cells, Ago is predominantly found 
in low molecular weight (LMW) RISC corresponding to the molecular weight of 
Ago and non-target bound miRNA (La Rocca et al., 2015). GW182 is not 
expressed in naive T cells and its expression correlated with HMW RISC 
formation following activation. Inhibition of PI3K and mTOR caused a reduction 
in GW182 expression and HMW RISC formation, whereas a constitutively 
active Akt in a cell line lead to increased HMW RISC formation (La Rocca et 
al., 2015). The PI3K-Akt-mTOR pathway may therefore promote GW182 
expression as well as its interaction with Ago.  
 
Formation of HMW RISC was shown to be crucial for regulation of miRNA 
suppressive function in T cells. Knocking down GW182 expression in T cells 
led to decreased miRNA target repression (La Rocca et al., 2015). T cell 
activation caused a global shift of miRNAs into HMW RISC, irrespective of 
changes in miRNA expression. miRNAs found in HMW RISC were shown to 
be more efficient at repressing their targets despite downregulation in their 
expression. For example, let-7 family miRNAs were shown to be 
downregulated upon activation, but were more efficient at repressing a target 
reporter in activated cells (La Rocca et al., 2015). There were individual 
differences in the extent of recruitment to HMW RISC, allowing for an 
additional layer of regulation in miRNA function in T cells. Despite global 
downregulation of miRNAs, some of these may be more functional in activated 




1.7 Key miRNAs and their targets in CD8+ T cells 
 
miRNAs have been shown to regulate most aspects of T cell activation, from 
TCR signalling to the acquisition of effector functions, cell migration, 
proliferation and survival, and the differentiation to long-lived memory cells. 
Key miRNAs and their relevant targets in CD8+ T cells in these processes are 
summarised in Figure 1.4 and described in the following paragraphs.  
 
Globally, miRNA expression is downregulated during T cell activation, with 
generally higher expression of miRNAs in naive and memory T cells compared 
to effector T cells (Wu et al., 2007). Expression studies have identified the most 
abundant miRNAs in CD8+ T cells. A small number of miRNAs were found to 
be highly expressed: miR-16, miR-21, miR-142-3p, miR-142-5p, miR-150, 
miR-15b and let-7f were shown to account for over half the expressed miRNAs 
in in vitro generated CTLs (Wu et al., 2007). During in vivo LCMV infection, 
mR-155 and members of the miR-17~92 cluster were shown to be highly 
expressed in effector cells compared to naive or memory cells (Wu et al., 
2007).  
 
1.7.1 miRNAs and their targets in the TCR signalling pathway 
 
Several miRNAs have been shown to target components of the TCR signalling 
pathway and affect T cell early activation. miR-181 is a key regulator of TCR 
signalling threshold and targets many phosphatases associated with the TCR, 
including Dusp5, Dusp6, Ptpn22 and Shp-2 (Li et al., 2007). Suppression of 
these phosphatases elevates TCR signalling in developing thymocytes, in 
which miR-181 expression is high, allowing positive selection to take place. 
miR-181 is crucial for TCR signal tuning and maintenance of tolerance, with 








Figure 1.4 miRNAs and their targets in CD8+ T cells 
A summary of key miRNAs and their target genes in different aspects of CD8+ 
T cell activation and differentiation (TCR signalling, acquisition of effector 
functions, cell survival, migration, memory cell differentiation and proliferation). 
When miRNA inhibition of its targets positively affects the described process 
(e.g. TCR signalling), this miRNA is coloured green, whereas negatively 




miR-146a is a miRNA that is upregulated by NF-κβ following TCR signalling. 
It subsequently initiates a negative feedback loop that downregulates NF-κβ 
through targeting the signal transducer Traf6 and Irak1 (Yang et al., 2012). In 
the absence of miR-146a, T cells exhibit hyperresponsiveness characterised 
by increased proliferation, cytokine production and lengthened survival. NF-κβ 
signalling was recently also shown to be negatively regulated by miR-34a. This 
miRNAs was shown to be gradually upregulated in activated T cells and 
targeted multiple components of the NF-κβ signalling pathway, including 
Nfkb1s, Cd3e and Pik3cb, leading to reduced cytotoxicity (Hart et al., 2019). 
Finally, miR-150 was recently shown to affect TCR signalling through playing 
an important role in regulating intracellular Ca2+ stores in naive CD8+ T cells 
(Kim et al., 2017). miR-150 deficiency increased levels of its target Tmem20, 
leading to an increase in intracellular Ca2+. This caused defects in subsequent 
T cell activation following stimulation, leading to an anergic phenotype.  
 
1.7.2 Negative regulators of T cell effector functions 
 
T cell activation results in widespread downregulation of miRNAs, which 
relieves the suppression on transcription factors and molecules needed for 
effector cell differentiation. For example, miR-139 and the let-7 family have 
been shown to target key transcription factors needed for effector cell 
differentiation. miR-139 was shown to target the transcription factor Eomes 
and the effector molecule perforin in CTLs. Its rapid downregulation upon 
activation allowed effector cell differentiation, whereas forced expression was 
disadvantageous for T cell function in infection (Trifari et al., 2013). Members 
of the let-7 miRNA family have also been shown to be downregulated in CD8+ 
T cells upon activation, and their forced expression resulted in defects in 
proliferation and effector function (Wells et al., 2017). In contrast, knockdown 
of this family was shown to improve effector function and responses in vivo. 
This miRNA family has also been shown to target key transcription factors like 
Eomes and Myc in CD8+ T cells, as well as components of the mTOR signalling 
pathway in CD4+ T cells (Marcais et al., 2014; Wells et al., 2017). The miR-
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15/16 cluster was also shown to target the mTOR pathway in CD8+ T cells, 
with deficiency in these miRNAs improving CD8+ T cell effector functions and 
tumour clearance (Yang et al., 2017).  
 
Other miRNAs have been shown to directly target effector molecules such as 
cytokines. miR-29a and miR-29b have been shown to be downregulated to 
allow IFN-γ production in both CD4+ and CD8+ T cells (Ma et al., 2011). miR-
29 was shown to directly inhibit IFN-γ mRNA and suppressed responses to 
intracellular bacteria. Effector functions are also attenuated by the miR-
23a~24~27a cluster, that has been shown to target IFNγ and Blimp-1 and 
reduced CD8+ T cell cytotoxicity (Chandran et al., 2014). The cluster can be 
induced by transforming growth factor (TGF-β) and was shown to inhibit anti-
tumour responses in both human and mouse CTLs (Lin, 2014). Tumour-
derived TGF-β has also been shown to cause upregulation of another negative 
regulator of T cell responses, miR-491 (Yu et al., 2016). This miRNA was 
shown to inhibit T cell proliferation and effector responses and promote 
apoptosis through targeting of Cdk4, Bcl-xl and Tcf1, leading to defective anti-
tumour responses. 
 
1.7.3 miRNA function in supporting T cell proliferation, survival and acquisition 
of effector functions 
 
Following engagement of the TCR, CD8+ T cells rapidly begin proliferating and 
differentiate into cytotoxic effector cells. Several miRNAs are upregulated 
upon T cell activation and are required for sustained proliferation and cell 
survival. miR-155 is a key miRNA for T cell activation and function. It is 
upregulated in vitro in a TCR-signal strength dependant manner as well as in 
vivo during LCMV infection (Dudda et al., 2013). miR-155 deficiency causes a 
failure in T cell expansion and impairs responses to infectious challenge and 
tumours (Dudda et al., 2013; Lind, Elford and Ohashi, 2013). In contrast, miR-
155 overexpression has been shown to enhance CD8+ T cell responses in vivo 
(Gracias et al., 2013). There has been some debate on the targets of miR-155 
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in CD8+ T cells, but it has been suggested to target components of a number 
of T-cell signalling pathways in particular those related to cytokine and 
interferon signalling. The STAT5 signalling pathway has been suggested to be 
induced by miR-155 through targeting of Socs1 and Ptpn2 (Dudda et al., 2013; 
Ji et al., 2015). miR-155 has also been suggested to target negative regulators 
the Akt-dependent pro-survival pathway, specifically Ship1 (Lind, Elford and 
Ohashi, 2013; Ji et al., 2015). miR-155 has been proposed to mediate its 
function through the synergistic effect of modest downregulation of many 
target gene groups, as opposed to having one key target (Gracias et al., 2013).  
 
Another important group of miRNAs for promoting CD8+ T cell proliferation and 
survival are members of the miR-17~92 cluster. Six miRNAs comprise the 
cluster: mR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1 
(Mogilyansky and Rigoutsos, 2013). Clustered miRNAs are transcribed as one 
unit, but the individual miRNAs are subject to post-transcriptional processing, 
maturation and stability. These miRNAs are often thought to target same or 
overlapping mRNAs or pathways, but this is not always the case, and the 
miRNAs may even antagonise one another. (Lai and Xiao, 2015) The miRNAs 
of the cluster are strongly induced during CD8+ T cell activation to promote cell 
cycle progression; deficiency in the cluster results in impaired proliferation and 
expansion of CD8+ T cells in vitro and in vivo during LCMV infection (Wu et al., 
2012; Khan et al., 2013). The cluster has been suggested to target Pten, Pd1 
and Btla, which are negative regulators of the mTOR pathway (Wu et al., 
2012). These proteins were found to be less expressed in miR17~92 
overexpressing cells, and in particular Pten was found to contain target sites 
for 5 family members of the cluster. Pten has also been shown to be targeted 
by other miRNAs in T cells, such as miR-21 and miR-214. The latter has been 
shown to promote T cell proliferation following activation (Jindra et al., 2010). 
miR-21 has been shown to improve anti-tumour responses and was also 
suggested to achieve this through targeting of Pten (He et al., 2017). miR-21 
is also induced upon T cell activation and has been suggested to inhibit cell 
apoptosis through targeting of Lats-1 (Meisgen et al., 2012; Teteloshvili et al., 
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2017). Another miRNA affecting T cell proliferation is miR-142. Deficiency in 
this miRNA causes cell cycling defects in thymocytes and mature T cells. miR-
142 is thought to promote expression of cell-cycle promoting genes through 
targets such as Cdkn1b and the atypical E2f transcription factors E2f7 an E2f8 
(Sun et al., 2015; Mildner et al., 2017). miR-191 has been shown to target Irs1 
and support T cell survival during cytokine-mediated homeostatic maintenance 
of peripheral T cells, and to further promote survival during effector responses 
(Lykken and Li, 2016). Finally, miR-31 is another miRNA that is induced 
following T cell activation. This miRNA has been suggested to promote IL-2 
production through inhibition of its suppressor Ksr2 (Xue et al., 2013). However 
in chronic viral infection this miRNA was shown to contribute to CD8+ T cell 
exhaustion, through targeting Ppp6c that regulates responsiveness to 
interferons (Moffett et al., 2017). 
 
1.7.4 The role of miRNAs in CD8+ T cell short-lived effector and memory cell 
differentiation 
 
Many miRNAs that are downregulated upon activation are re-expressed during 
the contraction phase of the immune response and memory cell differentiation, 
as cells cease proliferating and no longer need to produce effector molecules. 
Some miRNAs that are needed for T cell activation are also important for 
memory cell formation, such as miR-155. Deficiency causes a failure to 
expand at peak of infection and impaired memory formation three months later 
(Dudda et al., 2013). Deficiency has been shown to result in fewer effector -
and central memory cells (Gracias et al., 2013) though one study found 
preferential differentiation to central memory (Tsai et al., 2013). The miR-200 
family has been shown to be required for optimal CD8+ T cell memory 
formation, through targeting the terminal differentiation promoting transcription 
factor Zeb2 (Guan et al., 2018). 
 
Other miRNAs are required for the initial activation and promote skewing to 
short-lived effector cells, so their downregulation is crucial for memory cell 
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differentiation. The expression of the miR-17~92 cluster peaks in actively 
proliferating cells during day 5 of infection and is then downregulated by day 8 
during the contraction phase and memory cell differentiation. Forced 
expression of the cluster causes skewing to short-lived effector cell 
differentiation and impairs memory formation (Wu et al., 2012; Khan et al., 
2013). Another miRNA that promotes the differentiation of short-lived effector 
cells is miR-150. This was suggested to be through targeting of c-Myb and 
Foxo1. Its downregulation appears necessary for efficient memory formation, 
and miR-150 deficient cells were shown to preferentially differentiate into 







1.8 Aims of the PhD project 
 
CD8+ T cell activation and differentiation is known to be regulated by a network 
of miRNAs. These miRNAs have generally been identified through studying 
expression changes of miRNAs, and potential targets have been determined 
using bioinformatic predictions based on the miRNA seed region. Recent work 
has shown, that miRNA expression may not be the only determinant of its 
biological function. Formation of HMW RISC was shown to additionally 
promote the function of specific miRNAs in activated T cells, irrespective of 
changes in expression. Furthermore, since miRNAs often have the potential 
to target hundreds of mRNAs, it is often difficult to decipher the biologically 
relevant targets from bioinformatic predictions. However, knowing miRNA 
targets is crucial to understanding their function. Novel biochemical methods 
that use cross-linking of RNA to proteins, and ligation of miRNAs to their target 
mRNAs have the potential to directly determine miRNA targets. Therefore, in 
this project we aimed to study the following questions: 
 
1. Is HMW RISC formed in CD8+ T cells activated with an agonist peptide? 
What is the role of GW182 in this? 
2. Are specific miRNAs associated with HMW and LMW RISC in activated 
CD8+ T cells? Can we identify biologically active miRNAs from HMW 
RISC? (Fig.1.5) 




Figure 1.5 miRNA association with LMW and HMW RISC 
Activated T cells have been shown to contain both LMW and HMW RISC but 
miRNAs interacting with target mRNAs were suggested to be predominantly 
found in the latter. Can we enrich for biologically active miRNAs and their 
targets by purifying HMW RISC? 
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CHAPTER 2: Materials and Methods 
 
2.1 List of buffers 
 
Facs buffer (in PBS) 
2.5 % FBS  
0.05 % sodium azide  
 
WB washing buffer (in PBS) 
0.05 % Tween20 
 
WB transfer buffer 
24 mM Tris base 
192 mM glycine 
20 % methanol 
 
CLASH lysis buffer 
50 mM Tris/HCl pH=7.8 
300 mM NaCl 
1% Triton X100 
5 mM EDTA 
10 % glycerol 
 
Low salt (LS) IP wash buffer 
50 mM Tris/HCl pH= 7.5 
0.3 M NaCl 
5 mM MgCl2 
0.5 % Triton x100 
2.5 % glycerol 
 
High salt (HS) IP wash buffer 
50 mM Tris/HCl pH=7.5 
0.8 M NaCl 
10 mM MgCl2 
0.5 % Triton x100 
2.5 % glycerol 
 
Proteinase K buffer 
50 mM Tris/HCl pH=7.8 
50 mM NaCl 
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10 mM imidazole 
0.1 % NP-40 
5 mM EDTA 
5 mM beta-Mercaptoethanol 
 
PNK buffer 
50 mM Tris/HCl pH=7.5 
10 mM MgCl2 
0.5 % Triton X100 
50 mM NaCl 
 
Elution buffer 
4x LDS loading dye diluted in PNK buffer 
50mM DTT 
 
Superose 6 lysis buffer 
150 mM NaCl 
10 mM Tris/HCl pH=7.5 
2.5 mM MgCl2 
0.01 % Triton x100 
1 mM DTT 
 
Superose 6 buffer 
150 mM NaCl 
10 mM Tris/HCl pH=7.5 
2.5 mM MgCl2 




All mice were maintained and bred in pathogen-free conditions at the 
University of Edinburgh animal facilities in accordance with the UK Home 
Office and local ethically approved guidelines.  
 
2.2.1 OT-I hom RAG1-/- mice 
The OT-I TCR is MHC Class I restricted and binds the N4 peptide (SIINFEKL), 
corresponding to ovalbumin residues 257-264. RAG1-/- mice are deficient in 
the Rag-1 recombinase required for T and B cell receptor recombination, thus 
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only express the transgenic OT-I TCR (Mombaerts et al., 1992; Hogquist et 
al., 1994). The mice are on the C57BL/6 genetic background. 
 
2.2.2 Ago-2-flag OT-I hom RAG1-/- mice 
For some experiments, Ago-2-flag mice were used. These mice have a Flag-
purification tag, PreScission cleavage site and 6x His tag inserted at the 5’ end 
of Ago-2, before Exon 1. The knock-in mice were generated at the University 
of Edinburgh by using gene targeting to insert the tag. For some experiments 
(where indicated in the figure legends), these mice were used as well as, or 
instead of the OT-I hom RAG1-/- mice. 
 
2.3 T cell culture 
 
2.3.1 Preparation of single cell suspensions and cell counts 
Single cell suspensions were prepared mechanically from mouse lymph nodes 
using a 70 µm filter. Cells were washed by centrifugation at 300 x g for 5 min 
in cell culture medium. Cells were grown in Iscove’s Modified Dulbecco’s 
Medium (IMDM, Sigma Aldrich) supplemented with 10% Heat inactivated Fetal 
Calf Serum (FCS, Gibco), 100 U/mL Streptomycin (Gibco), 100 µg/mL 
penicillin (Gibco), 2 mM L-glutamine (Gibco) and 50 µM β-mercaptoethanol. 
Cells were counted using CASY cell counter (OMNI Life Science).  
 
2.3.2 OT-I T cell activation and differentiation 
To activate OT-I cells, 2 x 106 cells/mL were grown in media supplemented 
with 10 nM N4, T4 or G4 for 2 days. For effector or memory cell differentiation, 
cells were activated with N4 as before for two days, then resuspended at 2 x 
105 cells/mL in media supplemented with 20 ng/mL IL-2 (for effector cells, 
PeproTech) or 20 ng/mL IL-15 (for memory cells, PeproTech).  
 
2.3.3 miRNA inhibition 
miRNA inhibitors (miRCURY LNA miRNA power inhibitor with 5’-FAM, Qiagen) 
were added directly to culture media at the time of activation. 500 nM miRNA 
inhibitor (mmu-mir-7a-5p) or control inhibitor (negative control A) was added 
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to naive T cells in cell culture media with N4, and phenotype was assessed 
after 48 h.  
 
2.3.4 Ago-GW182 blocking peptide 
A peptide was designed to bind Ago-2 and block its binding to GW182, based 
on the known Ago binding motif (Elkayam et al., 2017). The Ago binding motif 
sequence was fused to a self-translocating peptide sequence, TP2 (He et al., 
2013). For a control, key Ago-binding residues were replaced with alanines 
(Fig.2.1). The peptides were synthesised by Royo Biotech. The peptides were 
incubated with cell lysates in vitro at 10-50 µM. 






Figure 2.1 Blocking peptide sequence 
The blue part shows the translocating peptide TP2 sequence, followed by two 
glycines and the Ago binding motif in red. Key residues for Ago-binding have 
been replaced with alanines for the control peptide (highlighted in green).  
 
2.4 Flow cytometry 
 
Table 2.1 Table of antibodies used for flow cytometry staining. 
Specificity Conjugate Clone Host Conc. Supplier 
CD8b PE/Cy7 H35-17.2 Rat 1:400 eBioscience 
CD25 APC PC61.5 Rat 1:200 eBioscience 
CD25 Alexa Fluor 488 PC61 Rat 1:200 Biolegend 
CD44 APC eFluor 780 IM7 Rat 1:200 eBioscience 
CD62L APC MEL-14 Rat 1:200 Biolegend 
CD69 APC H1.2F3 Hamster 1:200 Biolegend 
CD71 PE/Cy7 RI7217 Rat 1:200 Biolegend 
Intracellular stains 
Ki67  FITC B56 Mouse 1:100 BD Biosciences 
IFNγ Alexa Fluor 488 XMG1.2 Rat 1:400 Biolegend 
TNFα PercP/Cy5.5 MP6-XT22 Rat 1:200 BD Biosciences 
Granzyme B Pacific Blue GB11 Mouse 1:100 Biolegend 
Eomesodermin eFluor 660 Dan11mag Rat 1:100 eBioscience 
T-bet PercP Cy5.5 or PE 4B10 Mouse 1:100 eBioscience 
IRF4 eFluor 450 3E4 Rat 1:100 eBioscience 
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2.4.1 Surface staining 
Flow cytometry staining was undertaken in 96-well round-bottom plates with a 
minimum of 200,000 cells per well. Washing steps were performed by filling 
the wells with Phosphate Buffered Saline (PBS) or Facs buffer, and 
centrifuging the plate at 300 x g for 3 min then discarding the supernatant. 
Prior to staining, cells were washed in PBS. For staining dead cells, cell pellets 
were resuspended in LIVE/DEAD Fixable Aqua or Far Red Dead Cell Stain 
(Thermo Scientific) diluted in PBS at 1:700, and incubated at room 
temperature for 10 min. The cells were then washed in Facs buffer. For surface 
staining, antibodies were diluted in Facs buffer then incubated with the cells 
for 15 min at room temperature (Table 2.1). The cells were then washed in 
Facs buffer and resuspended in PBS for analysis on MacsQuant Analyzer 10. 
 
2.4.2 Cytokine staining and intranuclear staining 
Prior to measuring cytokine production, cells were re-stimulated with N4 in 
medium containing 2.5 µg/mL Brefeldin A (Cambridge Bioscience) for 4 h. 
Cells were then centrifuged, washed in Facs buffer and incubated with Fixation 
buffer (BioLegend) for 20 min at room temperature before washing. Washing 
steps from here on were performed in Intracellular Staining Permeabilization 
Wash Buffer (BioLegend) centrifuging at 330 x g for 3 min. Cytokine-specific 
antibodies were diluted in permeabilization buffer, and incubated with the cells 
for 20-30 min at room temperature (Table 2.1). The cells were then washed 
and resuspended in PBS. Intranuclear staining was performed as cytokine 
staining but using buffers from eBioScience Foxp3 / Transcription Factor 
Staining Kit (Thermo Scientific). 
 
2.4.3 CellTrace staining for proliferation 
To measure cell proliferation, cells were stained with CellTrace Violet (Thermo 
Scientific) prior to putting in culture. Cell pellets were resuspended in PBS with 
1:1000 dilution of CellTrace Violet, and incubated at 37°C for 20 min, protected 
from light. The cells were then centrifuged at 300 x g for 5 min and 
resuspended in fresh cell medium for cell culture.   
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2.5 Western blotting 
 
Specificity Conjugate Clone Host Conc. Supplier 
Ago-2 - DO-2 17F1-
C1 
Mouse 1:4000 InVivo BioTech 
(custom made) 
GW182 - Polyclonal Rabbit 1:4000 Bethyl Laboratories 
ZAP-70 - D1C10E Rabbit 1:4000 Cell Signalling 
 
Secondary antibodies 
Mouse IgG  Alexa Fluor 680 Polyclonal Goat 1:20,000 Thermo Scientific 
Mouse IgG  IRDye 800CW Polyclonal Goat 1:20,000 Li-cor 
Rabbit IgG Alexa Fluor 680 Polyclonal Goat 1:20,000 Thermo Scientific 
Rabbit IgG DyLight 800  Polyclonal Goat 1:20,000 Thermo Scientific 
 
Table 2.2 
Table of antibodies used for western blotting 
 
2.5.1 Cell lysis 
Cells were lysed in CLASH lysis buffer containing proteinase inhibitors 
(cOmplete protease inhibitor cocktail tablets, Roche), and if required, RNase 
inhibitors (RNasin Ribonuclease inhibitor, Promega). The cells were 
resuspended in lysis buffer at 1 x 108 cells/mL and incubated for 20 min on ice. 
The lysate was cleared by centrifugation at 13,000 rpm for 10 min. Protein 
concentration was measured with a spectrophotometric assay (Micro BCA 
protein assay, Thermo Scientific).  
 
2.5.2 Western blotting 
LDS sample buffer (NuPAGE, Thermo Scientific) containing 10% DTT or β-
mercaptoethanol was added to the lysate. The lysate was denatured by 
incubating at 95°C for 10 min. Sample was loaded on a 4-12% Bis-Tris gel 
(NuPAGE, Thermo Scientific) and ran in MOPS SDS running buffer (NuPAGE, 
Thermo Scientific) at 150V for 90-120 min, using a mini gel tank (Thermo 
Scientific). The proteins were then transferred from the gel onto a PVDF 
membrane (Immobilon-FL, Merck), that had been activated by wetting in 
methanol. Transfer was performed in transfer buffer for 105 min at 100V, using 
a wet transfer tank (mini Protean Tetra cell, Bio-rad). After transfer, the 
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membrane was blocked in Odyssey blocking buffer (Li-cor) for 1 h. Membrane 
was then incubated overnight at 4°C with a primary antibody in blocking buffer 
+ 0.1% Tween20 (Table 2.2). The membrane was washed in PBS + 0.05% 
Tween20 for 1 h with several changes of buffer. After washing, the membrane 
was incubated with the secondary antibody in blocking buffer + 0.1% Tween20 
+ 0.01% SDS for 30 min at room temperature. The membrane was then 




3-4 x 107 cells per IP were lysed as described for Western blotting. 50-100 µl 
Protein G Dynabeads (Thermo Scientific) per sample were used for the 
immunoprecipitations. The beads were washed three times in PBS + 0.01% 
Tween20 (PBS-T) by adding 1 mL of wash buffer and resuspending the beads, 
then removing the supernatant on a magnet. For binding antibody to Protein 
G Dynabeads, the beads were incubated at 4°C on rotation with 5-10 µg anti-
Ago-2 or anti-GW182 antibody (Table 2.2), or 5-10 µl mouse IgG or polyclonal 
rabbit serum for controls, in PBS-T for a minimum of 6 hours. The beads were 
then washed in PBS-T and lysis buffer, before adding sample lysate. The 
immunoprecipitations were performed at 4°C overnight on a rotator. The 
following day the unbound fraction was collected. The beads were then 
washed once with LS-IP wash, twice with HS-IP wash, once with LS-IP wash 
and once with PNK buffer. For the HS-IP washes, the beads were incubated 
with the wash buffer for 5 min on rotation at 4°C. The beads were then 
resuspended in 50-100 µl LDS sample buffer (NuPAGE, Thermo Scientific) 
containing 10% DTT or β-mercaptoethanol, and incubated on a shaker at 70°C 
for 10 min. The eluate was collected by removing the supernatant on a magnet. 
 
2.7 Size exclusion chromatography 
 
2.7.1 Cell lysis 
Cells were flash-frozen on dry ice or liquid nitrogen and lysed in 0.5 mL 
Superose 6 buffer for 20 min. The lysate was cleared by centrifugation at 
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13,000 rpm and filtering through a 20 µm filter. Protein concentration was 
measured with Qubit 3.0 fluorometer (Thermo Scientific) using the Qubit 
Protein Assay kit (Thermo Scientific).  
 
2.7.2 Chromatography 
Size exclusion chromatography was performed by Martin Wear at the 
Edinburgh Protein Production Facility. The sample was loaded on the 
Superose 6 column, washed with Superose 6 buffer and 0.5 mL fractions were 
collected. 
 
2.7.3 Protein extraction from fractions 
Protein was extracted from the fractions by TCA precipitation. 1 volume of TCA 
was added to 4 volumes of protein sample and incubated at 4°C for 10 min. 
The sample was then centrifuged at full speed for 10 min. The supernatant 
was removed and the pellet was washed by adding 200 µl cold acetone and 
centrifugation at full speed for 5 minutes. The washing step was repeated once 
for a total of 2 acetone washes. The pellet was then air dried and resuspended 
in LDS sample buffer (Thermo Scientific) containing 10% β-mercaptoethanol, 
and heated at 95°C for 10 min. The samples were then used for western 
blotting. 
 
2.8 quantitative real-time PCR (qPCR) 
 
2.8.1 RNA isolation 
5 x 106 cells were resuspended in 0.5 mL Trizol reagent (Thermo Scientific) 
for RNA purification. RNA was purified by using Direct-zol kit (Zymo Research) 
following kit instructions. RNA was resuspended in 20-40 µl dH2O and RNA 
concentration was measured with Nanodrop 1000 Spectrophotometer 
(Thermo Scientific).  
 
2.8.2 Reverse transcription 
RNA was reverse transcribed by using miScript RT kit (Qiagen). An equal 
amount of RNA was used for each sample per reaction (minimum 100 ng). The 
38 
 
template RNA was mixed with 5x miScript HiFlex buffer, 10x miScript Nucleics 
mix, miScript Reverse transcriptase mix and RNase free water. The mixture 
was then incubated for 60 min at 37°C then for 5 min at 95°C in a thermocycler.  
 
2.8.3 qPCR 
For qPCR, the cDNA was diluted 1:10 in dH2O. For detection of miRNAs, a 
master mix was prepared from 2x QuantiText SYBR Green PCR Master mix 
(Qiagen), 10x miScript Universal Primer (Qiagen) and dH2O. For each miRNA 
studied, specific miScript Primer Assay (Qiagen) was added. 8 µl of the mix 
was added to 2 µl cDNA per well in 96 or 384-well plates (LightCycler 480 
Multiwell plate, Roche). For detection of mRNA, predesigned qPCR primers 
were used (IDT) at a final concentration of 500 nM with the 2x QuantiText 
SYBR Green PCR Master Mix (Qiagen). The plates were run on LightCycler 
480 Instrument II (Roche) with the following cycling conditions.  
 
Step Time Temperature 
PCR initial activation step 15 min 95°C 
3-step cycling: (x40)   
Denaturation 15 s 94°C 
Annealing 30 s 55°C 
Extension 30 s 70°C 
 
 
2.9 Small RNA library preparation 
 
2.9.1 RNA isolation 
For small RNA library preparation, RNA was isolated from Ago-2-IP samples, 
as well as the IP input and unbound samples. For input samples, cells were 
resuspended in 0.5 mL QIAzol lysis reagent (Qiagen). For liquid input and 
unbound samples, 50 µl of sample was resuspended in 650 µl QIAzol. For IP 
samples, the beads were resuspended in 0.5 mL QIAzol. RNA was isolated 
using the RNeasy kit (Qiagen), following kit instructions. The RNA samples 
were eluted in 100 µl dH2O. The RNA was then ethanol precipitated by adding 
2.5 x volume 100% ethanol, 30 µl sodium acetate and 1 µl GlycoBlue 
Coprecipitant (Thermo Scientific). The samples were incubated overnight at    
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-20°C. The following day, the samples were centrifuged at full speed for 30 
min, then washed twice with 70% ethanol (10 min centrifugation at full speed). 
The pellets were air-dried on ice then resuspended in 10-15 µl dH2O and 
quantified with Qubit 3.0 fluorometer (Thermo Scientific) using the Qubit RNA 
HS Assay kit (Thermo Scientific).  
 
2.9.2 Adapters and reverse transcription 
Small RNA libraries were prepared using the TriLink CleanTag Ligation kit for 
Small RNA Library Preparation (Catalog #L-3206). When possible, 100 ng of 
RNA per sample was used for library preparation, as quantified with Qubit. For 
LMW RISC samples and all IP samples, the maximum amount of sample was 
used (2 µl, approximately 10-40 ng). The libraries were prepared following kit 
instructions for the four key steps: 3’ Adapter ligation to RNA template, 5’ 
Adapter ligation to tagged RNA template, Reverse Transcription reaction of 
tagged RNA library, and PCR amplification of RT product, using half-reaction 
volumes.  
 
2.9.2.1 3’ Adapter ligation 
2 µl of template RNA was heated at 70°C for 2 min. 3’ Adapter was diluted 1:2 
for high-input samples (100 ng), and 1:4 for low (40 ng) or 1:8 for very low (<10 
ng) input, then used to prepare the following reaction: 
Reagent Amount 
RNA template 2 µl 
Buffer 1 2.5 µl 
RNase inhibitor 0.5 µl 
Enzyme 1 0.5 µl 
CleanTag 3’ Adapter 0.5 µl 
6 µl 
 
2.9.2.2 5’ Adapter ligation 
The 5’ adapter was diluted as the 3’ adapter, and heated at 70°C for 2 min. 
The following mix was then added to the 3’ tagged RNA: 
Reagent Amount 
3’ tagged RNA 6 µl 
dH2O 1 µl 
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Buffer 2 0.5 µl 
RNase inhibitor 0.5 µl 
Enzyme 2 1 µl 
CleanTag 5’ Adapter 1 µl 
10 µl 
The mix was then placed in a thermocycler and heated at 28°C for 1 h, followed 
by 65°C for 20 min. 
 
2.9.2.3 Reverse transcription 
1 µl RT primer (5 µM) was added to tagged library and heated at 70°C for 2 
min. For reverse transcription, following mix was added: 
Reagent Amount 
RNA (10 µl + 1 µl RT primer) 11 µl 
dH2O 0.96 µl 
5x RT buffer 2.88 µl 
dNTPs (10mM) 0.72 µl 
DTT (100mM) 1.44 µl 
RNase inhibitor 0.5 µl 
RT Enzyme 0.5 µl 
18 µl 
The reaction mix was placed in a thermocycler and incubate at 50°C for 1 h 
 
2.9.2.4 PCR amplification 
The following PCR mix was prepared per reaction: 
Reagent Amount 
cDNA 18 µl 
High Fidelity PCR Master Mix 20 µl 
Forward primer 1 µl 
Index primer 1 µl 
40 µl 
 
The mix was placed in a thermocycler for the following cycling conditions: 
Step Time Temperature 
PCR initial activation step 30 s 98°C 
3-step cycling: (x21)   
Denaturation 10 s 98°C 











2.9.3 TBE gels and ethanol purification 
Following PCR amplification of the RT product, the samples were mixed with 
DNA loading dye (Gel Loading Dye, blue (6x), NEB) and ran with a digested 
plasmid ladder (quick load pBR322 DNA MspI digest, NEB) on 6% TBE gels 
(Thermo Scientific) in TBE running buffer (Thermo Scientific). Gels were ran 
at 80V for 90 min. The gels were then incubated with 50 mL TBE buffer 
containing SYBR Gold nucleic acid gel stain diluted 1:10,000 (Thermo 
Scientific) for 15 min on a plate shaker. The gels were then visualised on the 
D-Digit gel scanner (Li-cor). The bands corresponding to the tagged library 
were cut out with a scalpel over Large blue LED transilluminator (IO Rodeo). 
The gel pieces were shredded by centrifugation through pierced 0.5 mL 
Eppendorf tubes inside 1.5 mL Eppendorf tubes at 3,000 rpm for 2 min. 300 µl 
H2O was added to the gel pieces and the samples were rotated overnight at 
4°C. The samples were then centrifuged through spin tube filters (Spin-X 
Centrifuge tube filters, Corning Costar) for 5 min at full speed. To precipitate 
the libraries, 2.5 x volume 100% ethanol, 30 µl sodium acetate and 1 µl 
GlycoBlue Coprecipitant (Thermo Scientific) were added. The samples were 
ethanol precipitated overnight at -20°C. The tubes were centrifuged at full 
speed for 30 min, then washed twice with 70% ethanol (10 min centrifugation 
at full speed). The pellets were air-dried on ice then resuspended in 10-15 µl 
dH2O.  
 
2.9.4 Sample preparation for sequencing 
The sample concentration was measured with Qubit 3.0 fluorometer (Thermo 
Scientific) using the Qubit dsDNA HS Assay kit (Thermo Scientific). The 
samples were also measured on Agilent 2100 Bioanalyzer using the Agilent 
High Sensitivity DNA kit. 1 ng of input and unbound libraries, and 2 ng of IP 
libraries were pooled and concentrated to 15 nM in 50 µl for sequencing. The 








1 x 108 cells were washed by centrifugation at 300 x g for 5 min then 
resuspended in 10 mL PBS. For cross-linking, 5 mL cells were added on a 
Petri dish and placed on ice. Cross-linking was performed at 400 mJ/cm2 then 
twice at 200 mJ/cm2 using a UV Stratalinker 2400. Cells were collected from 
the Petri dishes and centrifuged at 300 x g for 5 min.  
 
2.10.2 Cell lysis 
Cells were lysed as described for Western blotting, including proteinase 
inhibitors (cOmplete protease inhibitor cocktail tablets, Roche) and RNase 
inhibitors (RNasin Ribonuclease inhibitor, Promega) in the CLASH lysis buffer. 
 
2.10.3 Ago-2 Immunoprecipitation 
100 µl Protein G Dynabeads (Thermo Scientific) were used per sample. The 
beads were washed three times in PBS + 0.01% Tween20 (PBS-T) by adding 
1 mL of wash buffer and resuspending the beads, then removing the 
supernatant on a magnet. For binding antibody to Protein G Dynabeads, the 
beads were incubated at 4°C on rotation with 5-10 µg anti-Ago-2 or anti-
GW182 antibody (Table 2.2) in PBS-T for a minimum of 6 hours. The beads 
were then washed in PBS-T and lysis buffer, before adding sample lysate. The 
immunoprecipitations were performed at 4°C overnight on a rotator. The 
following day the unbound fraction was collected. The beads were then 
washed once with LS-IP wash, twice with HS-IP wash, once with LS-IP wash 
and once with PNK buffer. For the HS-IP washes, the beads were incubated 
with the wash buffer for 5 min on rotation at 4°C. These wash conditions were 
also used for all the following wash steps. 
 
2.10.4 RNase digestion 
Following the washing steps, the beads were resuspended in PNK buffer 
containing RNase. 1 µl RNace-IT ribonuclease cocktail (diluted 1:40, Agilent) 
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was added to 500 µl pre-warmed PNK buffer. The beads were incubated at 
20°C for 7 min with intermittent shaking. Following the incubation, the sample 
was moved directly on ice and washed as before. 
 
2.10.5 T4 PNK phosphorylation 
For the RNA phosphorylation, 80 µl of reaction mix was added onto the beads 
and incubated 2.5 h at 20°C with intermittent shaking, after which the beads 
were washed. 
Reagent Amount Provider 
T4 PNK buffer (10x) 8 µl NEB 
rATP (100mM) 0.8 µl Promega 
RNasin ribonuclease inhibitor 2 µl Promega 
T4 PNK (3’ phosphatase minus) 4 µl NEB 
dH2O 65 µl  
 
2.10.6 Intermolecular ligation 
For intermolecular ligation of miRNAs and target mRNAs, 160 µl of reaction 
mix was added onto each sample and incubated overnight at 16°C with 
intermittent shaking, after which the beads were washed. 
Reagent Amount Provider 
T4 ligase buffer (10x) 16 µl NEB 
rATP (100mM) 1.6 µl Promega 
RNasin ribonuclease inhibitor 4 µl Promega 
T4 ligase I  8 µl NEB 
dH2O 130.4 µl  
 
2.10.7 TSAP phosphorylation 
For TSAP phosphorylation, 80 µl of reaction mix was added onto each sample 
and incubated 45 min at 20°C with intermittent shaking, after which the beads 
were washed. 
Reagent Amount Provider 
Multicore buffer (10x) 8 µl Promega 
RNasin ribonuclease inhibitor 2 µl Promega 
TSAP  8 µl Promega 





2.10.8 3’ Adapter ligation 
For 3’ adapter ligation, 80 µl of reaction mix was added onto each sample and 
incubated 6 h at 20°C in the dark with intermittent shaking, after which the 
beads were washed. 
Reagent Amount Provider 
T4 ligase buffer (10x) 8 µl NEB 
PEG 8000 (50%) 16 µl NEB 
3’ CleanTag IR800 (10 µM) 8 µl TriLink 
RNasin ribonuclease inhibitor 2 µl Promega 
T4 RNA ligase K227Q 4 µl NEB 
dH2O 42 µl  
 
2.10.9 Elution from beads 
After the final wash, the beads were resuspended in 50-100 µl elution buffer 
and incubated at 70°C for 10 min with constant shaking. The supernatant was 
then removed from the beads on a magnet and loaded on a protein gel, or kept 
overnight at -20°C. 
 
2.10.10 Protein gel 
Samples were loaded on a 4-12% Bis-Tris gel (NuPAGE, Thermo Scientific) 
and ran in MOPS SDS running buffer (NuPAGE, Thermo Scientific) at 120V 
for 90-120 min at 4°C, in a mini gel tank (Thermo Scientific) covered from light. 
The gel was then either directly scanned on Odyssey CLx scanner (Li-cor) or 
transferred on a HyBond-N+ membrane (GE Healthcare) for Western blotting. 
Transfer was performed using transfer buffer (NuPAGE, Thermo Scientific) 
containing 10% methanol, at 100V for 105 min in the dark. 
 
2.10.11 Elution from gel 
After visualisation of gel, RNA-band corresponding to Ago-2 was cut from the 
gel by using a small scalpel. The gel pieces were shredded by centrifugation 
through pierced 0.5 mL Eppendorf tubes inside 1.5 mL Eppendorf tubes at 
3,000 rpm for 2 min. 300 µl H2O was added to the gel pieces and the samples 
were rotated overnight at 4°C. The next day, 300 µl of 2x proteinase K buffer 
was added to the gel with 2 µl RNase inhibitor (Promega) and 100 µg 
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proteinase K (Ambion). The samples were incubated at 55°C for 2 h with 
constant shaking. The mix was supplemented with additional 50 µg proteinase 
K after 1 h.  
 
2.10.12 RNA extraction 
The samples were then centrifuged through spin tube filters (Spin-X Centrifuge 
tube filters, Corning Costar) for 5 min at full speed. The supernatant was 
moved to a new tube from which RNA was phenol-chloroform extracted by 
adding 1/10th volume 3 M sodium acetate (pH=5.5) and equal volume phenol 
chloroform. The mix was vortexed for 30 s then centrifuged at 10°C for 15 min. 
The upper layer was moved to a new tube, to which 2.5 x volume 100% ethanol 
was added with 1 µl GlycoBlue Coprecipitant (Thermo Scientific). The sample 
was then left to precipitate at -20°C overnight. The samples were centrifuged 
at full speed for 30 min, then washed twice with 70% ethanol (10 min 
centrifugation at full speed). The pellet was left to air-dry on ice, then 
resuspended in 15 µl water.  
 
2.10.13 Library Preparation 
RNA libraries were prepared as described for small RNA libraries, using the 
TriLink CleanTag small RNA library preparation kit. Since the RNA had already 
been labelled with the 3’ Adapter, the protocol was followed from the 5’ Adapter 
ligation step, using a 1:4 dilution of the Adapter. 2.5 µl of RNA was mixed with 
2.5 µl buffer 1 (from the 3’ Adapter ligation step) then used following the 
protocol using half reactions. After the PCR amplification, the samples were 
ran on TBE gels and purified as described for small RNA libraries. 
 
2.10.14 Sample quality control 
The sample concentration was measured with Qubit 3.0 fluorometer (Thermo 
Scientific) using the Qubit dsDNA HS Assay kit (Thermo Scientific). The 
samples were also measured on Agilent 2100 Bioanalyzer using the Agilent 
High Sensitivity DNA kit. 1-2 ng of each CLASH library was pooled and sent 
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for sequencing. The samples were sequenced using NovaSeq 100 bp single 
end or 75 bp paired end sequencing at Edinburgh Genomics. 
 
2.11 Data analysis 
 
2.11.1 Flow cytometry data 
Flow cytometry data were analysed using FlowJo 10 software. Geometric 
mean fluorescence intensity (gMFI) and percentages of populations were 
exported and plotted in GraphPad Prism. 
 
2.11.2 Western blot data 
Western blot data were analysed using ImageStudioLite (Li-cor). Band signal 
intensity was calculated using the software by drawing a shape around the 
band of interest. The median value of the pixels in the background area was 
subtracted. The signal was then normalised to any loading controls, and 
adjusted to naive or other control samples.  
 
2.11.3 qPCR data 
qPCR data were analysed in Microsoft Excel. Data were first normalised to 
snRNA U6, then calculated as fold change to naive, using the ΔΔCt value 
method. Data were plotted in GraphPad Prism. 
 
2.11.4 small RNA library sequencing data 
RNA sequencing data were processed by Dr Sujai Kumar to create miRNA 
count files. Cutadapt (version 1.15) (Martin, 2011) was used to trim the 3' small 
RNA adapter TGGAATTCTCGGGTGCCA and low quality 3' bases with quality 
below 20. Only reads with the adapter that were longer than 18 bases were 
retained. Reads were classified into RNA biotypes by mapping against sets of 
known mouse RNA sequences using bowtie2 (version 2.3.4) (Langmead and 
Salzberg, 2012) in the order given below. For example, if a read mapped to a 
known miRNA sequence then it was called a miRNA and not a YRNA even if 
it mapped equally well to the YRNA database. The order and sources of the 
mouse RNA sets are: 1. miRNAs from mmu-hairpin.fa miRBase (version 22) 
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(Kozomara, Birgaoanu and Griffiths-Jones, 2019); 2. Y_RNAs; 3. tRNAs; 4. 
rRNAs, all downloaded from the RNAcentral database (Sweeney et al., 2019); 
5. protein-coding mRNAs from Gencode version M16 (Frankish et al., 2019); 
6. snoRNAs; 7. piRNAs; 8. lncRNAs; 9. other (SRPRNAs, scRNAs, snRNAs, 
miscRNAs) from RNAcentral. Any reads not belonging to these categories but 
mapping to the Mouse genome (version GRCm38.p5) were classified as 
"uncategorized" and the remaining reads as "unmapped". Bowtie2 was used 
to assign reads to different RNA types to provide an overview of the RNA 
diversity of the sample. However, to assess the presence and counts of 
individual miRNAs, we used the more accurate and less redundant miRNA 
counting tool QuickMIRSeq (Zhao et al., 2017). QuickMIRSeq does its own 
read trimming and length selection using cutadapt, which we set to trim the 3' 
adapter TGGAATTCTCGGGTGCCAAGG, the 5' adapter 
AGATCGGAAGAGCACACGTCT, and choose only reads between 18 and 28 
bp in length for assigning to known miRNAs. The default QuickMIRSeq 
settings were used for identifying mouse miRNAs. The QuickMIRSeq output 
file miR.filter.Counts.csv was used for all downstream analyses.  The Principle 
Components Analysis (PCA) plot was made using the plotPCA function in 
DESeq2 (Love, Huber and Anders, 2014) after applying the 
varianceStabilizingTransformation function to the miRNA count data. The 
miRNA count files were then uploaded on the Degust (version 3.1.0) (Powell, 
2015, DOI: 10.5281/zenodo.3258933) web tool for visualisation of differential 
expression analysis. The differential analysis was performed using the 
Voom/Limma method and visualised on Degust. 
 
2.11.5 CLASH data 
Bioinformatic analysis of CLASH data was done by Dr Sujai Kumar. CLASH 
sequencing data quality checks were done the same way as the small RNA 
sequencing data, with initial trimming with Cutadapt, followed by RNA 
assignment with bowtie2. Libraries with 75 base paired-end reads were first 
trimmed as above and then merged using bbmerge.sh (version 37.90) 
(Bushnell, Rood and Singer, 2017) prior to classification to RNA biotypes. 
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Chimeric reads were classified as unmapped in the initial quality check 
because they did not map full-length to any of the RNA biotypes (e.g., miRNA, 
Y_RNA, tRNA, rRNA, etc.). Chimeric reads were identified using the 
CLASHchimeras python pipeline (Chhatbar, 2015, DOI: 
10.5281/zenodo.57076) using Mouse mature miRNA sequences from 
miRBase version 22 as the small RNA database, and Mouse protein-coding 
transcripts from Gencode version M16 as the target RNA database.  
 
2.11.6 Analysis of CLASH chimeric reads 
When the pc part of the chimeric read was less than 55 bp long, this was 
extended to 55 bp for further analysis. Low complexity reads were filtered out 
by using the DUST module (Morgulis et al., 2006). miRNA seed sites were 
identified from the protein coding reads by using a script written by Sujai Kumar 
(https://github.com/sujaikumar/kleinerna/blob/master/seeds_dust_targetfinder
.pl). MIRZA (Khorshid et al., 2013) was used to assign scores to the pairing 
between the miRNA and protein-coding parts of each chimera. The 
TargetScan mouse database version 7.1 (Agarwal et al., 2015) was used to 
check whether the protein-coding part of the chimera was a known miRNA 
target according to TargetScan. Gene Ontology (GO) enrichment analysis was 
performed on the Gene Ontology Research website using a tool from the 
PANTHER classification system (Mi et al., 2013). Functional annotation of 
genes was performed using the bioinformatic resource DAVID (v6.8), selecting 
1-3 GO terms to describe each gene (Huang, Sherman and Lempicki, 2009).  
 
2.11.7 Statistical analysis 










3.1.1 The role of miRNAs in CD8+ T cell activation and differentiation 
 
The expression of miRNAs is dynamically regulated during CD8+ T cell 
activation and cell differentiation to effector and memory cells. The majority of 
miRNAs are downregulated upon activation to relieve suppression on 
molecules required for effector cell differentiation, and expression comes back 
up in memory cells (Wu et al., 2007; Bronevetsky et al., 2013). miRNAs affect 
nearly all aspects of T cell activation, from TCR signalling to cell survival and 
proliferation, and acquisition of effector functions such as cytokine production, 
cytotoxicity and cell migration. Several key miRNAs regulate these processes, 
and it has been shown that deficiency or overexpression of single miRNAs can 
lead to serious defects in T cell activation. 
 
To confirm dynamic regulation of miRNA expression in activated CD8+ T cells 
and to ask how signalling with different affinity antigens might influence miRNA 
expression, we measured this in OT-I TCR transgenic cells. OT-I Rag-/- mice 
are deficient in the Rag1 recombinase required for TCR and BCR 
recombination, thus only express the transgenic OT-I TCR which is MHC Class 
I restricted and recognises a fragment of the ovalbumin protein. OT-I cells can 
be activated in vitro using the agonist peptide SIINFEKL (N4), or modified 
peptides with different affinity to the TCR. The variant peptides SIITFEKL (T4) 
and SIIGFEKL (G4) bind to the OT-I TCR with weaker affinity compared to N4.  
Following activation with the N4 peptide, the cells are grown into fully 
differentiated CTLs by culturing in IL-2, or into memory-like cells by culturing 
in IL-15. Using this system, we studied the expression of five miRNAs in these 
cells: miR-155, miR-17, miR-139, miR-150 and miR-181a. These five miRNAs 
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were chosen because they have been previously shown to have key roles in 
T cell activation and differentiation (Table 3.1).  
 
3.1.2 Upregulated miRNAs: miR-155 and the miR-17~92 cluster 
 
miR-155 and miR-17, a member of the miR-17~92 cluster, are both 
upregulated upon T cell activation and promote cell survival and proliferation. 
miR-155 is indispensable for competent CD8+ T cell mediated immunity: miR-
155 deficiency causes an impaired response to infectious challenge or 
tumours in vivo, with a failure to expand and form long-lasting memory (Dudda 
et al., 2013; Gracias et al., 2013; Lind, Elford and Ohashi, 2013). miR-155 has 
been suggested to regulate responsiveness to type I interferons during viral 
infection (Gracias et al., 2013).  Additionally, miR-155 has been shown to 
inhibit suppressors of cytokine signalling, such as Socs1, Ship1 and Ptpn2 
(Dudda et al., 2013; Ji et al., 2015). miR-155 inhibition of Socs1 was shown to 
be dispensable for CD8+ T cell responses to acute viral infection, but was 
required for the antiviral response in chronic infection (Lu et al., 2015). 
Recently, miR-155 targeting of Ship1 and subsequent upregulation of Akt 
signalling, was shown to have far-reaching effects in the epigenetic silencing 
of transcription factors regulating CD8+ T cell terminal differentiation and 
functional exhaustion during anti-tumour responses (Ji et al., 2019). Increased 
Akt signalling promoted expression of Phf19, which in turn enhanced the 
activity of the epigenetic silencing complex Polycomb repressor complex 2 
(PRC2), which inhibited the expression of pro-differentiation transcription 
factors. This showed how miR-155 indirectly promoted CD8+ T cell anti-tumour 
function through the Phf19-PRC2 axis.  
 
The miR-17~92 cluster is particularly important for cell proliferation, with miR-
17~92 deficient CD8+ cells showing defects in both in vitro and in vivo 
expansion (Wu et al., 2012; Khan et al., 2013). The miRNAs of this cluster 
promote a short-lived effector cell phenotype, with their downregulation 
required for memory cell differentiation (Wu et al., 2012). The effects of the 
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cluster are through direct targeting of Pten, and upregulation of the PI3K-Akt-
mTOR axis (Wu et al., 2012; Khan et al., 2013).  
 
3.1.3 Downregulated miRNAs: miR-139, miR-150 and miR-181 
 
In contrast to these two miRNAs, many miRNAs are more highly expressed in 
naive cells, and their downregulation is required for appropriate cell activation 
and differentiation. For example, miR-139 is strongly downregulated upon 
activation, to allow expression of its targets Eomes and perforin, that are 
important for effector cell differentiation and functions (Trifari et al., 2013).  
 
miR-150 is another miRNA that is downregulated upon TCR stimulation 
(Almanza et al., 2010). This miRNA has been described to have diverse 
targets and functions in naive CD8+ T cells, activated cells, and memory cells. 
In naive cells, miR-150 was recently shown to modulate Ca2+ levels through 
suppression of Tmem20. miR-150 deficiency caused an increase in 
intracellular Ca2+ levels, leading to upregulation of NFAT1 and induction of 
anergy-inducing genes in the absence of TCR stimulation (Kim et al., 2017). 
This led to defects in cell activation, proliferation and effector differentiation 
upon antigenic stimulation, a phenotype that had been previously described 
for miR-150 deficient cells (Smith et al., 2015). Interestingly, miR-150 appears 
to have a different role in memory cells, with miR-150 deficiency increasing 
memory cell differentiation in vitro and in vivo, through modulation of c-Myb 
and Foxo1 expression (Ban et al., 2017; Chen et al., 2017). Overexpression 
of this miRNA skewed the cells towards a short-lived effector phenotype (Chen 
et al., 2017).   
 
Finally, miR-181 plays an important role in the modulation of TCR signalling 
threshold, by increasing sensitivity to weak agonists. The targets of miR-181 
include the phosphatases Shp-2, Ptpn22, Dusp5 and Dusp6, which function to 
limit TCR signalling (Li et al., 2007). High expression of miR-181 in developing 
thymocytes allows positive selection against weak self-peptide agonists. Its 
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expression then decreases in mature T cells to decrease sensitivity to self-
peptides. Inhibition of miR-181 impairs T cell development and resulting 





miRNA Direct targets Overexpression Inhibition/knockout 
miR-155 Socs1 (Dudda et al., 
2013), Ptpn2, Ship1 (Ji et 
al., 2015) 
Improves effector functions 
(Gracias et al., 2013)  
Impairs responses to infection, tumour 
(Dudda et al., 2013; Lind, Elford and 
Ohashi, 2013). Failure to expand and 
impaired memory formation (Dudda et 
al., 2013; Gracias et al., 2013) 
miR- 
17~92 
Pten (Wu et al. 2012) More proliferation in vivo, skewing 
to short-lived effector phenotype 
(Wu et al., 2012; Khan et al., 2013) 
Impaired cell proliferation in vitro and 
expansion in vivo (Wu et al., 2012; Khan 
et al., 2013) 
miR-150 Foxo1 (Ban et al., 2017), 
c-Myb (Chen et al., 2017), 
Cd25 (Trifari et al., 2013), 
Tmem20 (Kim et al., 
2017) 
Reduction in memory formation, 
short-lived effector phenotype 
(Chen et al., 2017) 
Elevated Ca2+ in naive cells (Kim et al., 
2017). Defective activation and effector 
cell differentiation (Smith et al., 2015). 
Preferential differentiation to memory 
cells in vitro and in vivo (Ban et al., 
2017; Chen et al., 2017).  
miR-181 Shp-2, Ptpn22, Dusp5, 
Dusp6 (Li et al., 2007) 
Increased TCR-mediated 
activation (Li et al., 2007) 
Diminished TCR signalling and impaired 
T cell development (Li et al., 2007). 
Maturation of autoreactive cells (Ebert et 
al., 2009) 
miR-139 Perforin, Eomesodermin 
(Trifari et al., 2013) 
Disadvantage during infection, in 
vitro reduction in killing target cells 
(Trifari et al., 2013) 
  
Table 3.1 miRNA function and targets in CD8+ T cells 
Summary of validated targets and functions derived from overexpression/knockdown studies for miR-155, miR-17~92 cluster, miR-





3.2.1 miRNA expression changes during OT-I CD8+ T cell activation 
 
To study the role of miRNAs in CD8+ T cells, we activated OT-I cells with the 
agonist peptide N4 and measured the expression of known miRNA regulators 
of T cell activation during a 6-day time-course. We first assessed the level of 
activation in these cells following in vitro activation with N4 and subsequent 
supplementation of the cultures with IL-2. Two days after activation with N4, 
the cells had upregulated surface activation markers CD25 and CD44, had 
entered cell division as shown by the expression of the proliferation marker 
Ki67, and had also begun expressing the transcription factor T-bet and the 
cytotoxic effector molecule Granzyme B (Fig.3.1). After a further 4 days of 
culture in IL-2, the cells had become fully differentiated CTLs, with increased 
expression of Granzyme B and the transcription factor Eomes (Fig.3.1E-F). 
Next, we measured the expression of miRNAs from naive cells, and at different 
time points following activation with N4.  As expected, miR-155 and miR-17 
were upregulated upon activation (Fig.3.2A). In particular miR-155 was very 
strongly induced, with over 100-fold increase in expression in some 
experiments compared to naive cells. Both miRNAs were up one day after 
activation, and expression slowly decreased during 6 days of culture, 
remaining slightly elevated on day 6. In contrast to these two miRNAs, 
expression of miR-150, miR-139 and miR-181a was downregulated upon 
activation (Fig.3.2B). The expression of these miRNAs was halved on day 1, 
and further decreased during the 6 days in culture. Expression of the five 
miRNAs was therefore shown to dynamically change upon activation, in line 





Figure 3.1 Surface molecules, transcription factors and effector molecules are 
upregulated upon activation of naive OT-I CD8+ T cells with N4 
A-F Expression of CD25 (A), CD44 (B), Ki67 (C), T-bet (D), Eomesodermin 
(E) and Granzyme B (F) measured by flow cytometry in naive OT-I cells (grey), 
OT-I cells activate with N4 for 2 days (dashed red line), or OT-I cells activated 
with N4 for 2 days, then cultured in IL-2 for 4 days (solid red line). Graphs are 





Figure 3.2 miRNA expression changes dynamically upon OT-I CD8+ T cell 
activation  
A-B miRNA expression measured by qPCR during a time-course of OT-I cell 
activation. Cells were activated with N4 for 2 days then cultured in IL-2 for 4 
days. RNA was prepared from snap-frozen cell pellets at the indicated times 
and analysed by qPCR. miRNA expression was normalised to the internal 
control, small nuclear RNA U6 (snU6) and is shown as fold expression relative 
to naive cells. Graphs show mean and standard deviation from 3 independent 




3.2.2 miRNA expression levels depend on the strength of the activating TCR 
signal 
 
Next, we aimed to determine how the strength of the activating TCR signal 
affects miRNA expression. OT-I cells were activated with the strong agonist 
peptide N4 as before, or with the intermediate agonist peptide T4 or weak 
agonist peptide G4. Cell phenotype was examined 24 h after activation by flow 
cytometry, and RNA was extracted for qPCR analysis of miRNAs. Flow 
cytometry confirmed that activation markers such as CD25, CD44 and CD69, 
and transcription factors T-bet and IRF4 were upregulated with all peptides 
compared to naive cells (Fig.3.3A-F). N4 caused the strongest upregulation of 
the activation markers and transcription factors. Activation with T4 resulted in 
an intermediate phenotype, with slightly reduced expression of the above 
markers. Cells activated with G4 were clearly less activated; the cells were 
much smaller in size compared to ones activated with N4 and T4 and the 
expression of all activation markers was lower (Fig.3.3A-F). miRNA expression 
also differed between cells activated with N4, T4 or G4. miR-155 was induced 
by all peptides, with N4 causing the highest upregulation, followed by T4 then 
G4 (Fig.3.4A). miRNA downregulation was also affected by strength of the 
activating signal, with stimulation with N4 resulting in strongest 
downregulation, followed by T4 then G4, which was, in most cases, insufficient 
to cause downregulation of the measured miRNAs (Fig.3.4B-D). The only 
statistically significant difference in miRNA expression between the peptide 
stimulations was expression of miR-139 following activating with N4 vs G4. 
Statistical significance was not reached in most cases due to high variance in 
the fold induction of miRNAs from experiment to experiment, but the trend was 
the same in all three replicates (lowest point in each graph corresponds to the 
same experiment). These results show that the strength of the initial activating 
T cell signal affects miRNA up – and downregulation. Cells activated with 
weaker agonist peptides show a less activated phenotype, corresponding with 






Figure 3.3 Expression of activation markers and transcription factors following 
CD8+ T cell activation depends on strength of activating signal 
A-F Expression of surface markers and transcription factors in naive OT-I cells 
or following OT-I cell activation with N4, T4 or G4. After 24 h, flow cytometry 
was used to measure cell size (A), and expression of CD25 (B), CD44 (C), 
CD69 (D), T-bet (E) and IRF4 (F). Graphs are representative of 3 independent 







Figure 3.4 miRNA expression depends on strength of activating TCR signal 
A-D Expression of miR-155 (A), miR-150 (B), miR-139 (C) and miR-181a (D) 
measured by qPCR from naive OT-I cells and cells activated for 24 h with N4, 
T4 or G4. miRNA expression was normalised to snU6 and is shown as fold 
expression relative to naive cells. The graphs show mean and standard 
deviation from 3 independent experiments alongside adjusted P values. 
Statistical analysis was done using an ordinary one-way ANOVA with Tukey’s 
multiple comparisons test, to compare the conditions N4 vs. T4, N4 vs. G4 and 




3.2.3 Downregulated miRNAs are re-expressed in memory-like cells 
 
Memory cells, similar to naive cells, have been previously shown to have an 
increased global expression of miRNAs compared to effector cells. We wanted 
to determine how the expression of miRNAs changes during in vitro 
differentiation of effector cells grown in IL-2, or memory-like cells differentiated 
in IL-15. OT-I cells were activated with N4 for 2 days, then cultured with IL-2 
or IL-15 for 4 days. Effector or memory phenotype was confirmed by flow 
cytometry on day 6. Cells grown in IL-2 expressed more CD25, CD44 and the 
cytotoxic molecule Granzyme B, and produced proinflammatory cytokines 
IFNγ and TNFα upon re-stimulation with N4 (Fig.3.5A-F). IL-15 grown cells 
expressed lower levels of activation markers, produced less Granzyme B and 
proinflammatory cytokines, and expressed the secondary lymphoid organ 
homing receptor CD62L (Fig.3.5A-F). miRNA expression was measured in 
fully differentiated effector and memory-phenotype cells on day 6. The 
expression of miR-155 and miR-17 did not significantly differ between the 
effector and memory-like cells. Both miRNAs were induced by N4 and 
expression gradually reduced in culture with both IL-2 and IL-15. The 
expression of these miRNAs remained higher than in naive T cells for both 
effector and memory-like cells on day 6 (Fig.3.6A-B). miR-150, miR-139 and 
miR-181a were previously shown to be downregulated upon activation with 
N4, and to further decrease in expression in culture with IL-2 (Fig.3.2). Culture 
in presence of IL-15 resulted in re-expression of these miRNAs after the initial 
downregulation caused by activation. After 4 days of culture with IL-15, the 
expression of these miRNAs had returned to levels comparable to naive cells 
(Fig3.6C-E). These results show that there is differential regulation of miRNA 






Figure 3.5 Addition of cytokines to culture media can be used to differentiate 
effector or memory-like cells in vitro 
A-F Expression of surface markers and effector molecules in OT-I cells 
activated in N4, then cultured in IL-2 for 4 days for differentiation to effector 
cells, or cultured in IL-15 for 4 days for memory-like cells. On day 6, expression 
of C25 (A), CD44 (B), CD62L (C) and Granzyme B (D) was measured by flow 
cytometry. Expression of IFNγ (E) and TNFα (F) was measured following 4 h 
re-stimulation with N4 in the presence of Brefeldin A. Graphs are 





Figure 3.6 Differentiation to effector or memory-like cells alters miRNA 
expression 
A-E Expression of miR-155 (A), miR-17 (B), miR-150 (C), miR-139 (D) and 
miR-181a (E) was measured by qPCR from naive cells, and on day 6 from IL-
2 and IL-15 differentiated cells. Expression was normalised to snU6 and is 
shown as fold expression relative to naive cells. The graphs show mean and 
standard deviation from 4 independent experiments alongside adjusted P 
values. Statistical analysis was done using an unpaired two-tailed student’s t-








3.3.1 Regulation of miRNA expression  
 
The expression of the five studied miRNAs changed dramatically upon CD8+ 
T cell activation, depending on the strength of the activating signal and 
cytokines guiding cell differentiation. As previously reported, miR-155 and 
miR-17 were strongly induced upon activation. These, alongside other 
miRNAs of the 17~92 cluster and miR-21 are among the few miRNAs have 
been shown to be upregulated in activated T cells, with the majority of miRNAs 
downregulated (Wu et al., 2007; Bronevetsky et al., 2013). This was the case 
for miR-150, miR-139 and miR-181a, which all decreased in expression. 
miRNA expression can be regulated on the transcriptional level, through post-
transcriptional regulation of miRNA processing or by mature miRNA 
homeostasis, stability and loading onto RISC. Transcription factors can affect 
the expression of specific miRNAs, for example Myc and NF-κβ have been 
shown to bind miRNA promoters, with miRNAs often forming reciprocal 
negative feedback loops (Chang et al., 2008; Boldin and Baltimore, 2012). 
Globally, miRNA turnover has been shown to be accelerated in activated CD4+ 
T cells with continuous production of new miRNAs and Ago-proteins coupled 
with degradation (Bronevetsky et al., 2013). 
 
3.3.2 The effect of TCR signal strength on miRNA expression  
 
The strength of the activating TCR signal was shown to influence the extent of 
miRNA up-and downregulation. The cells activated with T4 showed 
intermediate changes in expression, whereas those activated with the weakest 
agonist G4 were similar to naive cells in their miRNA expression. This trend 
was clear for all the miRNAs studied, even though statistical significance was 
only reached in the case of miR-139. The cells activated with G4 exhibited a 
much less activated phenotype, compared to cells activated with N4 and T4. 
This presented as smaller cell size and lower expression of activation markers 
and the transcription factors T-bet and IRF4. This phenotype could be the 
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cause or the effect of the reduced miRNA downregulation. The activating 
signals provided by G4 may not be sufficient to activate the pathways normally 
leading to changes in miRNA expression. The altered miRNA expression could 
also subsequently contribute to the less activated phenotype of the cells 
activated with T4 or G4. For example, failure to downregulate miR-139 could 
lead to inhibition of its described targets Eomes and perforin, required for CTL 
function. Contrarily, failure to upregulate miR-155 could lead to increased 
expression of its targets, such as inhibitors of cytokine signalling. miR-155 
expression has previously been shown to be stronger with N4 compared to T4, 
in agreement with our findings (Dudda et al., 2013). This has been shown to 
be biologically relevant in the context of tumour clearance, in a study that 
compared miR-155 expression in OT-I T cells isolated from N4 and T4 
expressing B16 tumours. OT-I cells from the T4-tumours had lower expression 
of miR-155 compared to cells from N4 tumours, and low levels of miR-155 
expression were shown to correlate with bigger tumour volume for the T4-
tumours consistent with reduced effector function in cells with lower miR-155 
expression (Martinez-Usatorre et al., 2019).  
 
As well as the regulation of miRNA expression by TCR signal strength (as 
shown for miR-155), miRNAs can also influence the strength of TCR signalling. 
High levels of miR-181 in immature thymocytes increase TCR signalling 
through inhibition of phosphatases, allowing positive selection to take place (Li 
et al., 2007). In naive mature T cells miR-181 levels are decreased to adjust 
the threshold of TCR signalling and allow discrimination between strong and 
weak agonists. We showed that expression of miR-181 further decreases upon 
T cell activation, depending on the activating peptide. 
 
3.3.3 miRNA expression during effector and memory cell differentiation 
 
Various miRNAs have been shown to influence CD8+ T cell effector and 
memory cell differentiation. Expression of miR-155 is important for both 
effector functions and for mounting long-lasting memory (Dudda et al., 2013; 
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Gracias et al., 2013). miR-17~92 cluster is also required for effector cell 
responses, however its overexpression leads to skewing to a short-lived 
effector phenotype compromising memory formation (Wu et al., 2012; Khan et 
al., 2013). Similarly, overexpression of miR-150 has been shown to 
compromise CD8+ T cell memory (Chen et al., 2017).  
 
During in vitro activation of OT-I cells, upregulation of miR-155 and miR-17 
appeared to be transient, with levels slowly returning to baseline when cells 
were kept in culture, either with IL-2 or IL-15. This suggests that during in vitro 
activation, these miRNAs are important for the early events upon activation, 
causing inhibition of factors normally prohibiting cell proliferation and effector 
function. miR-139, miR-150 and miR-181a were downregulated upon 
activation and remained low in effector cells cultured in IL-2. However, culture 
in IL-15 lead to re-expression of these miRNAs. Memory cells have been 
previously shown to have a similar miRNA profile to naive cells (Wu et al., 
2007). The inhibition of the targets for these miRNAs was therefore potentially 
required to maintain the effector phenotype, but no longer needed when the 
cells acquired a memory-like phenotype. miR-155, miR-17 and miR-150 have 
all been described complex roles in effector and memory cell differentiation in 
vivo which are probably not recapitulated in the in vitro system based on 
signals from IL-2 versus IL-15. Differential expression of miRNAs has been 
previously studied in IL-2 and IL-15 differentiated CD8+ T cells (Almanza et al., 
2010). In line with our results, the expression of miR-150 but not miR-155 was 
shown to increase with IL-15. From their findings the authors suggested that a 
miR-150high, miR-155low phenotype guides the cells towards a central memory 
phenotype. In vivo studies have however since showed that miR-150 
overexpression causes a short-lived effector phenotype and miR-155 
deficiency impairs memory formation, highlighting the fact that miRNA 
expression in an in vitro setting may not always be representative of its 




miRNA function is regulated not only through their expression, but also through 
changes in the formation of RISC and expression of miRNA-associated 
proteins. To further understand the role of miRNAs in T cell activation, we next 
studied changes in the expression of RISC-interacting proteins and miRNA 









miRNAs bind and suppress their target mRNAs in the Ago-containing RISC. 
RISC is guided by the miRNA to its target mRNA through sequence-
complementarity between the miRNA seed region and the mRNA 3’ UTR. This 
leads to suppression of target gene expression, either by mRNA degradation 
or translational repression (O’Connell et al., 2010). Ago proteins are a core 
component of RISC and mediate target suppression either directly or through 
recruitment of other mRNA silencing effector molecules. Four Ago proteins 
exist in mammals, Ago-1-4, all of which bind miRNAs and can repress their 
target genes. Ago-2 differs from the other three by its endonucleolytic activity 
that allows direct cleavage of target mRNAs (Tuschl et al., 2004).  
 
Ago forms large multi-protein complexes with its interactors to mediate miRNA 
target suppression. A key interactor is GW182, that binds Ago PIWI region 
through its N-terminal GW-repeats (Lian et al., 2009; Elkayam et al., 2017). 
Knock-down of GW182 has shown that this interaction is essential for miRNA 
suppressive function (Eulalio, Huntzinger and Izaurralde, 2008; Lian et al., 
2009). GW182 functions as a scaffold protein recruiting RNA metabolism 
factors to RISC through its C-terminal domains. These GW182-binding 
proteins include poly(A) binding proteins (e.g. PABPC1), deadenylases (e.g. 
PAN2/3, CCR4/NOT), decapping proteins (e.g. DCP1/2) and exonucleases 
(XRN1), which together cause miRNA target gene silencing (Fabian and 
Sonenberg, 2012). GW182 is part of the TNRC6 (trinucleotide repeat-
containing protein 6) family of proteins encompassing TNRC6A (also known 
as GW182), TNRC6B and TNRC6C. The three paralogues share a conserved 
domain structure: all three proteins can bind Ago and have redundant functions 
in mediating miRNA silencing (Lazzaretti, Tournier and Izaurralde, 2009). 
Furthermore, several isoforms of GW182 exist. In mice, two alternatively 
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spliced isoforms are predicted; a full-length protein of 203kDa and a shorter 
splice-variant at 150kDa, missing the first five exons (Fig.4.1). Both isoforms 
contain the domains required for Ago binding and miRNA target silencing. The 
human protein has also been described to have at least three isoforms, named 
GW220/TNGW1, GW195 and GW185 after their molecular weights (Castilla-
Llorente et al., 2012). GW220 and GW195 transcripts contain additional exons 
at the N-terminus compared to GW182. GW220 and GW182 appear to be 
functionally similar, with both isoforms inducing mRNA degradation and 
translational repression to a comparable extent (Li et al., 2008).  
 
 
Figure 4.1 GW182 isoforms 
A graphical representation of the two isoforms from the GW182 gene in 
mouse. The blocks represent exons and the lines introns. The length of the 
introns has been reduced 10-fold for better visualisation of the exons.  
 
In T cells, GW182 expression has been shown to be induced upon activation 
(La Rocca et al., 2015). The other two GW182 paralogues TNRC6B and 
TNRC6C are also expressed in T cells. Analysis of existing proteomics data 
from P14 CD8+ T cells (Howden et al. 2019) indicated that expression of all 
three paralogues increases during CD8+ T cell activation, with a drastic 38-fold 
increase in copy number of GW182, and a more modest 5-fold and 3-fold 
change for TNRC6B and TNRC6C, respectively. TNRC6B was however the 
most abundant isoform in activated T cells with an average of ~16,000 copies 
in activated cells, compared to ~6,000 average copies of TNRC6A. However, 
it has been previously shown, that knock-down of GW182 but not TNRC6B or 
TNRC6C in T cells compromised miRNA suppressive function (La Rocca et al. 
2015). In naive T cells, in which GW182 is not expressed, Ago is predominantly 
found in LMW RISC (La Rocca et al., 2015). Upon activation, TCR signalling 
leads to GW182 protein upregulation, interaction with Ago and formation of 
HMW RISC. miRNAs that were associated with HMW RISC were shown to 
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have an increased suppressive capacity compared to those found in LMW 
RISC (La Rocca et al., 2015). Association with different Ago-complexes may 
therefore regulate miRNA function. We aimed to further study the formation of 
HMW and LMW RISC in activated CD8+ T cells, and to characterise the 






4.2.1 Ago-2 expression during CD8+ T cell activation 
 
To measure Ago-2 expression during CD8+ T cell activation, OT-I T cells were 
activated with N4 for 2 days, then the cultures were supplemented with IL-2 
for 4 days. Cells were collected for western blotting (WB) before activation, on 
day 1 (d1) and d2 after adding N4, then 2 and 4 days after addition of IL-2 (d4 
and d6). Ago-2 expression was quantified using ZAP-70 as a loading control. 
The expression of most proteins increases upon CD8+ T cell activation due to 
an increase in global protein production and cell size. As expected, the total 
amount of Ago-2 per cell increased after activation, as did that of ZAP-70 
(Fig.4.2A). When loading was normalised by adding the same concentration 
of protein per well for each of the samples, the relative abundance of Ago-2 
was found to be gradually decreasing after activation, during 6 days of culture 
(Fig.4.2B-C).  This decrease was only statistically significant on day 6 
(p=0.045) most likely due to the high variance arising from pooled data from 





Figure 4.2 Ago-2 is expressed in naive and activated CD8+ T cells 
A-C OT-I cells were activated with N4 for 2 days then cultured with IL-2 for 4 
days. Cells were lysed and 5 x 105 cells (A) or 7 µg of protein (B) were loaded 
for western blotting. Relative abundance of Ago-2 was quantified from B by 
measuring band intensity of Ago-2 normalised to the loading control ZAP-70.  
The relative abundance is shown in C as expression relative to naive cells. 
The graph is showing the mean and standard deviation from three biological 
replicate experiments. Statistical analysis was performed by doing a one 
sample t-test comparing each activated time-point to the hypothetical mean 1.  




4.2.2 GW182 expression in CD8+ T cells and its interaction with Ago-2 
 
GW182 has been previously shown to be a key interactor of Ago and an 
important component of RISC. We therefore aimed to confirm the expression 
of GW182 in OT-I T cells and to study the dynamics of its interaction with Ago-
2 following T cell activation. First, we measured the expression of Ago-2 and 
GW182 mRNA. RNA was extracted from naive cells, and at different 
timepoints after activation with N4. Ago-2 mRNA expression remained 
unchanged during 6 days of culture (Fig.4.3A). However, GW182 mRNA was 
upregulated at 24 hours, and remained higher at later time-points compared 
to naive cells (Fig.4.3B). We also confirmed expression of GW182 in activated 
cells by immunoprecipitation (IP) of GW182 or Ago-2 from d6 activated cells. 
In the input lysate, probing with anti-GW182 antibody revealed several bands 
around the correct molecular weight. In the GW182 IP with the same antibody 
there was enrichment of two clear bands, both between 150-250 kDa 
(Fig.4.3C). The mouse GW182 isoforms have predicted molecular weights of 
150 kDa and 203 kDa, whereas the human protein has at least three isoforms 
at 220, 195 and 182 kDa. The two bands may therefore correspond to the 203 
kDa large isoform and a previously uncharacterised isoform, or the shorter 150 
kDa isoform running at a higher molecular weight than expected. The other 
bands seen in the WB of the total input lysate could be non-specific 
interactions with the polyclonal anti-GW182 rabbit antibodies. The two bands 
also co-immunoprecipitated with Ago-2 in the Ago-2 IP, further supporting that 
these are genuine GW182 isoforms (Fig.4.3C). Alignment of the protein 
sequence of GW182 with its two paralogues TNRC6B and TNRC6C showed 
poor conservation of the region recognised by the GW182 antibody, making it 








Figure 4.3 GW182 is expressed and binds Ago-2 in activated CD8+ T cells 
A-B Ago-2 and GW182 mRNA expression during OT-I T cell activation 
measured by qPCR from samples taken at indicated time-points. The Ct 
values were normalised to snRNA U6 to obtain delta Ct values. The graph is 
showing mean and standard deviation from three technical replicates. Data 
are representative of two independent experiments.  
C Western blot showing Ago-2 and GW182 expression in input lysate, GW182 
and Ago-2 IPs and unbound fractions from d6 activated CTLs. GW182 was 
immunoprecipitated with a rabbit polyclonal antibody and Ago-2 was 
immunoprecipitated with a mouse monoclonal antibody. The input, IP and 
unbound samples were run on a gel for western blotting, probed again with the 
same GW182 and Ago-2 antibodies and fluorescently labelled secondary 
antibodies, then visualised on a western blot imaging scanner. Data are 






After confirming the expression of GW182 and its association with Ago-2 in 
activated CD8+ T cells, we followed this interaction during a time-course of T 
cell activation with the aim to determine the stoichiometry of binding between 
GW182 and Ago-2 in naive and activated cells. We undertook a series of Ago-
2 and GW182 IPs to confirm that the binding of the two proteins was specific 
to activated cells. Ago-2 IP efficiently pulled down Ago-2 from both naive and 
activated cells, as almost no Ago-2 was detected in the WB of the unbound 
fraction (Fig.4.4A). GW182 was not detected in the Ago-2 IP from naive cells 
but could be pulled down in the Ago-2 IP from activated cells. Next, we 
immunoprecipitated GW182. In naive cells, the GW182 IP potentially pulled 
down a small amount of the longer isoform, not detected from the Ago-2 IP 
(Fig.4.4A). All Ago-2 however remained in the GW182 unbound fraction, 
confirming that the interaction was specific to activated cells. In activated cells, 
Ago-2 distributed between GW182-bound and unbound fractions. 
 
The amount of GW182 that co-immunoprecipitated with Ago-2 was quantified 
from a time-course of cell activation (Fig.4.4B). The amount of GW182 relative 
to Ago-2 was at its highest soon after activation, on d1-d2 (Fig.4.4C). The 
interaction was however detectable during 6 days in culture. Two isoforms 
could be detected, with the shorter isoform being predominant in the Ago-2 IP 
on d4-d6 (Fig.4.4C). Both isoforms could be detected equally from the GW182 
IP on day 6, suggesting Ago-binding of one isoform may specifically be 
reduced (Fig.4.4A). Based on the previous results, not all Ago-2 was engaged 
in a complex with GW182 in activated cells, and we next attempted to 
determine what this proportion was. We quantified Ago-2 from GW182 IP 
bound and unbound fractions and showed that approximately 40% of Ago-2 
was bound to GW182 with 60% remaining unbound (Fig.4.4D, E). The amount 
of GW182-bound Ago-2 appeared at its highest at earlier timepoints, but this 
trend was however not replicated in a repeat experiment. Unfortunately, due 
to the background noise of the anti-GW182 antibody we were unable to do the 
reciprocal calculation and accurately quantitate the proportion of GW182 that 




Figure 4.4 Dynamics of Ago-2 and GW182 interaction upon T cell activation 
Immunoprecipitations using a polyclonal rabbit GW182 antibody and a 
monoclonal mouse Ago-2 antibody. All WBs were probed with the same 
antibodies that were used for the IPs. Ago-2-flag mice were used for these 
experiments apart from D-E. 
A Ago-2 and GW182 were immunoprecipitated from naive and d6 activated 
cells. Input lysate, unbound fraction, and eluted IP samples are shown on a 
WB probed with the Ago-2 and GW182 antibodies. 
B-C Ago-2 was immunoprecipitated from OT-I T cell lysates taken at the 
indicated time points. The eluted IP samples are shown on a WB probed with 
Ago-2 and GW182 antibodies (B). GW182 relative abundance was quantified 
by measuring GW182 band intensity (as sum of the two bands) relative to Ago-
2 band intensity and is shown normalised to expression on d2 (C). The 
proportions of the two GW182 bands were also calculated. Mean and standard 
deviation from two independent experiments are shown.  
D-E GW182 was immunoprecipitated from lysates taken at the indicated time-
points. The unbound fraction was used for an Ago-2 IP. The eluted IP fractions 
are shown on a WB probed with Ago-2 and GW182 antibodies (D). Amount of 
Ago-2 found in GW182 IP or Ago-2 IP from GW182 unbound fraction was 
quantified and is shown normalised to expression on d2 (E). Mean and 
standard deviation from two independent experiments is shown.  
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4.2.3 Formation of HMW and LMW RISC during CD8+ T cell activation 
 
Ago-2 has been previously shown to form a HMW RISC containing GW182 in 
activated T cells. We wanted to see if the GW182-bound Ago-2 corresponded 
to HMW RISC. Size exclusion chromatography was used to separate protein 
complexes by size from naive and d2 activated OT-I T cells. Large complexes 
were eluted in the first fractions, followed by intermediate sized complexes and 
lastly uncomplexed proteins. Proteins were precipitated from the different size 
fractions, and Ago-2 was detected by WB. In naive cells, Ago-2 was found 
predominantly in LMW fractions, whereas in activated cells it could be detected 
from both low and high MW fractions (Fig.4.5A-B). In fact, Ago-2 could be 
detected from a range of fractions from low to intermediate to high.  
 
GW182 was previously reported to be an important component of HMW RISC 
in activated T cells. To confirm interaction of Ago-2 with GW182 in HMW RISC, 
Ago-2 was immunoprecipitated from the fractions. Based on the WB, we 
pooled fractions corresponding to ‘HMW’, ‘intermediate’ and ‘LMW’ complexes 
in activated cells, and ‘LMW’ in naive cells. GW182 was shown to co-
immunoprecipitate with Ago-2 from the HMW complex, whereas a weak signal 
was seen from the intermediate complexes, and no signal from the LMW 
complex from either the naive or the activated cells (Fig.4.5C). These findings 
confirm that Ago-2 is found in a non-GW182 bound LMW RISC in naive cells. 
LMW complex is also present in activated cells, but Ago-2 but can additionally 





Figure 4.5 Ago-2 forms HMW RISC with GW182 in activated CD8+ T cells 
A-B Protein elution curves and WB from size exclusion chromatography 
fractions. Fractions were obtained by running naive or d2 activated cell lysate 
through a Superose 6 gel filtration column. 0.5 mL fractions were eluted from 
the column and protein content was measured by absorption at 280 nm (shown 
in milli-Absorption Units). Protein was precipitated from the fractions and used 
for western blotting to detect Ago-2. Dashed lines in A and B indicate location 
of HMW and LMW Ago-2 in the elution profile, corresponding to the WB.  
C Ago-2 was immunoprecipitated from HMW, intermediate and LMW fractions, 
pooled together as indicated in the WBs in A-B. The eluted IP samples are 
shown on a WB probe with Ago-2 and GW182 antibodies. Ago-2-flag mice 
were used for this experiment. 
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4.2.4 Blocking Ago-GW182 binding with a peptide  
 
To determine whether the interaction between Ago and GW182 was required 
for T cell activation, we attempted to block their binding. We designed a 
peptide based on the Ago binding sequence of GW182. GW182 has been 
described to have three Ago binding sites, motif 1, motif 2 and the hook motif 
(Elkayam et al., 2017). Each of these peptide motifs was previously shown to 
bind Ago in vitro and could displace other peptides from Ago in titration 
experiments. We designed our peptide based on motif 1. To get the peptide 
into our cells, we linked the Ago binding motif sequence to the sequence of a 
described translocating peptide TP2. This translocating peptide sequence was 
shown to transport molecular cargo across cell membranes through 
spontaneous translocation (He et al., 2013). We named this the GW TP2 
peptide, and also designed a control peptide with key Ago binding residues 
mutated to alanine residues (Fig.2.1). To test the function of the peptides, we 
made lysates from d2 activated OT-I T cells and and incubated these with the 
peptides during an Ago-2 IP for 6 h, with the intention to displace GW182 from 
Ago-2. After the 6 h IP, we eluted the samples and visualised these on a WB 
probed with Ago-2 and GW182 antibodies. GW182 co-immunoprecipitated 
with Ago-2 as expected, but addition of the GW TP2 at 10 µM or 50 µM did not 
reduce the amount of co-immunoprecipitating GW182 (Fig.4.6). No GW182 
could be detected from the unbound fractions.  
 
Potentially, the peptide was not strong enough to displace GW182, as it had 
previously only been shown to displace other short peptides (Elkayam et al., 
2017). It is possible that the concentration of the peptide may not have been 
high enough to displace GW182, or addition of the TP2 sequence may have 
altered the binding of the peptide. Since we did not see any reduction in Ago-
2 and GW182 binding in vitro, we did not expect the peptide to have a 
significant effect when delivered to live cells, thus decided not to pursue this 






Figure 4.6 GW TP2 does not block Ago-2 and GW182 binding in an Ago-2 IP 
Ago-2 IPs and unbound fractions from d2 activated OT-I T cells shown on a 
western blot probed with Ago-2 and GW182 antibodies. GW TP2 or control 
TP2 were added directly to the lysates and incubated for 6 h during Ago-2 IP 





4.3.1 Summary of findings 
 
These experiments show that GW182 is not expressed, or is very weakly 
expressed, in naive CD8+ T cells but is upregulated upon activation. The 
protein was quickly recruited to RISC after activation and remained bound to 
Ago-2 during 6 days of culture. In activated cells, Ago-2 was found associated 
and non-associated with GW182. Approximately 40% of Ago-2 was found to 
be engaged with GW182 in activated cells, with 60% remaining unbound. Size 
exclusion chromatography also confirmed the presence of a GW182-non-
associated LMW RISC, and a GW182-associated HMW RISC in activated 
cells.  
 
4.3.2 Changes in Ago expression 
 
The availability of miRNA-associated protein machinery changes upon T cell 
activation. In CD4+ T cells, a previous study showed ubiquitination and 
degradation of all Ago proteins upon cell activation, which was suggested to 
cause global downregulation of miRNAs (Bronevetsky et al., 2013). In CD8+ T 
cells, a gradual decrease in the relative amount of Ago-2 per cell could be 
noted in the 6 days following activation, with statistical significance reached on 
day 6. However, unlike shown for CD4+ T cells, the protein was not completely 
degraded as it could still be readily detected from both naive and activated 
cells. Since we did not measure expression in CD4+ T cells, it is unclear 
whether this is a difference between the types of T cells, or a difference in 
experiments, for example the method of activation (cognate peptide versus 
anti-CD3/28 antibody). Other studies have also shown expression of Ago-2 in 
both naive and activated T cells (composed of a mix of CD4+ and CD8+ cells) 




4.3.3 Ago-interacting proteins and RISC composition 
 
Association of Ago-2 with other proteins changes dramatically upon T cell 
activation. We showed that in agreement with previous work, Ago-2 binds 
GW182 in activated cells (La Rocca et al., 2015). Two isoforms of GW182 co-
immunoprecipitated with Ago-2, with the shorter isoform being the 
predominant one. Several isoforms of GW182 have been reported in human 
cells and these were shown to have redundant functions (Li et al., 2008; 
Castilla-Llorente et al., 2012). The longest human isoform, GW220 contains 
N-terminal polyQ-repeats not present in the other isoforms, and it has been 
suggested these may influence protein-protein interactions, and could play a 
role in the localisation of RISC in processing bodies (P-bodies) versus the 
cytoplasm (Castilla-Llorente et al., 2012). These polyQ repeats are also 
conserved on the 203 kDa mouse GW182, but not the 150 kDa isoform. 
 
Approximately 40% of Ago-2 was bound to GW182 in activated cells, with the 
rest remaining unbound. Ago-2 IP from size fractionated samples showed that 
GW182-unbound Ago-2 was predominantly found in LMW or intermediate size 
complexes, whereas GW182-bound Ago-2 formed HMW RISC. Some GW182 
signal could also be detected from the intermediate size complexes, 
suggesting these may be smaller complexes composed of only Ago-2 and 
GW182, whereas HMW RISC contains additional proteins. These intermediate 
complexes could be precursors of the HMW RISC, or a separate complex 
composed of different proteins. Different sized Ago-complexes have been 
previously separated by sucrose gradients, and proteomic analysis of these 
showed differences in the protein composition of these complexes (Höck et al., 
2007). RISC-associated proteins can for example include Dicer, mRNA 
metabolism factors and ribosomal proteins. Dicer was found to associate with 
a low density Ago complex, in which miRNA loading to RISC occurs. This 
complex was separate from the effector miRNA complexes to which Ago was 
recruited after miRNA loading (Höck et al., 2007; Landthaler et al., 2008). 
Proteins involved in gene silencing, mRNA binding and RNA metabolism were 
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found in intermediate to large Ago-complexes (Höck et al., 2007). Larger Ago 
complexes were also shown to co-sediment with ribosomal proteins and 
polysomes (Landthaler et al., 2008). Depletion of ribosomal proteins has been 
shown to reduce miRNA mediated suppression, and lead to a shift of miRNA 
targeted transcripts from monosomes to polysomes (Janas et al., 2012). The 
GW182 containing HMW RISC separated by size exclusion chromatography 
was also shown to contain RNA metabolism factors such as PABP1 and 
ribosomal proteins and rRNA (La Rocca et al., 2015). 
 
4.3.4 Regulation and function of different RISC complexes 
 
Mitogenic stimuli such as growth factors and glucose have been shown to 
regulate the formation of LMW and HMW RISC in immortalised IL-3 dependent 
haematopoietic cells and mouse embryonic fibroblasts. Withdrawal of growth 
factors or glucose resulted in decreased expression of GW182 and formation 
of a LMW RISC, whereas reintroduction led to reincorporation of miRNA-Ago 
complexes to functional HMW RISC (Olejniczak et al., 2013). As opposed to 
de novo synthesis of a HMW RISC, this complex was shown to be formed from 
LMW RISC following specific signalling, demonstrating the dynamic nature of 
these associations. In Drosophila, mitogenic signals were also shown to alter 
RISC composition. A constitutively expressed RISC named G-RISC was 
shown to be composed of Ago-1 and GW182. Mitogenic signals led to the 
formation of an alternative complex named P-RISC, that associated with 
polysomes and did not include GW182. The authors suggested that both 
complexes caused mRNA translational repression through different means, G-
RISC inhibiting translation initiation, and P-RISC elongation (Wu, Isaji and 
Carthew, 2013).  
 
In T cells, TCR signalling causes upregulation of GW182 and formation of 
HMW RISC, possibly through the mTOR pathway (La Rocca et al., 2015). 
These changes in RISC composition are likely to have important 
consequences for miRNA function.  Most miRNAs are downregulated upon T 
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cell activation. However, the specific induction of GW182 and the formation of 
HMW RISC upon cell activation suggests that miRNA function is not shut 
down. Instead, miRNA function might indeed increase irrespective of 
expression changes, if recruited to HMW RISC, which contains GW182 and 
other silencing effector proteins. To further understand the role of HMW RISC 
in activated T cells, we next isolated HMW and LMW RISC bound miRNAs and 










After confirming the formation of HMW RISC and LMW RISC in activated CD8+ 
T cells, we aimed to identify which miRNAs are associated with the two 
complexes. We attempted to determine whether miRNAs were evenly 
distributed between HMW and LMW RISC in activated cells or whether specific 
miRNAs were found enriched within HMW RISC. In Chapter 3 we noted drastic 
changes in miRNA expression upon T cell activation and wanted to see how 
these related to miRNA distribution between HMW and LMW RISC. It was 
previously reported, that while majority of miRNAs were downregulated upon 
T cell activation, their occupancy in HMW RISC increased in activated cells, 
compared to naive cells (La Rocca et al., 2015). This study also suggested 
that the shift to HMW RISC varied for individual miRNAs. Many miRNAs that 
were downregulated upon activation, were found in HMW RISC in activated 
cells and were shown to be actively suppressing their targets. These included 
miRNAs of the let-7 family and miR-15/16 family, that were shown to have an 
increased ability to suppress a reporter construct in activated cells despite 
downregulation in expression. Consequently, instead of miRNA expression 
changes, presence in HMW RISC may be more predictive of miRNA biological 
function. We therefore aimed to identify the involvement of miRNAs in 
regulating activated CD8+ T cells by measuring differential miRNA abundance 
in naive versus activated cells, along with miRNA distribution between HMW 







5.2.1 Generation of small RNA libraries from HMW and LMW RISC 
 
To identify which miRNAs were associated with Ago-2 in naive and activated 
cells, we activated OT-I cells with N4 for 2 days and collected samples for Ago-
2 IPs. Ago-2 was immunoprecipitated from three biological replicates of naive 
cells, and for two of these we had a corresponding activated sample. In 
addition, two replicates of Ago-2 IPs from activated cells were also included 
from a separate experiment.  Ago-2 was efficiently immunoprecipitated from 
all the input lysates (Fig.5.1A-B). GW182 co-immunoprecipitated with Ago-2 
from activated, but not naive cells, as expected (Fig.5.1A-B). As a control, we 
performed an IP from activated cells with mouse IgG antibody. As expected, 
Ago-2 was found in the input, but remained in the unbound fraction following 
IgG IP (Fig.5.1B). Similarly, no GW182 was pulled down from the IgG IP.  
 
We also wanted to separate HMW and LMW RISC in the activated cells, to 
identify which miRNAs were associated with each. Three more biological 
replicates of day 2 activated cells were prepared for size exclusion 
chromatography to separate HMW and LMW RISC. Following the size 
separation, protein was precipitated from the fractions and used for a WB to 
detect Ago-2. This showed presence of Ago-2 in high, intermediate and low 
molecular weight fractions (Fig.5.1C). The HMW and LMW fractions were 
pooled and Ago-2 was immunoprecipitated from these. A small amount of 
immunoprecipitated material was used for a WB, and as expected, GW182 co-









Figure 5.1 Ago-2 IPs from naive cells, activated cells, HMW RISC and LMW 
RISC 
A-B WBs from input, Ago-2 IP and unbound fractions from naive and d2 
activated OT-I cells. Blots probed with Ago-2 and GW182 antibodies. Three 
biological replicates are shown for naive and activated cells. 
C WB from protein precipitated from size exclusion fractions. Blot probed with 
Ago-2 antibody. One replicate is shown as representative of all three.  
D Ago-2 IP from the pooled HMW (lanes 2-3) and LMW (lanes 10-12) fractions 
shown in C. WB probed with Ago-2 and GW182 antibodies. All three biological 
replicates are shown.  




Next, we isolated RNA that was present in the cell input, the Ago-2 IP and the 
Ago-2 unbound fraction from naive cells and activated cells. For the size 
fractionated samples, we also isolated RNA from the from the HMW and LMW 
fractions prior to the Ago-2 IP (input), the Ago-2 IP and then Ago-2 unbound 
fractions. Once RNA was purified from all of the Ago-2 IPs, as well as the input 
for each IP and the unbound fractions, small RNA libraries were prepared from 
each sample. 3’ and 5’ adapters were ligated to the RNA, which was then 
reverse transcribed and amplified by PCR. The prepared input, Ago-2 IP and 
unbound libraries were pooled and run on TBE gels (Fig.5.2A). PCR products 
of the miRNAs with adapters ran at approximately 145 bp, and an adapter 
dimer band could be seen just below. The input and unbound libraries 
contained several bands of different sized RNAs, whereas the Ago-2-IP 
samples were enriched for miRNAs (Fig.5.2A). A distinct small RNA band 
could be seen for all the Ago-2 IPs, including the HMW and LMW RISC 
samples (Fig.5.2B). The IgG IP control sample did not have this band, and 
instead mostly contained adapter dimers (Fig.5.2B). The small RNA band at 
145 bp was cut from each set of samples. Following gel purification, the 
samples were combined to make a final pool. The samples were measured on 
a Bioanalyzer to confirm the expected size (Fig.5.2C). The libraries were then 







Figure 5.2 Generation of small RNA libraries from Ago-2 IPs 
ATBE gels showing small RNA libraries made from the input, Ago-2 IP and 
unbound samples that have been pooled together from naive and activated 
cells and HMW and LMW RISC. The miRNA band is seen at 145 bp. 
B TBE gels showing each individual Ago-2 IP sample and the IgG IP control. 
C Bioanalyzer measurement of pooled input, Ago-2 IP and unbound samples, 
and final pool containing all samples. 
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5.2.2 miRNAs are enriched following Ago-2 immunoprecipitation 
 
To determine the predominant RNA biotypes found in the samples, the 
sequencing reads were mapped to known mouse RNA families. The naive and 
activated input samples were similar in RNA content, containing approximately 
40% miRNAs, with ribosomal (rRNA) and transfer RNAs (tRNA) being the next 
most abundant groups (Fig.5.3A). The other RNA detected contained some 
protein coding reads and long-non-coding RNAs, though most had been 
eliminated during size selection of libraries. Activated cells contained more 
rRNAs whereas naive cells were more enriched in tRNAs (Fig.5.3A). HMW 
and LMW RISC input samples contained fewer miRNA reads compared to the 
total unfractionated input, approximately 25% for HMW and only 5% for LMW 
(Fig.5.3A). The rest of the reads in the HMW sample were mostly ribosomal 
and in the LMW sample they were tRNAs (Fig.5.3A). miRNA reads were 
strongly enriched in all Ago-2 IP samples, making up 80-95% of all reads, 
whereas the unbound fractions contained only 5-20% miRNAs (Fig.5.3B-C). 
The unbound fractions contained mostly rRNA and tRNA (Fig.5.3C). The 
control IgG-IP contained only 5% miRNAs, whereas the IgG unbound fraction 




Figure 5.3 RNA composition of libraries  
A-C RNA biotypes in input (A), Ago-2 IP (B) and unbound (C) samples. 
Proportion of reads corresponding to miRNAs, tRNAs, rRNAs, other types of 
RNAs (including protein coding reads and uncategorised RNA) or unmapped 
reads is shown. 
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Next, the miRNA content in each sample was compared by principal 
component analysis (PCA). Naive samples clustered together to one side of 
the plot, with the naive input, Ago-2 IP and unbound samples all forming their 
own small cluster (Fig.5.4). For the activated samples, even though two 
separate experiments were pooled, the miRNA expression profile appeared to 
be similar for all these. Total Ago-2-IP from activated samples clustered 
together with HMW Ago-2 IP samples, and LMW Ago-2 IP samples clustered 
next to these. IgG IP sample did not cluster with any other samples. However, 
the IgG unbound sample clustered together with the activated input samples 





Figure 5.4 Principal component analysis of miRNAs in all sequencing samples. 




5.2.3 Specific miRNAs are not enriched in Ago-2 unbound fractions 
 
To get a global picture of the miRNA profile in the cells, we compared the 
miRNA reads in the input, Ago-2 IP and unbound samples. RISC association 
has been suggested to be a better determinant of miRNA suppressive function 
than total miRNA expression (Flores et al., 2014). We looked for the presence 
of non-Ago-2 bound miRNAs, by looking for the enrichment of specific miRNAs 
in the input or unbound samples compared to the Ago-2 IP. The average 
expression (AveExpr) of miRNAs is shown as the average read counts per 
million (CPM) of miRNA across all samples on a log2 scale (Fig.5.5). This was 
used as an approximate measure of the general abundance of the miRNAs. 
To compare miRNA expression between the Ago-2 IP and the input and 
unbound fractions, fold change differential expression was calculated. miRNAs 
with a high average expression were enriched in the Ago-2 IP compared to 
both the input and the Ago-2 unbound samples (Fig.5.5A-B). It was previously 
shown in human monocytic THP-1 cells and human embryonic kidney 293T 
cells, that only the most abundant miRNAs in the cell mediated significant 
target suppression (Mullokandov et al., 2012). Most suppression was found for 
miRNA expressed at above 1000 CPM, and no suppression was found for 
those expressed at less than 100 CPM (Mullokandov et al., 2012). Very few 
miRNAs were significantly enriched in the input or unbound samples compared 
to Ago-2 IP at AveExpr > 6, which corresponds to 64 CPM (26). This suggests 





Figure 5.5 Most miRNAs are enriched in Ago-2 IP compared to input and 
unbound samples  
A-B Differential expression of miRNAs in d2 activated OT-I cell Ago-2 IPs 
versus input and unbound samples. x-axis shows average expression 
(log2(CPM)), y-axis shows log2 fold change in Activated Ago-2 IP relative to 
Activated input (A) or Activated unbound (B). Average expression is average 
CPM across naive and activated Ago-2 input, IP and unbound samples, on a 
log2 scale. Dashed lines show miRNAs with AveExpr > 6. miRNAs with FDR 






5.2.4 T cell activation induces dynamic changes in miRNA expression 
 
Next, we compared miRNAs from the naive and activated cells, in both the 
input and the Ago-2-IP. As expected, T cell activation induced many changes 
in miRNA expression, with most miRNAs differentially expressed between the 
naive and activated cells (Fig.5.6A-B). We listed the miRNAs with the largest 
fold difference between the naive and activated cells, only including miRNAs 
with a high average expression (AveExpr > 10 (CPM > 1024)) and a significant 
change in expression, defined as low false discovery rate (FDR < 0.01) (Table 
5.1). Many of the same miRNAs were found to be significantly changed in the 
input and Ago-2 IP samples. Previously described T cell regulators such as 
miR-155, miR-21 and members of the miR-17~92 cluster were amongst the 
most upregulated miRNAs in both the input and the Ago-2 IP. Other miRNAs 
that were enriched in the activated cells in both the input and the Ago-2 IP 
included miR-298, miR-182, miR-148, miR-186, miR-191 and miR-7. The 
miRNAs that were most downregulated upon activation included miR-150 and 
miR-181 in both input and Ago-2 IP. Let-7 family members and miR-26 were 
also enriched in the input and Ago-2 IP in naive cells compared to activated 
cells. These findings confirm dynamic changes in miRNA expression upon 
activation, apparent in both total input RNA and Ago-2 bound RNA. These 
results also correlate with findings in Chapter 3, showing upregulation of miR-





Figure 5.6 Differential expression of miRNAs between naive and d2 activated 
cells 
Average expression and log2 fold change in Activated input relative to Naive 
input (A) or Activated Ago-2 IP relative to Naive Ago-2 IP (B). Average 
expression is average CPM across naive and activated Ago-2 input, IP and 
unbound samples, on a log2 scale. Dashed lines show miRNAs with AveExpr 
















miR-298-5p 5.60 9.71E-14 miR-150-5p -3.97 6.64E-13 
miR-155-5p 3.81 5.76E-12 miR-181a-5p -3.44 9.71E-14 
miR-182-5p 3.50 7.06E-12 miR-29a-3p -2.47 3.85E-12 
miR-148a-3p 1.76 1.53E-06 let-7b-5p -2.34 5.27E-10 
miR-186-5p 1.34 7.14E-09 miR-26a-5p -2.31 9.71E-14 
miR-98-5p 1.33 6.86E-07 miR-181b-5p -2.01 2.36E-11 
miR-7a-5p 1.24 4.52E-07 miR-142a-3p -1.97 1.26E-10 
miR-191-5p 1.24 2.52E-08 miR-140-3p -1.97 6.52E-12 
miR-17-5p 1.15 1.33E-04 miR-26b-5p -1.93 3.97E-13 
miR-342-5p 1.12 8.74E-04 let-7c-5p -1.87 3.75E-09 
miR-423-5p 1.08 6.21E-03 miR-181c-5p -1.87 1.52E-09 
miR-423-3p 1.02 1.34E-06 miR-142a-5p -1.85 1.26E-07 
miR-21a-5p 1.02 9.23E-05 miR-378a-3p -1.76 6.58E-12 
miR-20a-5p 0.92 8.00E-03 miR-1839-5p -1.65 8.19E-10 





miR-17-5p 5.21 2.87E-15 miR-181a-5p -4.04 6.29E-17 
miR-20a-5p 5.03 2.78E-13 miR-150-5p -3.97 4.21E-15 
miR-298-5p 4.55 5.16E-16 let-7b-5p -3.26 7.21E-15 
miR-20b-5p 4.51 8.42E-16 miR-181b-5p -2.74 8.42E-16 
miR-155-5p 3.55 8.17E-14 miR-181c-5p -2.63 3.32E-14 
miR-182-5p 3.42 2.26E-14 let-7c-5p -2.44 2.10E-13 
miR-21a-5p 3.04 2.71E-13 miR-142a-5p -1.94 4.69E-09 
miR-186-5p 2.77 1.64E-15 miR-1839-5p -1.89 5.55E-13 
miR-191-5p 2.57 4.83E-15 miR-423-5p -1.41 2.11E-05 
miR-24-3p 2.29 4.06E-14 miR-26a-5p -1.40 1.10E-12 
miR-7a-5p 2.18 8.44E-13 miR-26b-5p -1.28 9.09E-13 
miR-93-5p 2.01 1.06E-12 miR-669p-5p -1.07 1.84E-07 
miR-148a-3p 2.00 6.80E-09 miR-140-3p -1.02 1.57E-09 
miR-19b-3p 1.92 1.14E-09 miR-342-5p -0.99 2.10E-04 
miR-22-3p 1.57 8.39E-09 let-7a-5p -0.81 8.18E-07 
 
Table 5.1 miRNA enrichment in naive and activated cells 
Differentially expressed miRNAs between naive and d2 activated cells, ranked 
by log2 fold change (FC). Table shows the top 15 miRNAs with biggest fold 
change difference between naive and activated cells, in the input and Ago-2 
IP samples. Table includes miRNAs with AveExpr > 10 and FDR < 0.01. 
Average expression is log2 of average CMP across naive and activated Ago-




5.2.5 Specific enrichment of miRNAs in HMW and LMW RISC 
 
Next, we wanted to see if miRNAs were differentially associated with HMW 
and LMW RISC in the activated cells. The fold change differential expression 
of miRNAs between HMW and LMW RISC was plotted against the average 
expression of these miRNAs (Fig.5.7A) and -log10 FDR (Fig.5.7B). Many 
miRNAs were found to be differentially associated with one complex or the 
other. We wanted to focus our attention to the miRNAs with a relatively high 
average expression, and a significant difference in fold change expression 
between HMW and LMW RISC across the three replicates. The average 
expression limit was set to 6, corresponding to 64 CPM, as it was previously 
suggested that miRNAs with lower than 100 CPM expression did not cause 
significant suppression of targets (Mullokandov et al., 2012). We however kept 
miRNAs with a low-to-average expression (64-1024 CPM, AveExpr 6-10), 
since we hypothesised these may play a biological role if enriched in HMW 
RISC. miRNAs with low average expression (AveExpr < 6) and those with FDR 
> 0.01 were filtered out. This left 50 HMW RISC and 42 LMW RISC enriched 
miRNAs. These miRNAs were ranked by the fold change difference between 
HMW and LMW RISC (Table 5.2). The most enriched miRNAs in HMW RISC 
included miR-378c, let-7g, miR-210, miR-34a and miR-7a. Other highly 
enriched miRNAs included those from the miR-17~92 cluster. In the LMW 
RISC, the differential expression analysis showed enriched of miR-211, miR-
486b, miR-150, miR-320 and miR-181. Interestingly, the 5p strand of miR-210 






Figure 5.7 Differential expression of miRNAs in HMW and LMW RISC 
A miRNA average expression and log2 fold change in HMW RISC Ago-2 IP 
relative to LMW RISC Ago-2 IP. Average expression is average CPM across 
Ago-2 IP from naive, activated, HMW and LMW RISC samples, on log2 scale. 
Dashed line shows miRNAs with AveExpr > 6, shown in Table 5.2. miRNAs 
with FDR < 0.01 are highlighted in red.  
B log2 FC as above, plotted against negative log10 of FDR. Plot includes all 
miRNAs irrespective of average expression. miRNAs with FDR < 0.01 are 




HMW enriched LMW enriched 
miRNA FC FDR miRNA FC FDR 
miR-378c 3.41 4.45E-09 miR-211-5p -2.92 6.61E-09 
let-7g-5p 3.28 1.02E-10 miR-486b-5p -2.68 3.21E-05 
miR-210-3p 2.67 1.28E-07 miR-150-5p -2.44 9.71E-08 
miR-34a-5p 2.58 1.29E-06 miR-320-3p -2.42 3.47E-07 
miR-7a-5p 2.44 5.17E-08 miR-181a-3p -2.42 4.62E-09 
miR-18a-5p 2.27 2.47E-05 miR-210-5p -2.33 1.83E-06 
miR-140-5p 2.23 2.82E-07 miR-142a-5p -2.28 2.28E-07 
miR-28a-5p 2.21 2.19E-08 miR-126a-5p -2.14 7.36E-09 
miR-20b-5p 2.14 3.30E-06 miR-151-3p -2.12 1.38E-06 
miR-185-5p 2.05 1.04E-07 miR-342-3p -2.11 2.12E-07 
miR-148b-3p 1.96 1.08E-08 miR-192-5p -2.04 2.12E-07 
miR-31-5p 1.88 4.84E-07 miR-146b-5p -2.03 6.28E-06 
miR-106a-5p 1.84 2.49E-05 miR-99b-5p -1.85 2.07E-07 
miR-17-5p 1.80 8.49E-05 let-7d-3p -1.69 4.54E-07 
miR-15a-5p 1.72 4.84E-07 miR-423-5p -1.67 1.19E-04 
miR-378a-5p 1.70 9.32E-07 miR-1981-5p -1.61 6.75E-06 
miR-423-3p 1.66 1.29E-08 miR-130b-5p -1.61 2.03E-06 
miR-296-5p 1.61 8.72E-05 miR-92b-3p -1.51 2.39E-06 
miR-24-3p 1.57 3.79E-06 miR-16-2-3p -1.43 1.01E-04 
miR-20a-5p 1.51 1.56E-03 miR-30e-3p -1.31 1.35E-06 
 
Table 5.2 miRNA enrichment in HMW and LMW RISC 
Differentially expressed miRNAs between HMW and LMW Ago-2 IP, ranked 
by log2 fold change (FC). Table shows the top 20 miRNAs with biggest fold 
change difference between HMW and LMW RISC. Table includes miRNAs 
with AveExpr > 6 and FDR < 0.01. Average expression is log2 of average CPM 




We were also interested in the most abundant miRNAs found in HMW RISC, 
based on ranking by CPM, irrespective of the differential expression compared 
to LMW RISC. These overlapped with those that were in general abundant in 
the total Ago-2 IP from activated cells, as expected. The most abundant 
miRNA was miR-92a, followed by miR-21, and miR-155 in fifth place (Table 
5.3). Many miRNAs from the let-7 family were found to be abundantly present 
in HMW RISC. For these abundant miRNAs, we calculated the ratio of the 
miRNA found in HMW RISC compared to LMW RISC as the fraction of the 
normalised read count (CPM) of the miRNA in HMW RISC over the sum of the 
read count in both complexes (HMW CPM / (HMW CPM + LMW CPM)).  From 
these highly abundant miRNAs, miR-210-3p, miR-7a, miR-17 and let-7g were 







Figure 5.8 Ratio of miRNAs in HMW and LMW 
RISC 
Ratio is calculated as miRNA average CPM in 
HMW Ago-2 IP samples over the sum of the read 
count in both HMW and LMW Ago-2 IP (HMW CPM 
/ (HMW CPM + LMW CPM). Ratio is shown for the 
top 20 most abundant miRNAs in HMW RISC 




Table 5.3 Most abundant miRNAs in HMW RISC 
The top 20 most abundant miRNAs in HMW RISC Ago-2 IP ranked by average 














































































































































5.2.6 miRNA expression changes cannot predict association with HMW or 
LMW RISC 
 
We saw significant changes in miRNA expression upon activation, as well as 
differences in association with HMW and LMW RISC within activated cells. 
Next, we wanted to see how miRNA up - and downregulation correlated with 
subsequent association with HMW and LMW RISC in the activated cells. To 
get a global picture of miRNA expression changes in respect to HMW/LMW 
RISC association, we filtered out very lowly expressed miRNAs (AveExpr < 2, 
CPM < 4) and split the miRNAs into two groups: miRNAs with significant (FDR 
< 0.01) upregulation upon activation and miRNAs with significant 
downregulation, based on differential expression between naive Ago-2 IP and 
activated Ago-2 IP samples. We ended up with 227 miRNAs, 122 of which 
were significantly upregulated and 105 downregulated. We then calculated the 
ratio of the miRNAs in HMW RISC versus LMW RISC. For each miRNA, the 
ratio of the normalised read count (CPM) in HMW RISC over total CPM was 
calculated, with upregulated and downregulated miRNAs considered 
separately. On average, upregulated miRNAs were found equally distributed 
between HMW and LMW RISC (average proportion in HMW RISC: 52%) 
(Fig.5.9A). Downregulated miRNAs were also divided between both 
complexes; however, these were on average slightly more present in LMW 
RISC (average proportion in HMW RISC: 41%) (Fig.5.9C). We then ranked the 
miRNAs based on the level of up -or downregulation, to see if stronger 
upregulation correlated with higher occupancy in HMW RISC, and vice versa, 
stronger downregulation with higher occupancy in LMW RISC. There 
appeared to be no such correlation, with miRNAs apparently distributing to 
HMW and LMW RISC irrespective of changes in expression (Fig.5.9B,D). 
Some highly upregulated miRNAs were found in LMW RISC, and some 
strongly downregulated miRNAs were found in HMW RISC. We then examined 
both the up-and downregulated miRNAs with the highest occupancy in HMW 
RISC (Table 5.4). The most HMW RISC enriched miRNAs were miR-671, miR-
669f, miR-466f, miR-210-3p and miR-147 for the upregulated, and miR-5099, 
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miR-387c, miR-6240, miR-28a and miR-378a for the downregulated. In 
addition, miR-210-3p, miR-34a, miR-7a, miR-378 and let-7 family miRNAs 






Figure 5.9 miRNA expression changes do not correlate with distribution to 
HMW and LMW RISC 
Ratio of upregulated (A-B) and downregulated (C-D) miRNAs in HMW and 
LMW RISC. Ratio is calculated as miRNA average CPM in HMW Ago-2 IP 
samples over the sum of the read count in both HMW and LMW Ago-2 IP 
(HMW CPM / (HMW CPM + LMW CPM). Analysis includes miRNAs with 
AveExpr > 2. Average expression is log2 of average CPM across Ago-2 IP 
from naive, activated, HMW and LMW RISC samples. Upregulated miRNAs 
are those with significant enrichment in activated Ago-2 IP compared to naive 
Ago-2 IP (FDR < 0.01), downregulated miRNAs are significantly enriched in 
naive Ago-2 IP versus activated Ago-2 IP (FDR < 0.01). Each bar represents 
a single miRNA. A and C ranked by proportion of miRNA in HMW RISC. B and 
D are ranked by fold change upregulation or downregulation, with biggest fold 







Upregulated  Downregulated  
miRNA Ratio (%) miRNA Ratio (%) 
miR-671-5p 95 miR-5099 92 
miR-669f-5p 89 miR-378c 91 
miR-466f 87 miR-6240 86 
miR-210-3p 86 miR-28a-5p 81 
miR-147-3p 86 miR-378a-5p 74 
miR-34a-5p 84 let-7f-5p 72 
miR-7a-5p 84 miR-669a-3p 71 
miR-466a-5p 82 miR-297b-3p 71 
miR-140-5p 81 miR-1839-5p 71 
miR-18a-5p 80 miR-15b-5p 69 
miR-363-5p 80 let-7a-5p 68 
miR-20b-5p 79 miR-466i-3p 67 
miR-5104 79 let-7e-5p 66 
miR-148b-3p 78 miR-669p-5p 66 
miR-31-5p 77 miR-322-5p 65 
miR-330-5p 77 miR-500-3p 65 
miR-326-3p 76 miR-195a-5p 63 
miR-106a-5p 76 let-7j 62 
miR-17-5p 75 miR-378d 61 
miR-423-3p 75 miR-466d-3p 60 
 
Table 5.4 Up- and downregulated miRNAs with highest ratio in HMW RISC 
Upregulated and downregulated miRNAs ranked by the proportion of miRNA 
found in HMW RISC. Ratio is calculated as miRNA average CPM in HMW 
Ago-2 IP samples over the sum of the read count in both HMW and LMW Ago-
2 IP (HMW CPM / (HMW CPM + LMW CPM)x100). Analysis includes miRNAs 
with AveExp > 2. Average expression is log2 of average CPM across Ago-2 
IP from naive, activated, HMW and LMW RISC samples. Upregulated miRNAs 
are those with significant enrichment in activated Ago-2 IP compared to naive 
Ago-2 IP (FDR < 0.01), downregulated miRNAs are significantly enriched in 
naive Ago-2 IP versus activated Ago-2 IP (FDR < 0.01).   
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Next, to better to visualise miRNA expression changes alongside distribution 
to HMW and LMW RISC, we plotted the miRNAs with both a significant change 
in expression, and in distribution between HMW/LMW RISC (FDR < 0.01), 
excluding miRNAs with very low average expression (AveExp < 2). This 
divided the miRNAs into four quadrants: upregulated miRNAs in HMW RISC 
or LMW RISC, and downregulated miRNAs in HMW RISC or LMW RISC 
(Fig.5.10A). Out of a total of 145 miRNAs with significant changes in both 
expression and HMW/LMW RISC distribution, 49 were upregulated and found 
predominantly in HMW RISC, 32 were upregulated but found mostly in LMW 
RISC, 18 were downregulated and found in HMW RISC, and 46 were 
downregulated and enriched in LMW RISC. Interestingly, we noted that 
members of a particular miRNA family were often associated specifically with 
HMW or LMW RISC. For example, members of the miR-17~92 cluster and the 
two paralogous clusters, miR-106b~25 and miR-106~363, were all 
upregulated and almost exclusively found enriched in HMW RISC, with the 
exception of miR-92a (Fig.5.10B). Similarly, members of the miR-449 family, 
which contains miR-34a, were found upregulated and in HMW RISC 
(Fig.5.10C). Downregulated miRNAs found in HMW RISC were the smallest 
group of the four quadrants. The let-7 family of miRNAs was downregulated 
upon activation, but interestingly many members of this family were enriched 
in HMW RISC, with some enriched in LMW RISC (Fig.5.10D). Similarly, 
miRNAs of the miR-378 family were downregulated but enriched in HMW RISC 
(Fig.5.10E). For each quadrant, we listed the miRNAs with the biggest fold 
difference between HMW and LMW RISC, including only those with AveExpr 
> 6 (Table 5.5). As well as the miRNA families discussed above, the 
upregulated miRNAs found in HMW RISC included many miRNAs already 
identified in the previous analyses, such as miR-210-3p, miR-7a and miR-34a, 
whereas the downregulated included miR-28a. Many miRNAs were found 
upregulated but enriched in LMW RISC. Notably, this group included miR-155, 
one of the most strongly upregulated miRNAs (Table 5.5). Finally, many 
downregulated miRNAs were found enriched in LMW RISC, such as miR-211, 





Figure 5.10 Upregulated and downregulated miRNA families enriched in HMW 
and LMW RISC 
A shows log2 fold change differential expression between naive and activated 
Ago-2 IP (x-axis) and HMW and LMW Ago-2 IP (y-axis). Upregulated miRNAs 
are those with significant enrichment (FDR < 0.01) in activated Ago-2 IP 
compared to naive Ago-2 IP, downregulated miRNAs are significantly enriched 
in naive Ago-2 IP versus activated Ago-2 IP and these are separated into HMW 
Ago-2 IP enriched and LMW Ago-2 IP enriched miRNAs. Figure includes 
miRNAs with AveExpr > 2. Average expression is log2 of average CPM across 
Ago-2 IP from naive, activated, HMW and LMW RISC samples. B-E highlight 
members of miR-17~92 cluster and related families (B), miR-449/34 family (C), 
let-7 family (D) and miR-378 family (E). 
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Downregulated/HMW RISC Upregulated/HMW RISC 
miRNA Expression HMW/ LMW miRNA Expression 
HMW/ 
LMW 
miR-378c -0.92 3.41 miR-210-3p 7.88 2.67 
miR-28a-5p -1.97 2.21 miR-34a-5p 2.53 2.58 
miR-378a-5p -1.08 1.70 miR-7a-5p 1.85 2.44 
let-7f-5p -0.57 1.46 miR-18a-5p 5.17 2.27 
miR-1839-5p -2.22 1.39 miR-140-5p 0.71 2.23 
miR-15b-5p -0.59 1.24 miR-20b-5p 4.18 2.14 
let-7a-5p -1.14 1.22 miR-148b-3p 0.76 1.96 
let-7e-5p -1.03 1.09 miR-31-5p 6.51 1.88 
miR-669p-5p -1.40 1.03 miR-106a-5p 4.75 1.84 
let-7j -1.77 0.87 miR-17-5p 4.88 1.80 
Downregulated/LMW RISC Upregulated/LMW RISC 
miRNA Expression HMW/ LMW miRNA Expression 
HMW/ 
LMW 
miR-211-5p -4.34 -2.92 miR-210-5p 8.30 -2.33 
miR-486b-5p -7.22 -2.68 miR-130b-5p 2.21 -1.61 
miR-150-5p -4.30 -2.44 miR-183-5p 3.87 -1.23 
miR-320-3p -2.83 -2.42 miR-146a-5p 0.75 -1.05 
miR-181a-1-3p -1.72 -2.42 miR-24-2-5p 1.67 -1.04 
miR-142a-5p -2.28 -2.28 miR-504-5p 1.14 -1.03 
miR-151-3p -2.37 -2.12 miR-186-5p 2.44 -0.95 
miR-342-3p -2.34 -2.11 miR-182-5p 3.09 -0.72 
miR-192-5p -2.70 -2.04 miR-155-5p 3.22 -0.65 
miR-146b-5p -1.62 -2.03 miR-92a-3p 1.08 -0.56 
 
Table 5.5 Upregulated and downregulated miRNAs enriched in HMW and 
LMW RISC 
Table shows log2 fold change differential expression between naive and 
activated Ago-2 IP (Expression, FDR < 0.01) and HMW and LMW Ago-2 IP 
(HMW/LMW, FDR < 0.01), ranked by FC enrichment in HMW or LMW RISC. 
Upregulated miRNAs are those with significant enrichment in activated Ago-2 
IP compared to naive Ago-2 IP, downregulated miRNAs are significantly 
enriched in naive Ago-2 IP versus activated Ago-2 IP and these are separated 
into HMW Ago-2 IP enriched and LMW Ago-2 IP enriched miRNAs. Table 
includes miRNAs with AveExpr > 6. Average expression is log2 of average 





Finally, we decided to focus on the RISC distribution of miRNAs known to 
regulate T cell responses, the expression of which was studied in Chapter 3. 
miR-155 and miR-17 were shown to be strongly induced upon activation by 
qPCR measurements (Fig.3.2). The sequencing data also showed 
upregulation of these miRNAs, both in the input and the Ago-2-IP (Fig.5.11A-
B). Interestingly miR-155 was found enriched in LMW RISC despite very 
strong upregulation (Fig.5.11A). However, looking at the CPM in each sample, 
it was also found in HMW RISC in high abundance. miR-17 was found 
enriched in HMW RISC, as shown previously for most of the miRNAs from this 
cluster (Fig.5.10, 5.11B). miR-139, miR-150 and miR-181a were previously 
shown to be downregulated (Fig.3.2). Again, the sequencing results correlated 
with this, showing downregulation in both input and Ago-2-IP for all three 
miRNAs (Fig.5.11C-E). miR-150 and miR-181a were enriched in LMW RISC, 
with miR-139 equally distributed between the complexes (Fig.5.11C-E). 
However, as these miRNAs were strongly downregulated upon activation, the 
amount of miRNA remaining in the activated cells was quite low, particularly 






Figure 5.11 Expression and HMW/LMW association of miRNAs known to 
regulate T cells 
A-E Expression is shown as CPM of miRNA in naive and activated input and 
Ago-2 IP samples. HMW/LMW association is shown as CPM of miRNA in 
HMW and LMW Ago-2 IP. The mean and standard deviation of three biological 
replicates are shown. Statistical analysis is done using a two-tailed unpaired 
student’s t-test. (*) p-value < 0.05, (**) p-value < 0.01, (***) p-value < 0.001.  
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3.2.7 miR-7a inhibition affects CD8+ T cell activation 
 
We wanted to focus our attention to specific miRNAs that were found enriched 
in HMW RISC. Many miRNAs were consistently found enriched in HMW RISC 
in the different analyses. These included the upregulated miRNAs miR-17~92, 
miR-210-3p, miR-7a and miR-34a, and the downregulated miRNAs miR-378, 
let-7 and miR-28a. We decided to confirm the upregulation of miR-7a and miR-
210-3p by qPCR, during a 6-day activation time-course of OT-I cells. Both 
miRNAs were upregulated by d2, as shown by both qPCR and sequencing 
data (Fig.5.12). miR-7a expression was induced early, by d1 and remained up 
during 6 days of culture. miR-210 expression was upregulated slightly later, 
with maximal induction on d2. 
 
 
Figure 5.12 miR-7a and miR-210-3p are upregulated upon T cell activation and 
are enriched in HMW RISC 
A-B miRNA expression measured by qPCR during a time-course of OT-I T cell 
activation. Cell were activated with N4 for 2 days then cultured in IL-2 for 4 
days. Expression was normalised to snU6 and is shown as fold expression 
relative to naive cells. Figure is showing a single experiment. 
C-D miRNA expression and HMW RISC association from sequencing data, 
shown in in counts per million of miRNA. miRNA in naive and activated input 
and Ago-2 IP samples. HMW/LMW association is shown as counts per million 
of miRNA in HMW and LMW Ago-2 IP. Statistical analysis is done using a two-
tailed unpaired student’s t-test. (**) p-value < 0.01, (***) p-value < 0.001.  
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We decided to focus on the role of miR-7a in CD8+ T cells, as this miRNA had 
not been previously described in T cells, despite being a well-known tumour-
suppressive miRNA. Expression of miR-7a was inhibited with an antagomir 
linked to a 5’FAM (fluorescein) tag. For a negative control, an inhibitor with no 
known targets in the mouse genome was used. The inhibitors have locked 
nucleic acid (LNA) and phosphorothioate (PS) modifications to protect them 
from enzymatic degradation and can be added directly to culture medium 
without the need for transfection reagents, and are instead taken up by the 
cells by gymnosis. The inhibitors were added to OT-I cells with 10 nM N4 and 
left for 2 days to monitor their unassisted uptake by the cells.  On d2, the 
fluorescence of the cells was measured using flow cytometry. The cells 
receiving the control or the miR-7a inhibitor became brightly fluorescent, 
suggesting the inhibitor had been taken up (Fig.5.13A).  We next measured 
the effect of the inhibitors on the cell number and on cell viability, in cells 
activated with 10 nM or 1 nM N4 for 2 days. Reducing the concentration of 
activating peptide resulted in fewer cells per well on d2 (Fig.5.13B). Slightly 
fewer cells were also recovered from the wells receiving the inhibitors, with a 
decrease with miR-7a inhibition in particular (Fig.5.13B). Cell viability was not 
affected by the inhibitors (Fig.5.13C).   We next measured cell proliferation 
following miR-7a inhibition.  While the control inhibitor had no effect on cell 
proliferation, miR-7a inhibition lead to a slight decrease in proliferation 
(Fig.5.14). All the cells had entered the cell cycle, but fewer cells had 
undergone the final divisions, resulting in a lower overall proliferation index 
with both 10 nM and 1 nM N4. Lastly, we studied the effect of miR-7a inhibition 
on the cell phenotype. We measured the expression of the surface markers 
CD25 (IL-2 receptor), CD44 and CD71 (transferrin receptor) on d2. The 
expression of all three markers was increased in cells receiving the miR-7a 





Figure 5.13 miR-7a inhibitor is taken up by CD8+ T cells and does not reduce 
cell viability 
A-C Cells were activated with 10 nM or 1 nM N4 and cultured with no inhibitors, 
with a negative control inhibitor, or a miR-7a inhibitor for 2 days. 
A Fluorescence intensity from inhibitor 5’FAM-tag, measured by flow 
cytometry on d2.  
B-C Total cell number per well (B) and proportion of live cells (C) measured by 
flow cytometry of Live/Dead stained cells on d2. 
The figure shows the mean and standard deviation of two biological replicates 





Figure 5.14 Cells receiving the miR-7a inhibitor proliferate less 
A-C Cells were activated with 10nM (A) or 1nM (B) N4 and cultured with no 
inhibitors, with a negative control inhibitor, or a miR-7a inhibitor for 2 days. 
Cells were stained with CellTrace proliferation dye prior to activation. 
A-B Fluorescence intensity of CellTrace on d2 measured by flow cytometry. 
C Quantification of the proliferation index measured from CellTrace staining. 
Proliferation index is the total number of divisions divided by the number of 
cells that went into division. 
The figure shows the mean and standard deviation of two biological replicates 





Figure 5.15 Cells receiving miR-7a inhibitor express higher levels of surface 
activation markers 
A-B Cells were activated with 10 nM (A) or 1 nM (B) N4 and cultured with no 
inhibitors, with a negative control inhibitor, or a miR-7a inhibitor for 2 days.  
A Expression of CD25, CD44 and CD71 measured by flow cytometry on d2. 
Figure is representative of two experiments. 
B Geometric mean fluorescence intensity of CD25, CD44 and CD71.  
The figure shows the mean and standard deviation of two biological replicates 







5.3.1 Summary of findings 
 
miRNA expression was shown to change upon CD8+ T cell activation, with 
differential expression of many miRNAs between naive and activated cells. In 
addition to changes in expression, miRNAs were also differentially distributed 
between HMW RISC and LMW RISC in activated T cells. The miRNA 
expression changes did not predict which RISC complex an individual miRNA 
was found in. Many miRNAs were found to be strongly downregulated, but 
what remained was predominantly found in HMW RISC. Similarly, many 
upregulated miRNAs were not enriched in HMW RISC but instead were found 
in both complexes, or in LMW RISC. Most miRNAs were found in both 
complexes to some extent.  
 
5.3.2 miRNA expression and RISC organisation in naive T cells 
 
miRNA association with HMW and LMW RISC has been previously studied in 
T cells (La Rocca et al., 2015). The key finding from this study was that while 
the majority of miRNAs were downregulated upon T cell activation, they shifted 
to HMW RISC. The authors found that in naive cells most miRNAs were 
associated with LMW RISC, whereas in activated cells the miRNAs were 
mostly found in HMW RISC. We did not compare miRNA association between 
HMW and LMW RISC in naive cells, because we could not detect GW182 
protein expression or HMW RISC prior to activation. If naive cells contain HMW 
RISC at very low levels (or undetectable in our study), this automatically 
suggests that HMW RISC association would increase upon activation.   
 
miRNA expression is high in naive cells, but the cells may not express all of 
the factors required for efficient miRNA suppression of genes. LMW RISC 
does not contain GW182, which has been shown to be essential for miRNA 
suppressive function through the recruitment of proteins mediating mRNA 
degradation and translational repression (Behm-Ansmant et al., 2006). 
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Despite downregulation upon activation, some miRNAs such as members of 
the let-7 and miR-15/16 families were shown to be better at suppressing a 
reporter construct in activated cells compared to naive (La Rocca et al., 2015). 
miRNAs in naive T cells may therefore be stored in LMW RISC, ready to exert 
their action upon recruitment of GW182 and formation of HMW RISC. Since 
global transcription substantially increases upon T cell activation, some miRNA 
targets may only be expressed upon activation. These miRNAs may then play 
important roles in the early activation of cells. Consistent with this idea, Dicer 
deficient naive CD8+ T cells that are deficient in miRNAs, appear normal with 
unchanged expression of the surface markers CD44 and CD62L (Zhang and 
Bevan, 2010). However upon activation these cells enter the cell cycle more 
rapidly and express higher levels of CD69, suggesting miRNAs are required 
at this stage to control level of activation (Zhang and Bevan, 2010). 
 
5.3.3 HMW and LMW RISC in activated T cells 
 
In activated T cells, both HMW and LMW RISC are present. Several 
possibilities could exist for the distribution of miRNAs between the two 
complexes, which were considered here: i) miRNAs may be evenly distributed 
in both complexes, ii) all miRNAs may be predominantly recruited to one 
complex upon activation or iii) distribution may vary for individual miRNAs.  We 
clearly showed the third option to be true, with significant differential 
expression of miRNAs between the two complexes. This was also in 
agreement with the study by La Rocca et al., where they noted that while most 
miRNAs were recruited to HMW RISC upon activation, there were differences 
for individual miRNAs. In other cell types, miRNA RISC-association has also 
been shown to change following a stimulus. In chondrocytes, IL-1β treatment 
was shown to dramatically change the profile of Ago-2 associated miRNAs, 
without a change in the expression of these miRNAs (Haseeb et al., 2017). 
This suggested some specificity in RISC recruitment for these miRNAs, even 
though association with HMW or LMW RISC was not studied. 
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We studied the distribution of miRNAs between HMW and LMW RISC for 
upregulated and downregulated miRNAs. Upregulated miRNAs were on 
average more prevalent in HMW RISC compared to downregulated miRNAs 
(52% in HMW compared to 42%). Most miRNAs were found in both complexes 
to some extent. It might be expected, that at least a portion of an expressed 
miRNA needs to be found in HMW RISC for the miRNA to be functional. For 
highly expressed miRNAs, these may be found in both complexes because 
they have saturated HMW RISC. For example, miR-155 and miR-92 which 
were some of the most strongly upregulated miRNAs, were found in high levels 
in both complexes, and in fact enriched in LMW RISC. The proportion of 
miRNA in HMW RISC may be more important for less abundant miRNAs. If a 
miRNA is not very abundant or is downregulated upon activation, but most of 
this miRNA is found in HMW RISC, this could suggest that it is still functional. 
Conversely, if a lowly expressed miRNA is only found in LMW RISC, this may 
suggest that it is not actively suppressing its targets. Distribution between 
HMW and LMW RISC could therefore be another layer of regulation for the 
function of lowly expressed miRNAs. Specific recruitment to HMW RISC could 
allow even a small amount of miRNA to have a biological effect.  
 
For the purpose of this study, we only considered HMW and LMW RISC as the 
two complexes that contain miRNAs, and not any intermediate complexes. 
Depending on the protein composition of these complexes, these could also 
be important in miRNA suppression. It is possible that some of the LMW RISC 
enriched miRNAs could be found in intermediate complexes and suppress 
their targets in these, depending on the protein co-factors. The intermediate 
complexes showed weak immunoprecipitation with GW182 which is usually 
needed for miRNA target suppression (Chapter 4). However non-GW182 
containing RISC complexes may suppress miRNA target through alternative 
pathways, such as repression of translational elongation, as has been 




5.3.4 Regulation of miRNA recruitment to HMW and LMW RISC 
 
Since miRNAs were shown to be differentially distributed between HMW and 
LMW RISC, this suggests there could be some specificity to the recruitment to 
each complex. miRNA expression did not directly determine association with 
either complex, though the tendency was for low abundance downregulated 
miRNAs to be more enriched in LMW RISC. Instead, miRNA distribution in 
HMW and LMW RISC could hypothetically be influenced by factors such as 
target abundance, miRNA localisation, modifications in miRNA or Ago, and 
other RNA-binding proteins (RBPs), each of which is discussed below. 
  
Availability of miRNA targets could influence RISC association of the miRNA. 
LMW RISC bound miRNAs were suggested not to be interacting with their 
targets (La Rocca et al., 2015). High target abundance could therefore result 
in higher proportion of the miRNA in HMW RISC. It was previously shown that 
overexpression of mRNAs containing miRNA target sites increased the RISC-
occupancy of these miRNAs (Flores et al., 2014). miRNA target availability 
may change following T cell activation due to 3’UTR shortening of certain 
transcripts, thus potentially influencing RISC-association of these miRNAs 
(Sandberg et al., 2008). Subcellular localisation of miRNAs has been 
suggested to be a big determinant of miRNA function. Recently, Ago-2 and 
GW182 were shown to form molecular condensates which concentrated 
miRNA targets with decay-mediating proteins, thus promoting miRNA function 
(Sheu-Gruttadauria and MacRae, 2018). miRNA localisation in the cell could 
determine its association with HMW or LMW RISC. Nuclear miRNAs were 
shown to be found in a LMW RISC and to be less effective at target 
suppression compared to cytoplasmic miRNAs in HMW RISC (Pitchiaya et al., 
2017). miRNA nuclear localisation and stability were affected by target and 
Ago abundance, with Ago loading and target binding competing with miRNA 




Modifications in the miRNA itself, or Ago and associated proteins could 
potentially influence recruitment to LMW or HMW RISC. miRNAs can be edited 
through a variety of methods, such as RNA editing or alternative cleavage of 
miRNA precursors, or non-templated nucleotide addition to mature miRNAs 
(Gebert and MacRae, 2019). 5’ modification can affect the seed sequence and 
miRNA target pool, whereas 3’ modifications generally affect the stability and 
turnover of the miRNA. 3’ uridylation has been shown to play a role in targeting 
miRNAs for degradation following T cell activation (Gutiérrez-Vázquez et al., 
2017). miRNA function can also be regulated by phosphorylation in some 
cases. miR-34 was shown to be activated through 5’ phosphorylation in 
response to DNA damage (Salzman et al., 2016). An inactive pool of non-
phosphorylated miR-34 was found non-associated with Ago-2, whereas 
phosphorylation led to loading onto Ago-2. Modifications of Ago proteins could 
also play a role in regulating miRNA loading. Ago phosphorylation on S387 
has been previously shown to regulate association with GW182 and 
subcellular localisation to P-bodies (Zeng et al., 2008; Horman et al., 2013; 
Bridge et al., 2017). Ago binding to miRNAs and mRNAs can also be affected 
by phosphorylation. Ago-2 phosphorylation cycle at S824-834 promoted target 
turnover (Golden et al., 2017). Y529 phosphorylation was shown to reduce 
miRNA binding and was suggested to function as a molecular switch 
controlling miRNA loading on Ago (Rüdel et al., 2011). Ago phosphorylation 
therefore regulates its miRNA, target and GW182 association. 
 
Finally, other RBPs could influence miRNA recruitment to HMW and LMW 
RISC. Many Ago-interacting proteins have been described which can facilitate 
or counteract miRNA suppression of targets (Krol, Loedige and Filipowicz, 
2010). For example, importin 8 was shown to stabilise Ago binding to target 
mRNAs, and heat shock protein 90 (HSP90) was shown to be a chaperone for 
miRNA loading (Weinmann et al., 2009; Iwasaki et al., 2010). Other mRNA 
interacting proteins that bind the target mRNA could also influence miRNA 
function. The RBP dead end 1 (DND1) was shown to bind mRNAs and prevent 
several miRNAs from binding to their target sites (Kedde et al., 2007). The 
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RBP TDP-43 was shown to specifically disrupt the RISC association of miR-1 
and miR-206, but not miR-133 family (King et al., 2014). Some RBPs can 
promote or inhibit miRNA function depending on the context: HuR has been 
shown relieve miR-122 mediated suppression of Cat-1 in human 
hepatocarcinoma cells subject to stress conditions (Bhattacharyya et al., 
2006). Contrary to this, HuR was shown to promote let-7 mediated c-Myc 
suppression in cervical carcinoma cells by associating with c-Myc 3’UTR and 
recruiting let-7 loaded RISC to its target (Hyeon et al., 2009). HuR has also 
been shown to play a role in T cells, promoting Th2 and Th17 differentiation 
by interacting with mRNAs coding for key cytokines and transcription factors 
(Stellato et al., 2011; Chen et al., 2013). 
RBPs have been shown to interact with miRNAs in T cells as well. Roquin is 
an RBP known to be important for post-transcriptional regulation of mRNAs in 
T cells.  It functions to maintain tolerance and guide T helper cell differentiation 
through suppression of its mRNA targets (Bertossi et al., 2011; Vogel et al., 
2013). It was recently shown that Roquin interacts with miRNAs as well: it was 
shown to bind Ago-2, miR-146a and its target Icos in CD4+ T cells to facilitate 
target decay (Srivastava et al., 2015). Roquin also affected miR-146a stability, 
with increased 3’ uridylation of this miRNA in the absence of Roquin.  
Furthermore, Roquin has been shown to interact with the miR-17~92 target 
Pten, preventing the binding of members of this cluster (Essig et al., 2017). 
This led to increased mTOR signalling in the absence of Roquin, affecting 
differentiation of regulatory T cells and conventional CD4+ T cells to Th17 and 
Tfh. Various RBPs have therefore been shown to influence function and target 
binding of specific miRNAs and could also play a role in miRNA recruitment or 
exclusion from HMW RISC.  
 
5.3.5 HMW enriched miRNAs 
 
We identified many miRNAs that were enriched in HMW RISC, summarised in 
Table 5.6. Some of these miRNAs, such as members of the let-7 family have 
been previously shown to be enriched in HMW RISC in activated T cells (La 
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Rocca et al., 2015). However, our data differ from the study by La Rocca et al. 
in a few aspects. Firstly, instead of comparing miRNA association with HMW 
RISC between naive and activated cells, we focused on the distribution of 
miRNAs between HMW and LMW RISC in activated cells. Secondly, the 
previous study used a mix of CD4+ and CD8+ polyclonal T cells that were 
activated with anti-CD3 and anti-CD28 for 3 days in the presence of IL-2. 
Instead of a mixed polyclonal cell population, we used OT-I CD8+ T cells that 
were activated with agonist peptide for 2 days. Even though many of the same 
miRNAs are expressed by CD4+ and CD8+ T cells, their functions may be quite 
different, particularly in respect to CD4+ T cell differentiation to T helper 
subtypes, and CD8+ T cell differentiation to CTLs (Rodríguez-galán, 
Fernández-messina and Sánchez-madrid, 2018). Activating cells through the 
TCR with cognate peptide is also different from non-specific activation with 
anti-CD3/28. Some miRNAs and their target genes were previously shown to 
be differentially regulated in T cells stimulated through different methods (Sun 
et al., 2013). 
 
5.3.6 Upregulated HMW enriched miRNAs 
 
Well described regulators of T cell activation were among the most abundant 
miRNAs in HMW RISC: miR-155, miR-21 and miR-17~92 cluster have been 
widely studied in T cells. miR-155 and miR-17~92 cluster have already been 
broadly discussed in previous chapters and are well known for their roles in 
promoting CD8+ T cell responses. miR-21 is another miRNA that is induced 
upon in vitro activation of T cells (Carissimi et al., 2014). miR-21 inhibition was 
shown to increase apoptosis in T cells, and it has been suggested to target the 
pro-apoptotic protein Lats1 (Meisgen et al., 2012; Teteloshvili et al., 2017). 
miR-21 and miR-155 were not found enriched in HMW RISC, in fact miR-155 
was found predominantly in LMW RISC. However, since these miRNAs are so 
abundant, the miRNAs were in fact found present at high levels in both 
complexes, and thus still appeared as some of the most abundant miRNAs in 
HMW RISC. Percentage of distribution between HMW and LMW RISC may 
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therefore be less informative for such highly expressed miRNAs. Other 
miRNAs that were not specifically enriched in HMW RISC but nevertheless 
abundant included miR-25, miR-16 and miR-191.  
 
 
Upregulated   
miRNA Expression FC 
HMW/LMW 
FC % HMW CPM HMW 
miR-210-3p 7.88 2.67 86 8805 
miR-34a-5p 2.53 2.58 84 343 
miR-7a-5p 1.85 2.44 84 24932 
miR-18a-5p 5.17 2.27 80 566 
miR-140-5p 0.71 2.23 81 331 
miR-20b-5p 4.18 2.14 79 5658 
miR-148b-3p 0.76 1.96 78 2078 
miR-31-5p 6.51 1.88 77 2044 
miR-106a-5p 4.75 1.84 76 2409 
miR-17-5p 4.88 1.80 75 9124 
Downregulated   
miRNA Expression FC 
HMW/LMW 
FC % HMW CPM HMW 
miR-378c -0.92 3.41 91 249 
miR-28a-5p -1.97 2.21 81 352 
miR-378a-5p -1.08 1.70 74 159 
let-7f-5p -0.57 1.46 72 92421 
miR-1839-5p -2.22 1.39 71 748 
miR-15b-5p -0.59 1.24 69 752 
let-7a-5p -1.14 1.22 68 37837 
let-7e-5p -1.03 1.09 66 312 
miR-669p-5p -1.40 1.03 66 840 
let-7j -1.77 0.87 62 210 
 
Table 5.6 Summary of HMW RISC enriched miRNAs 
The table shows the top 10 up - and downregulated miRNAs enriched in HMW 
RISC, based on FC difference between HMW and LMW RISC. Table shows 
Expression (log2 FC between naive and activated Ago-2 IP), HMW/LMW (log2 
FC between HMW and LMW Ago-2 IP), % HMW (ratio in HMW as shown in 
Table 5.4) and average CPM in HMW RISC. Table includes miRNAs with 




miRNAs from the miR-17~92 cluster were consistently found upregulated and 
enriched in HMW RISC. The only miRNA of this cluster enriched in LMW RISC 
was miR-92-3p. Counterintuitively, this miRNA was however the most 
abundant miRNA in HMW RISC, similar to the other abundant miRNAs miR-
155 and miR-21. The same trend for upregulation and HMW enrichment was 
true also for the related miRNA clusters miR-106b~25 and miR-106~363. Each 
of the three clusters is transcribed as a single pri-miRNA that is processed into 
multiple mature miRNAs. The clusters contain miRNAs from three families, 
each characterised by a shared seed sequence: miR-17, miR-18, miR-19 and 
miR-92 families (Mogilyansky and Rigoutsos, 2013). The miRNAs from the 
same cluster may however share targets, for example Pten was shown to 
contain seed sides for 5 of the 6 miRNAs of the miR-17~92 cluster (Wu et al., 
2012). The HMW RISC enrichment also appears to be regulated cooperatively 
for the miRNAs from the related clusters and families, with most found 
enriched in HMW RISC. Since the miRNAs are all expressed together, this 
could also lead to coordinated loading to RISC. Other properties such as the 
shared seed region and targets within a miRNA family could also influence 
enrichment in HMW RISC. Another miRNA family that was enriched in HMW 
RISC was miR-449/34. miR-34a has recently been shown to be an important 
T cell regulator. This miRNA was shown to be upregulated in both CD4+ and 
CD8+ T cells and targeted multiple components of the NF-κβ signalling 
pathway, causing downregulation of Nfkb1a and the TCR, detrimental to T cell 
function (Hart et al., 2019). Interestingly, miR-34a shares a seed sequence 
with miR-449 family miRNAs miR-449a, 449b and 449c, which were also all 
upregulated and found in HMW RISC. miR-449 family was recently linked to 
CD4+ T cell metabolism, specifically mitochondrial respiration. miR-449a was 
shown to be expressed in activated CD4+ T cells, and reduction in expression 
decreased mitochondrial respiration (L. Huang et al., 2018).  
 
Other upregulated HMW RISC enriched miRNAs included mR-7a, miR-210-
3p, miR-140, miR-31 and miR-148b. Some of these miRNAs have been 
described roles in T cells. For example, miR-31 has been implicated in CD8+ 
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T cell activation, and was suggested to promote IL-2 production in activated T 
cells (Xue et al., 2013). In another setting, this miRNA was implicated in CD8+ 
T cell exhaustion during viral infection and contributed to cell dysfunction 
particularly during exposure to type I interferons (Moffett et al., 2017). miR-148 
has been shown to be induced by T-bet in CD4+ T cell and promoted cell 
survival (Maschmeyer et al., 2018). miR-210-3p was shown to be enriched in 
HMW RISC, however interesting the 5p strand was enriched in LMW RISC. 
Originally it was assumed that one strand is selected as the guide strand 
whereas the other strand is rapidly destroyed (Schwarz et al., 2003). However 
it is now understood that both strands can operate as guides, for example for 
miR-142, in which case the two strands have different seed sequences and 
could repress a different set of targets (Wu et al., 2009). In the case of miR-
210, miR-210-3p was the more abundant of the two strands in our study, and 
also one that has been previously described in T cells (Wang et al., 2014). 
miR-210 was shown to be upregulated upon TCR stimulation, and expression 
further increased in hypoxic conditions, where miR-210 was upregulated by 
Hif1α. miR-210 was shown to target Hif1α in a negative feedback loop, causing 
inhibition of Th17 differentiation (Wang et al., 2014).  
 
5.3.7 Downregulated HMW enriched miRNAs 
 
Downregulated HMW RISC enriched miRNAs included the let-7 family, miR-
378 family and miR-28. Particularly, the let-7 family members were amongst 
the most abundant miRNAs in HMW RISC. Let-7 was also found to be enriched 
in HMW RISC in a separate study, and to more efficiently suppress a target 
reporter in activated cells compared to naive (La Rocca et al., 2015). This 
family has been previously suggested to tone down CD8+ T cell responses, 
particularly though targeting several T cell regulators such as Rictor, mTOR, 
Myc and Eomes. The miR-378 family was also downregulated but enriched in 
HMW RISC. miR-378 has no described role in T cells, but was shown to inhibit 
granzyme B in NK cells (Liu et al., 2016). In other cell types it has been shown 
to regulate cell metabolism, to promote cell survival and reduce apoptosis 
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(Florczyk et al., 2015). miR-28 has been shown to play a role in T cell 
exhaustion through targeting of PD-1 (Li et al., 2016). High levels of these 
miRNAs in HMW RISC suggests that they may retain some functionality after 
downregulation, perhaps depending on the availability of their targets. These 
HMW enriched miRNAs and their proposed functions in T cells are 




RISC Function  
miR-17~92 Up HMW Regulation of T cell survival 
and proliferation 
miR-7a Up HMW Tumour suppressor, not 
described in T cells 
miR-210 Up HMW Hypoxia inducible, inhibits 
Th17 response in CD4+ T cells 
miR-31 Up HMW May regulate IL-2 production, 
linked to exhaustion of CD8+ T 
cells 
miR-449/34 Up HMW miR-34a targets components 
of the NF-κβ pathway 
miR-449a regulates CD4+ T 
cell mitochondrial respiration 
miR-140 Up HMW Induced by T-bet in CD4+ T 
cells, promotes cell survival 
miR-21 Up HMW/LMW Anti-apoptotic in activated T 
cells 
miR-155 Up LMW Key regulator of T cell survival 
and proliferation 
let-7 family Down HMW Negative regulation of CTLs, 
targets mTOR, Myc, Eomes 
miR-378 Down HMW Inhibits granzyme B in NK cells 
miR-28 Down HMW Plays a role in T cell 
exhaustion through targeting 
PD-1 
Table 5.7 Function of HMW RISC enriched miRNAs in T cells  
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5.3.8 A role for miR-7a in T cell activation? 
 
miR-7a was found to be consistently upregulated and enriched in HMW RISC 
in our study. Since this miRNA had not been previously described a role in T 
cells, we investigated its function by using an inhibitor. miR-7a is a known 
tumour suppressor, and targets components of the mTOR pathway in cancer, 
specifically Pik3c, p70s6k, eIF4E, Mknk1, Mknk2 and Mapkap1 (Fang et al., 
2011; Wang et al., 2013). It has also been suggested to affect cell survival 
through targeting Bcl-2 (Xiong et al., 2011). We found that inhibition of miR-7a 
resulted in decreased proliferation and higher expression of activation markers 
following CD8+ T cell activation. All cells entered the cell cycle, but the cells 
went through fewer divisions, resulting in a lower total cell number. The cells 
also expressed higher levels of the IL-2 receptor CD25, transferrin receptor 
CD71 and the activation marker CD44. The cells may be more activated in the 
absence of miR-7a, or these surface markers may accumulate in the cell if 
proliferation is impaired. If miR-7a normally functions to suppress the mTOR 
pathway and/or cell survival through Bcl-2, miR-7a inhibition could promote 
cell activation. Further work is needed to understand the role of miR-7a and its 
targets in T cells.   
 
Interestingly, miR-7 function in the brain has been shown to be regulated by a 
network of non-coding RNAs. miR-7 can be bound by a long-non coding RNA 
(lncRNA) Cyrano that promotes its degradation, or a circular RNA (circRNA) 
Cdr1as that has been suggested to stabilise miR-7 (Piwecka et al., 2017; 
Kleaveland et al., 2018). Furthermore, Cdr1as is regulated by another miRNA, 
miR-671 that causes its degradation. This complex interplay between the two 
miRNAs, lncRNA and circRNA is incompletely understood, but highlights how 
controlling the level and activity of this miRNA may be very important in some 
contexts. Interestingly, miR-671 was one of the most HMW RISC enriched 
miRNAs in activated OT-I T cells. Even though its expression was too low to 
pass most expression level filtering, 95% of the miRNA was found in HMW 




To understand miRNA function it is crucial to know their targets. Following 
identification of HMW RISC enriched miRNAs, we next aimed to identify the 




CHAPTER 6:  




6.1.1 Current methods for miRNA target identification 
 
In order to understand miRNA functions, their biological targets must be 
determined. Canonical miRNA targeting consists of the miRNA 5’ seed region 
(nucleotides 2-7) binding to 3’UTR of the target mRNA through complementary 
base-pairing. This mode of recognition has been the basis for bioinformatic 
identification of targets, through scanning of target gene 3’UTRs for sites 
complementary to the miRNA seed. By this approach hundreds of potential 
target genes can be identified for each miRNA, due to likelihood of finding a 
match to the short length of the seed region. Many of these potential targets 
are false positives that may not be biologically relevant targets. 
Bioinformatically predicted targets require additional experimental validation, 
such as luciferase reporter assays, and over-expression or knock-down of 
miRNA followed by measurement of target gene expression by qPCR and/or 
western blotting (Kuhn et al., 2008). However, this does not differentiate 
between direct and indirect targets. Furthermore, while many miRNA-target 
interactions are canonical, it has more recently become apparent that miRNA-
mRNA interactions can involve positions in the miRNA beyond the seed, and 
can also target the mRNA at positions outside the 3’UTR (e.g. the coding 
regions). These non-canonical targets are not predicted bioinformatically.  
 
More recently, the identification of miRNA targets has been facilitated by 
biochemical methods based on cross-linking immunoprecipitation (CLIP) of 
Ago proteins. UV-irradiation can be used to covalently cross-link RNA to RBPs 
which are then immunoprecipitated. This has been combined with high 
throughput sequencing of the RNA bound to the protein of interest in HITS-
CLIP (high throughput sequencing of RNA isolated by CLIP) (Licatalosi et al., 
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2008; Chi et al., 2009). Ago HITS-CLIP has been used to isolate and sequence 
Ago-bound miRNAs and target mRNAs (Chi et al., 2009). From the mRNA 
reads, Ago-binding sites named Ago-mRNA footprints, can be identified and 
were shown to be enriched for miRNA seed matches (Chi et al., 2009). This 
complements bioinformatic identification of miRNA targets by restricting the 
sequence to be analysed for seed matches to the 45-60 nucleotide Ago-mRNA 
footprint. Many variations of the original protocol have been developed to study 
RNA-protein interactions, including photoactivatable-ribonucleoside-
enhanced CLIP (PAR-CLIP, Hafner et al., 2010), individual nucleotide 
resolution CLIP (iCLIP, König et al., 2010; Huppertz et al., 2014), infrared CLIP 
(irCLIP, Zarnegar et al., 2016), enhanced CLIP (eCLIP, Van Nostrand et al., 
2016) and PABP-mediated mRNA 3’ end retrieval by CLIP (PAPERCLIP, 
Hwang et al., 2016). 
 
While HITS-CLIP facilitates the identification of miRNA targets, these still need 
to be assigned computationally by searching for seed matches. Cross-linking, 
ligation and sequencing of hybrids (CLASH) and related methods include an 
additional RNA-RNA ligation step, physically linking miRNAs to their mRNA so 
targets can be identified directly (Kudla et al., 2011; Helwak et al., 2013; 
Helwak and Tollervey, 2014). Following Ago IP, the bound RNAs are 
sequenced and miRNA targets are identified from chimeric reads composed 
of both a miRNA and its target mRNA. This RNA-RNA ligation has been shown 
to naturally occur in the presence of endogenous ligases following RNA 
trimming, but adding an exogenous ligase increases the efficiency of chimera 
generation (Grosswendt et al., 2014). Several other protocols involving RNA-
RNA ligation have been described since, including modified in vivo PAR-CLIP 
(iPAR-CLIP, Grosswendt et al., 2014), covalent ligation of endogenous 
Argonaute-bound RNAs CLIP (CLEAR-CLIP, Moore et al., 2015), RNA hybrid 
and iCLIP (hiCLIP, Sugimoto et al., 2017) and quick CLASH (qCLASH, Gay et 
al., 2018). Generation of chimeras removes unambiguity in assigning miRNAs 
to their targets, which is particularly important for Ago-binding sites that may 
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contain complementarity to multiple miRNA seeds (Broughton and Pasquinelli, 
2016). Furthermore, this allows the identification of non-canonical targets.  
 
6.1.2 Non-canonical targeting 
 
The chimeric reads identified from CLASH and related methods have been 
shown to be enriched in seed matches, however these canonical interactions 
only make up a proportion of chimeric reads. Canonical binding minimally 
requires a perfect match to the miRNA 6mer seed region (nucleotides 2-7 of 
miRNA), and binding can be enhanced by longer matches and an adenosine 
at position 1 of the target. Only 37% of miRNA-mRNA chimeras detected by 
CLASH in HEK cells, and ~30% by modified iPAR-CLIP in C.elegans and 
CLEAR-CLIP in mouse brain involved uninterrupted seed pairing (Helwak et 
al., 2013; Grosswendt et al., 2014). Other types of binding have been 
described, that can involve nucleotide mismatches or bulges in the seed region 
(Chi, Hannon and Darnell, 2012; Loeb, A. A. Khan, et al., 2012). For the targets 
detected by iPAR-CLIP and CLEAR-CLIP, 80% of chimeras involved the seed 
region when 1-2 nucleotide mismatches were allowed. As well as binding 
through the seed region, the 3’ end of the miRNA has also been suggested to 
contribute to binding, and may compensate for imperfect complementarity of 
the seed region (Moore et al., 2015; Broughton et al., 2016). The functionality 
of non-canonical sites that do not have perfect seed complementarity has been 
controversial. While many studies noted a slight but significant repression of 
these targets, a separate independent analysis found no effect (Helwak et al., 
2013; Agarwal et al., 2015). While miRNAs canonically target the 3’UTR of 
mRNAs, many chimeric reads were shown to map to the coding sequence 
(CDS) of mRNAs (Helwak et al., 2013; Moore et al., 2015). While some studies 
found no significant suppression of miRNA binding sites in CDS, others have 
suggested a different mode of translational repression for these sites (Hsin et 





6.1.3 Summary of the CLASH protocol 
 
We used a modified protocol of CLASH to identify miRNA targets in CD8+ T 
cells. The key steps of the protocol are described below and in Figure 6.1. The 
first step in CLASH is the UV-crosslinking of RNA and RBPs. UV-irradiation is 
applied to a cell suspension after which the cells are lysed. Ago-2 is then 
immunoprecipitated from the lysate. Following the IP, the bound RNA is 
trimmed with RNase and the 5’ end is phosphorylated to prepare the RNA for 
the ligation reaction. The ligase enzyme is incubated with the samples to 
produce chimeras of the miRNA and RNA target with which it interacts. Next, 
the ends of the RNA are dephosphorylated and a 3’ adapter is added to the 
RNA, prior to running the samples on SDS-PAGE. We used an adaptor linked 
to IR800-dye to visualise RNA on the gel. The band corresponding to Ago-2 is 
cut from the gels and treated with proteinase K to release Ago-bound RNA. 
This RNA is then phenol-chloroform extracted and used for making 
sequencing libraries. From the sequencing reads, miRNA targets can be 
identified as chimeric miRNA-mRNA reads. With this method, we aimed to 
identify biologically relevant miRNA target pairs from activated CD8+ T cells. 
We also attempted to enrich for chimeric reads by isolating GW182-bound 







Figure 6.1 Summary of CLASH protocol 
Overview of the CLASH protocol. Cells are UV-irradiated and lysed, followed 
by immunoprecipitation of Argonaute and interacting RNA. The miRNA-mRNA 
pairs are ligated together, purified, reverse transcribed, amplified and 







6.2.1 Generation of CLASH libraries 
 
To prepare CLASH libraries from OT-I CD8+ T cells, the cells were activated 
with N4 for 2 days for the earlier time-point (d2), or cultured with IL-2 for a 
further 4 days for fully differentiated CTLs (d6). Proteins and bound RNAs were 
covalently cross-linked using a UV-crosslinker on ice, after which the cells 
were lysed. Ago-2 was immunoprecipitated from the lysates using magnetic 
beads. As a control, we used non-crosslinked samples. We hypothesised, that 
most of the miRNA-target interactions would be occurring in GW182-
containing HMW RISC. We therefore immunoprecipitated GW182 and from 
the GW182 unbound fraction, Ago-2. Finally, we also immunoprecipitated Ago-
2 from HMW and LMW RISC size-separated fractions (Table 6.1).  
 
 
 Samples Cross-link IP 
Experiment 1 Total Ago-2 Yes Ago-2 
D6 CTL No cross-link control No Ago-2 
Experiment 2 Total Ago-2 Yes Ago-2 
D6 CTL GW182 bound Ago-2 Yes GW182  
GW182 unbound Ago-2 Yes Ago-2  
No cross-link control No Ago-2 
Experiment 3 Total Ago-2 (1) Yes Ago-2 
D2 T cells Total Ago-2 (2) Yes Ago-2 
(1) & (2) = 
biological 
replicates 
HMW RISC Ago-2 (1) Yes Ago-2 
HMW RISC Ago-2 (2) Yes Ago-2 
LMW RISC Ago-2 (1) Yes Ago-2 
LMW RISC Ago-2 (2) Yes Ago-2 
 
Table 6.1 Summary of three CLASH experiments 
First experiment contains total Ago-2 IP from cross-linked cells and a non-
cross-linked control from d6 CTLs. Second experiment contains total Ago-2 IP 
and GW182 IP from cross-linked cells, Ago-2 IP from GW182 IP unbound 
fraction, and a non-cross-linked control from d6 CTLs. Third experiment 
contains two biological replicates of total Ago-2 IP and Ago-2 IP from size 
separated HMW and LMW RISC, using cross-linked d2 activated T cells. Ago-
2-flag mice were used for Experiments 1 and 2.    
133 
 
After the immunoprecipitations, we carried out the CLASH protocol as 
described above. Ago-2-RNA complexes were eluted from the IP-beads and 
ran on SDS-PAGE. To visualise Ago-2, the proteins and bound RNA were 
transferred on a membrane for western blotting. Ago-2 could be seen 
overlaying with a band corresponding to the IR800-dye labelled Ago-2 bound 
RNA (Fig.6.2A). The amount of Ago-2 co-immunoprecipitating with GW182 
was very low compared to the total Ago-2 IP sample (Fig.6.2A). Similarly, 
amount of Ago-2 from the size separated HMW and LMW complexes was very 
low compared to total Ago-2 IP (not shown). The amount of input Ago-2 was 
lower for the GW182 IP and for size fractionated samples, and furthermore the 
repeated washing steps throughout the CLASH protocol may have led to 
additional loss of material. For all samples, the band corresponding to Ago-2 
and bound RNAs was cut, then treated with proteinase K prior to RNA 
extraction. 
 
Small RNA libraries were then generated from the extracted RNA in a process 
involving reverse transcription, addition of 5’ adaptor, PCR amplification and 
gel purification of the product. A band of approximately 145 bp could be seen 
when the PCR product was measured on a Bioanalyzer, corresponding to the 
length of the miRNAs containing 3’ and 5’ adaptors. Above this strong band, a 
smear could be seen, containing longer fragments of RNA, such as mRNAs 
and possibly chimeric reads. A strong signal could be detected from all the 
samples after the PCR. Despite a low amount of co-immunoprecipitating Ago-
2 from the GW182 IP, this sample contained lots of RNA (Fig.6.2B). Similarly, 
despite a low input, RNA could be isolated from the HMW and LMW RISC 







Fig 6.2 Preparation of CLASH libraries from CD8+ T cells 
A WB showing immunoprecipitated Ago-2 and GW182 with bound RNA 
containing the labelled 3’adapter (IR800-dye). Ago-2 and GW182 were 
immunoprecipitated from cross-linked d6 CTLs. In addition, Ago-2 was 
immunoprecipitated from the GW182 unbound fraction and from non-cross-
linked cells. WB was probed with Ago-2 antibody. Overlay is shown with 
reduced intensity for Ago-2 to show overlay with RNA band. 
B-C Bioanalyzer measurements showing CLASH libraries from the samples in 
A (B), and from total Ago-2 IP and Ago-2 IP from size separated HMW and 




6.2.2 Identification of miRNA-mRNA chimeras and their binding properties 
 
Following sequencing of the CLASH libraries, the reads were mapped to 
known mouse RNA families to identify miRNA, mRNA and chimeric reads from 
the three experiments. The total number of reads varied between experiments 
and between samples. All samples contained miRNA and protein coding (pc) 
reads, however in many cases rRNA also made up a large proportion of library. 
The total Ago-2 IP libraries contained 10-40% miRNA reads and around 10-
20% pc reads (Fig.6.3A). rRNA reads were abundant in all libraries and made 
up more than 90% of the reads in some cases. Particularly the GW182 IP 
sample contained very few miRNAs reads, instead consisting 90% of rRNA. 
This experiment as a whole contained more ribosomal reads than the other 
two experiments. GW-unbound Ago-2 IP was similar to the total Ago-2 IP in its 
read composition (Fig.6.3A). The HMW and LMW RISC IPs contained fewer 
reads in total, as well as a smaller proportion of miRNA reads compared to the 
total Ago-2 IP (Fig.6.3A-B). The HMW RISC sample however had a similar 
proportion of pc reads than the total Ago-2 IP, whereas LMW RISC contained 
very few pc reads (Fig.6.3A). This is consistent with the idea that while HMW 
RISC and LMW RISC both contain miRNAs, these are mostly associated with 
their target mRNAs in HMW RISC. HMW RISC also contained a high 
proportion of ribosomal reads, which may be expected as HMW Ago 
complexes have previously been shown to co-fractionate with polysomes 




Figure 6.3 RNA composition of CLASH libraries 
RNA biotypes in three separate CLASH experiments  
A Proportion of RNA biotypes in three CLASH experiments, two from d6 CTLs 
(first and second graphs) and one from d2 activated cells (last graph). 
Proportion of reads corresponding to miRNAs, rRNAs, pc reads (mRNAs), 
other types of RNAs (including tRNA, lncRNA and uncategorised RNA) or 
unmapped reads is shown. 






Next, we calculated the number of chimeric reads for each sample. The 
chimeric reads were identified as mapping to both a miRNA and a protein 
coding region of the genome. The first experiment yielded 0.53% chimeric 
reads from the Ago-2 IP, as a proportion of total reads. However, in 
subsequent experiments this proportion was much lower, with approximately 
0.01% chimeric reads of total reads. We filtered out low quality reads, and 
calculated the number of unique chimeric reads. We measured unique reads 
instead of total reads, since multiples of each unique reads may arise from 
PCR amplification which could be biased towards certain reads, and thus may 
not represent the true abundance of the reads. In the first experiment, the total 
Ago-2 IP contained 1769 unique chimeric reads whereas the other three total 
Ago-2 IPs had around 300-400 (Fig.6.4A). GW182 IP, GW-unbound-Ago-2 IP 
and HMW-Ago-2 IP yielded fewer chimeras than the total Ago-2 IPs, at around 
100-250 unique chimeras, and the LMW-Ago-2 IP contained almost no 
chimeric reads (Fig.6.4A). Next, we analysed the type of binding in the 
chimeric reads by looking for perfect matches to the miRNA seed. For the total 
Ago-2 IPs, 7-23% of the chimeric reads contained a perfect seed match to the 
miRNA, depending on the experiment (Fig.6.4B). This was slightly less than 
expected based on previous CLASH experiments, in which approximately 30-
40% of chimeric reads were reported to contain perfect seed matches (Helwak 
et al., 2013; Grosswendt et al., 2014; Moore et al., 2015). 
 
We had expected to enrich for bona fide chimeric reads by selecting GW182-
bound Ago-2 or HMW RISC Ago-2, however, in fact this reduced the number 
of chimeras recovered. Both the GW182 IP and the HMW RISC IP contained 
much less Ago-2 as starting material compared to the total Ago-2 IP, which 
probably compromised efficient recovery of chimeric reads. Based on these 
results, we decided to consider only the total-Ago2 IP samples for further 
analysis, since these appeared to be the highest quality samples with the 
highest numbers of chimeras. For these samples, we determined the type of 
seed that was found, calculating the average proportion of seed matched 
chimeras with a 6mer (exact match to positions 2-7 of miRNA), offset 6mer 
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(positions 3-8), 7mer-A1 (positions 2-7 followed by an adenosine), 7mer m8 
(positions 2-8) or 8mer (positions 2-8 followed by an adenosine) match. The 
predominant seed type was an offset 6mer (28.3%) followed by 6mer (26.2%), 
7mer m8 (22%), 8mer (13%) and 7mer A1 (10.5%). Next, we looked whether 
the part of the chimera containing the mRNA mapped to the 3’UTR, CDS or 
5’UTR of the gene. We found that for the reads with a canonical seed match, 
41.6% matched 3’UTR and 54.5% CDS, with rest matching 5’UTR or regions 
in between. For the non-canonical targets, 50.6% matched 3’UTR and 44% 
CDS. Other CLASH experiments have similarly reported frequent binding to 




Figure 6.4 Number of unique chimeric reads from CLASH experiments 
A Number of unique chimeric reads in three separate CLASH experiments as 
described in Table 6.1. 




6.2.3 Characterisation of miRNAs found in chimeric reads 
 
We then identified which miRNAs were enriched in the chimeric reads. We 
calculated the number of unique chimeric reads per miRNA, and the number 
of unique targets per miRNA. These values differ since multiple unique reads 
could exist of a single miRNA-target interaction, that differ in the start position 
or length of the read. We considered chimeric reads containing a seed match 
separately from those that did not, combining data from all four total Ago-2 IPs. 
In all cases, miR-142a-3p had the most unique reads and unique targets, with 
a total of 35 unique targets containing a seed match and 339 that did not (Table 
6.2). The number of potential targets identified was much higher for the 
chimeras not containing a seed match. These could be non-canonical 
interactions not involving a perfect seed match, or some could be non-specific 
background. Other miRNAs that had a high number of potential targets 
included other highly abundant miRNAs in T cells such as the 5p strand of 
miR-142a, miR-155, miR-21a and miRNAs from the 17~92 cluster. Of interest, 
many miRNAs identified as HMW enriched in the previous chapter, such as 
miR-210-3p, miR-7a, let-7 family and miR-378a were also abundant amongst 
the chimeric reads (Table 6.3). Finally, we measured how many miRNAs were 
targeting a single target mRNA, and found that all targets that were identified 




   
Seed match No seed match 







miR-142a-3p 70 35 miR-142a-3p 757 339 
miR-142a-5p 22 9 miR-21a-5p 275 115 
miR-155-5p 21 3 miR-210-3p 86 37 
miR-92a-3p 17 7 miR-16-5p 86 44 
miR-27a-3p 11 9 miR-92a-3p 83 49 
miR-27b-3p 9 6 miR-378a-3p 72 46 
miR-16-5p 9 5 miR-155-5p 67 28 
let-7i-5p 9 3 miR-147-3p 61 35 
miR-22-3p 8 5 let-7i-5p 56 32 
miR-23a-3p 8 6 miR-7a-5p 54 23 
miR-29a-3p 6 5 miR-142a-5p 52 28 
miR-210-3p 6 5 miR-103-3p 51 28 
miR-324-5p 5 2 miR-26a-5p 43 16 
miR-17-5p 5 4 let-7f-5p 43 24 
let-7f-5p 5 1 miR-17-5p 42 23 
miR-139-5p 4 1 miR-106a-5p 39 15 
miR-296-5p 4 1 let-7d-5p 39 21 
let-7g-5p 4 1 miR-27a-3p 38 25 
let-7d-5p 4 3 miR-182-5p 38 18 
miR-7a-5p 4 2 miR-19b-3p 32 14 
 
Table 6.3 miRNAs with most chimeric reads 
The top 20 miRNAs with the most chimeric reads. Chimeric reads from all four 
total Ago-2 IP experiments were pooled. Table is showing unique chimeric 
reads per miRNAs as well as number of unique targets, taken from chimeras 




6.2.4 Characterisation of miRNA targets found in chimeric reads 
 
We then looked at how many miRNA targets were shared between the 
experiments. We compared the pc reads in chimeric reads between the two 
experiments using d2 activated T cells or d6 activated CTLs. We found poor 
overlap between the experiments, with 37 shared targets on d2 and 65 on d6 
(Fig.6.5A-B). Most chimeric reads were therefore specific to one experiment. 
We also compared the overlap of targets recovered by GW182 IP or GW182-
unbound Ago-2 IP, compared to the total Ago-2 IP. For these reads we again 
found little overlap between the three samples (Fig.6.5C). Due to the low 
number of chimeric reads that were found, these likely only provided a snap-




Figure 6.5 Shared miRNA targets between experiments 
A-C Overlays of the number of unique miRNA targets from chimeric reads in 
different experiments. 
A Targets in chimeras from total Ago-2 IP CLASH samples from d2 activated 
T cells. 
B Targets in chimeras from total Ago-2 IP CLASH samples from d6 CTLs. 
C Targets in chimeras from total Ago-2 IP, GW182 IP and GW182 unbound 
(Ago-2 IP) from d6 CTLs. 
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We also performed Gene Ontology (GO) enrichment analysis of the miRNA 
targets found in chimeric reads. For this analysis we combined data from all 
four Ago-2 IPs but only considered chimeras that contained a miRNA seed 
match. This showed the enrichment of several processes, related to T cell 
activation, cell migration and cell metabolism (Table 6.2). The TCR signalling 
pathway and lymphocyte activation and differentiation associated proteins 
included Ptpn22, Bcl-10, Id2, NF-kb-inhibitor d, Nfatc3, Roquin-1, and Cd28.  
 





Positive regulation of filopodium 
assembly 
4 16.63 1.48E-04 
Regulation of T cell receptor signaling 
pathway 
5 15.72 2.71E-05 
Dendritic spine development 4 14.32 2.50E-04 
Adipose tissue development 4 13.93 2.75E-04 
ATP synthesis coupled electron transport 5 11.72 9.90E-05 
Regulation of antigen receptor-mediated 
signaling pathway 
5 11.31 1.16E-04 
Oxidative phosphorylation 5 10.07 1.93E-04 
Aerobic respiration 5 9.91 2.06E-04 
Cellular respiration 9 8.59 1.80E-06 
Positive regulation of plasma membrane 
bounded cell projection assembly 
6 7.3 2.33E-04 
mRNA transport 6 7.3 2.33E-04 
ATP metabolic process 8 6.06 7.37E-05 
Negative regulation of lymphocyte 
activation 7 5.94 2.37E-04 
Energy derivation by oxidation of organic 
compounds 9 5.92 3.13E-05 
Aging 7 5.86 2.56E-04 
Negative regulation of cellular catabolic 
process 9 4.94 1.20E-04 
Homeostasis of number of cells 9 4.55 2.16E-04 
Negative regulation of catabolic process 10 4.41 1.23E-04 
Lymphocyte differentiation 9 4.33 3.08E-04 
 
Table 6.2 GO term enrichment analysis of miRNA targets containing a 
canonical seed match 
Targets from chimeric reads from all four total Ago-2 IP experiments were 
pooled and chimeras not containing a seed match were filtered out. The 
targets were analysed for GO term enrichment. Number of genes in each 
biological process (GO term) is shown, with fold enrichment and p-value. The 
top 20 significant hits are shown ranked by fold difference.   
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6.2.5 Bioinformatic validation of chimeric reads with TargetScan and Mirza  
 
Since we found a large number of potential targets for several miRNAs, 
particularly ones that did not contain a perfect seed match, we further analysed 
these using available bioinformatic tools. We used TargetScan to identify 
predicted miRNA targets from the data and Mirza to calculate binding energies 
of potential novel targets. TargetScan is a target prediction program that 
combines information from the binding site and other features identified from 
experimental data to predict the most effectively targeted mRNAs (Agarwal et 
al., 2015). TargetScan developers found no suppressive function to non-
canonical sites and thus only consider types of canonical binding, which must 
include a perfect match to miRNA seed in the 3’UTR of the target mRNA. We 
additionally used the Mirza algorithm to predict miRNA targets (Khorshid et al., 
2013). This program combines energy parameters from CLIP data for a 
biophysical model to calculate the binding energy of the interaction and 
assigns a score based on this, with high scores indicating positive binding 
energy and increased likelihood that the binding is real. In contrast to 
TargetScan, Mirza also considers non-canonical targeting.  
 
First, we separated the data into chimeric reads containing a perfect seed 
match, and those that did not, then calculated TargetScan and Mirza scores 
for these. The process for analysing chimeric reads is summarised in Figure 
6.6. Most chimeric reads were found as a single unique read. However, as 
expected, the reads containing a seed match had high TargetScan and Mirza 
scores. Of the seed-containing targets in 3’UTR, 34% were predicted as 
targets by TargetScan. These are likely to be real interactions causing target 
suppression (Table 6.4). TargetScan has strict criteria for assigning predicted 
miRNA targets, whereas Mirza can be used to predict the binding energy for 
any pattern of complementarity in the interaction (beyond the seed site). 
Several interactions were found that were not TargetScan predicted targets for 
the miRNA but had high Mirza scores (Table 6.5). Many of these were 
interactions with the CDS of the target gene since these are not considered by 
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TargetScan (Table 6.6). These are also likely to be real interactions, but may 
not result in efficient target suppression.  For the chimeras with a perfect seed 
match, gene annotation of the identified miRNA targets showed proteins 
involved in various processes such as regulation of gene transcription, cell 
metabolism, protein transport and signalling pathways, with very few T cell 






Figure 6.6 Bioinformatic analysis of chimeric reads 
Chimeric reads from all four total Ago-2 IP experiments were pooled The reads 
were separated into those containing a perfect seed match to the miRNA and 
those not containing a seed match. Each group was divided into chimeric 
reads where the read maps to 3’UTR or CDS of the mRNA. Reads containing 
a perfect seed match in the 3’UTR were analysed by TargetScan and Mirza, 
whereas reads not containing a perfect seed match, or mapping to the CDS, 




miRNA Target Unique reads Mirza TS Gene Annotation 
miR-147-3p Ndufa4 1 2091.3 99 Transport, mitochondrion, 
oxidative phosphorylation 
miR-27a-3p Lpar6 1 306.2 99 Signal transduction, G-protein 
coupled receptor signaling 
pathway 
miR-296-3p Mt2 3 203.6 99 Cellular zinc ion homeostasis, 
nitric oxide mediated signal 
transduction 
miR-142a-5p Slc39a1 3 17.8 99 Metal ion transport 
miR-92a-3p Sertad3 1 3174.5 98 Regulation of transcription, 
negative regulation of cell growth 
miR-17-5p Nabp1 1 473.5 98 DNA repair 
miR-25-3p Sertad3 1 188.7 98 Regulation of transcription, 
negative regulation of cell growth 
miR-23b-3p Sbno1 1 136.1 97 Regulation of transcription 
miR-32-5p Srpr 3 101.6 97 Intracellular protein transport 
 
Table 6.4 Chimeric reads containing a perfect seed match in 3’UTR 




miRNA Target Unique 
reads 
Mirza Gene Annotation 
miR-26b-5p Capn10 1 1150.9 Mitophagy, proteolysis 
miR-20a-5p Nabp1 1 457.6 DNA repair 
miR-17-5p Mtf1 2 316.2 Regulation of transcription, response to 
oxidative stress 
let-7f-1-3p Mkln1 1 210.6 Cell matrix adhesion, actin cytoskeleton 
reorganization 
let-7g-5p Hps1 4 168.6 Organelle organization, blood coagulation, 
positive regulation of natural killer cell 
activation 
miR-210-3p Aebp2 2 142.4 Regulation of transcription 
miR-27b-3p Fam46a 1 127.6 Regulation of gene expression 
miR-23a-3p Vrk3 1 120.2 Protein phosphorylation, negative 
regulation of ERK1 and ERK2 cascasde 
miR-23b-3p Fmr1 1 50.1 Regulation of alternative mRNA splicing 
miR-24-3p Rnf138 2 47.3 Protein ubiquitination, DNA repair 
miR-142a-5p Trps1 1 46.7 Regulation of transcription, cell 
development 
 
Table 6.5 Chimeric reads containing a perfect seed match in 3’UTR 







miRNA Target Unique reads Mirza Gene Annotation 
miR-27a-3p Jmjd1c 2 971.6 Epithelial cell morphogenesis, 
transcription 
miR-210-3p Fnbp1 1 515.9 Endocytosis, vesicle mediated transport 
miR-106a-5p Plekhm1 1 497.4 Protein transport, autophagy 
miR-29a-3p Fh1 1 484.3 Citric cycle (TCA cycle) 
miR-27b-3p Fam69a 1 392.6 Endoplastic reticulum membrane 
miR-320-3p Oaz1 1 291.8 Polyamine metabolic process 
miR-324-5p Anxa2 4 269.2 Angiogenesis, membrane raft assembly 
miR-22-3p Mertk 1 256.4 Natural killer cell differentiation, negative 
regulation of cytokine production 
miR-378a-5p Exo1 1 233.6 Immune system process, somatic 
hypermutation of immunoglobulin genes 
miR-155-5p mt-Nd1 18 232.1 Oxidative phosphorylation 
 
Table 6.6 Chimeric reads containing a perfect seed match in CDS 




Next, we inspected the chimeric reads that did not contain a perfect seed 
match, which was the vast majority of chimeras (88%). We calculated Mirza 
scores for these reads and found several chimeric reads with relatively high 
scores (Tables 6.7 and 6.8). These usually involved some binding in the seed 
region but contained a mismatch, a gap or bulge in the sequence. These 
interactions with relatively high Mirza scores are again likely to be real but may 
not cause target suppression, in particular for those found in the CDS. The 
non-canonical targets included the transcription factor Nfat5 as well as other 
transcription regulators and proteins linked to protein transport, oxidative 
phosphorylation, autophagy, hypoxic response and cell migration. Many 
chimeric reads also had very low Mirza scores (<1) with only short matches to 
the seed region or in some cases no clear pattern of binding which we 






Table 6.7 Chimeric reads with no seed match, mapping to 3’UTR 
The top 10 chimeric reads without a perfect seed match, mapping to 3’UTR, 
ranked by Mirza score. 
 
 
miRNA Target Unique 
reads 
Mirza Gene Annotation 
miR-142a-3p Smchd1 2 47.3 Inactivation of X chromosome by 
DNA methylation 
miR-342-3p Hsp90b1 3 25.2 Response to hypoxia, protein folding 
miR-30e-5p Ppib 1 21.3 Protein peptidyl-prolyl isomerization, 
protein folding 
miR-142a-3p Atp6v1e1 3 20.1 ATP hydrolysis coupled proton 
transport, oxidative phosphorylation 
miR-145a-5p Necap2 1 18.0 Protein transport, endocytosis 
miR-21a-5p Ssr1 1 17.6 Protein processing in endoplastic 
reticulum 
miR-744-5p Akna 2 17.4 Regulation of transcription 
miR-21a-5p Dhx36 1 13.7 Regulation of transcription 
miR-378a-3p Cpne3 1 13.2 Positive regulation of cell migration, 
cellular response to calcium ion 
miR-361-5p Acadm 1 12.8 Fatty acid degradation, 
oxidoreductase activity 
 
Table 6.8 Chimeric reads with no seed match, mapping to CDS 
The top 10 chimeric reads without a perfect seed match, mapping to CDS, 
ranked by Mirza score. 
 
  
miRNA Target Unique reads Mirza Gene Annotation 
miR-29b-3p Nfat5 1 55.8 Cytokine production, regulation of 
transcription 
miR-182-5p Fam107b 3 36.4 Sensory perception of sound 
miR-26a-5p Wipi2 1 34.2 Autophagosome assembly 
miR-23a-3p Mlxip 1 32.2 Regulation of transcription 
miR-17-5p Cmtm3 1 31.5 Chemotaxis, positive regulation of 
BCR signaling pathway 
miR-15b-5p Pdap1 5 26.2 Platelet derived growth factor 
binding 
miR-142a-3p Ms4a4b 3 21.0 Integral component of plasma 
membrane 
miR-27a-3p Atp5f1 2 12.8 ATP synthesis coupled proton 
transport, oxidative phosphorylation 
miR-21a-3p Vmp1 2 12.6 Exocytosis, autophagy 
miR-142a-3p Efcab11 1 10.3 Calcium ion binding 
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6.2.6 Identification of potential targets for specific miRNAs  
 
Next, we examined the targets for specific miRNAs known to be important for 
T cell activation. We decided to look at targets for miR-142a-3p, since this 
miRNA had the most chimeric reads, and is also a known regulator of T cell 
proliferation. We also identified potential targets for miR-17 and miR-92 which 
are well known for their role in supporting effector T cell proliferation. Finally, 
we looked at the potential targets for the HMW RISC enriched miRNAs miR-
7a and miR-210-3p.  
 
miR-142a-3p had the most chimeric reads out of all miRNAs in all four 
experiments. This miRNA has previously been described to be abundant in T 
cells and to regulate T cell proliferation. A number of cell cycle regulatory 
genes have been shown to be dysregulated in miR-142 KO cells (Sun et al., 
2015; Mildner et al., 2017). The atypical transcription factors E2f7 and E2f8 
and the cell cycle regulator Cdkn1b were suggested to be direct targets of miR-
142 (Sun et al., 2015; Mildner et al., 2017). We ranked the top 20 chimeric 
targets for miR-142-3p from our data by the Mirza scores (Table 6.9). These 
include targets that have a perfect seed match to miR-142 as well as some 
that do not. Many of the targets were found in the CDS whereas some were 
canonical targets in the 3’UTR. We identified a few genes that are linked to 
regulation of the cell cycle, notably Mki67 and Mcm6. Both of these however 
contain a seed match in the CDS of the gene, making it unclear whether these 
are functional targets. Potential canonical targets that were identified included 
Rc3h1 (Roquin-1) which is an mRNA binding protein that has a key role in 
suppressing spontaneous T cell activation and differentiation (Chang et al., 
2012; Vogel et al., 2013). Another canonical target was Coro1c (coronin), 
which is a protein involved in regulation of cell adhesion and cytoskeleton, and 
has been shown to be enriched in F-actin rich membrane protrusions in 





Target Site Unique reads Mirza 
Seed 
match? Gene Annotation 
Rpl24 CDS 8 74.9 yes Ribosomal large subunit 
assembly 
Mki67 CDS 3 72.5 yes Regulation of mitotic cell division 
Smchd1 CDS 2 47.3 no Inactivation of chromosome X by 
methylation 
Ash1l CDS 1 46.5 yes Negative regulation of acute 
inflammatory response 
Tm9sf2 CDS 1 45.7 yes Endosome membrane 
Gm13248 UTR5 1 42.4 yes 
 
Gtf3c2 UTR3 2 30.8 yes Transcription 
Zfp120 UTR3 1 28.3 yes Regulation of transcription 
Coro1c CDS-
UTR3 
1 24.3 yes Actin cytoskeleton organization, 
regulation of focal adhesion 
assembly 
3110057O12Rik UTR3 3 22.0 yes 
 
Ms4a4b UTR3 3 21.0 no Integral component of plasma 
membrane 
Atp6v1e1 CDS 3 20.1 no ATP hydrolysis coupled proton 
transport 
Rc3h1 UTR3 1 19.4 yes mRNA binding, regulation of T 
cell proliferation 
Txnip UTR3 2 19.3 yes Regulation of transcription, 
response to oxidative stress 
Srrm2 CDS-
UTR3 
1 18.4 yes mRNA processing, RNA splicing 
Tceb3 UTR3 1 13.4 yes Regulation of transcription 
Gng5 UTR3 1 13.1 yes G-protein coupled signalling 
pathway  
Ogt CDS 7 13.0 yes Regulation of protein 
phosphorylation, protein O-
linked glycosylation  
Mcm6 CDS 3 12.1 yes DNA replication, cell cycle 
Prss16 UTR3 1 11.9 yes Proteolysis, serine-type 
peptidase activity 
 
Table 6.9 Potential miR-142a-3p targets 
The top 20 chimeric reads for miR-142a-3p, ranked by Mirza score. 
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Several potential targets were identified for miR-17 and miR-92. These 
miRNAs are encoded by the same miRNA cluster but have different seed 
sequences. The miRNAs from this cluster have however been suggested to 
regulate partly overlapping targets: for example, Pten was shown to be bound 
by five of the six miRNAs of the miR-17-92 cluster (Wu et al., 2012). However, 
we could not find this target in our data, nor any other shared targets. We found 
one TargetScan-predicted target for each miRNA (Nabp1 and Sertad3) and 
potential novel targets involved in a variety of broad biological processes, such 
as regulation of transcription, DNA repair, proteolysis, cell metabolism and 
ribosome formation (Tables 6.10 and 6.11). 
 
 
Target Site Unique reads Mirza 
Seed 
match? Gene Annotation 
Nabp1 UTR3 1 473.5 yes DNA repair 
Mtf1 UTR3 2 316.2 yes Regulation of transcription, response 
to oxidative stress 
Oas2 CDS 1 14.8 yes Immune system process, purine 
nucleotide biosynthetic process 
Ctsa CDS 1 9.8 yes Proteolysis involved in cellular 
catabolic process 
Paip1 UTR3 1 2.3 no Regulation of translation 
Mipep CDS 5 2.3 no Proteolysis, peptide metabolic 
process 
Tmem30a UTR3 1 1.6 no Transmembrane transport 
 
Table 6.10 Potential miR-17-5p targets 
Chimeric reads for miR-17-5p, ranked by Mirza score (excluding reads with 





Target Site Unique reads Mirza 
Seed 
match? Gene Annotation 
Sertad3 UTR3 1 3174 yes Regulation of transcription 
Mdh1 CDS 1 172.4 yes Malate dehydrogenase activity, 
regulation of defense response to 
virus, citrate cycle (TCA) 
Atp5j UTR5 2 63.4 yes ATP synthesis coupled proton 
transport 
Atp10a CDS 2 40.5 yes Phospholipid transporting ATPase 
activity 
Opa1 CDS 2 11.0 yes Mitochondrial genome 
maintenance 
Hmgcr UTR3 3 10.2 yes Lipid metabolic process, NADPH 
activity 
Baz1b UTR3 3 6.9 no Chromatin remodeling, double-
strand break repair 
Cnot6l CDS 3 4.5 no mRNA deadenylation dependent 
decay 
Ptpn22 CDS 6 2.8 yes Phosphoprotein phosphatase 
activity, negative regulation of TCR 
signaling pathway  
Gm10036 CDS 1 2.3 no Ribosomal large subunit assembly 
Rpl11 CDS 1 2.3 no Ribosomal large subunit assembly 
 
Table 6.11 Potential miR-92a-3p targets 
Chimeric reads for miR-92a-3p, ranked by Mirza score (excluding reads with 
Mirza score < 1). 
 
Finally, we looked at the potential targets for the HMW RISC enriched miRNAs 
miR-210-3p and miR-7a. miR-7a has been shown to target the mTOR 
signalling pathway in other cells types but has not been studied in T cells 
(Wang et al., 2013). We only found two potential targets for miR-7a, both of 
which contained a perfect seed match (Table 6.12). One of these was an 
uncharacterised gene, whereas the other regulates tRNA synthesis. miR-210-
3p has been shown to regulate CD4+ T cell activation and responses to 
hypoxia by targeting Hif1α in a negative feedback loop. In our data, the only 
canonical target with a seed site in the 3’UTR was Aebp1 which has no 
reported role in T cells (Table 6.13). Potential non-canonical targets include 
the sodium ion transporter Slc9a3r1 (NHERF-1), which has been shown to 
play an inhibitory role in the formation of the immune synapse upon T cell 




Target Site Unique reads Mirza 
Seed 
match? Gene Annotation 
AA474408 UTR3 2 2.4 yes 
 
Lars2 UTR3 2 1.7 yes Aminoacyl tRNA biosynthesis 
 
Table 6.12 Potential miR-7a-5p targets 
Chimeric reads for miR-7a-5p, ranked by Mirza score (excluding reads with 




Target Site Unique reads Mirza 
Seed 
match? Gene Annotation 
Fnbp1 CDS 1 515.9 yes Endocytosis, vesicle-mediated 
transport 
Wdr12 UTR5 1 263.6 yes Maturation of 5.8S rRNA 
Aebp2 UTR3 2 142.4 yes Regulation of transcription 
Gatad2b CDS 1 37.7 yes Regulation of transcription, DNA 
methylation 
Polh CDS 4 10.2 no DNA replication, DNA repair 
Slc9a3r1 UTR3 6 9.5 no Sodium ion transport, regulation 
of signaling pathways 
Chtop UTR3 4 5.1 no mRNA export from nucleus 
Chfr UTR3 1 4.1 no Protein polyubiquitionation, 
mitotic cell cycle 
Kif21b UTR3 2 1.9 no Microtubule based movement 
Prrc2a CDS 1 1.5 no Poly(A) protein binding, cell 
differentiation 
 
Table 6.13 Potential miR-210-3p targets 
Chimeric reads for miR-210-3p, ranked by Mirza score (excluding reads with 





6.3.1 Generation of CLASH libraries – issues and future considerations 
 
6.3.1.1 Target abundance and reproducibility 
 
We generated CLASH libraries from activated CD8+ T cells with the aim of 
identifying miRNA targets from chimeric reads. While we successfully isolated 
Ago-2 bound miRNAs and mRNAs, the main issue faced was a low recovery 
of chimeric reads. While one experiment yielded around 1,800 unique chimeric 
reads, the three other experiments only had a few hundred chimeras. This is 
not unprecedented, with most CLASH experiments producing a low proportion 
of chimeric reads, at 0.24% for modified iPAR-CLIP, 0.3-1% for qCLASH and 
~2% for CLASH and CLEAR-CLIP (Helwak et al., 2013; Grosswendt et al., 
2014; Moore et al., 2015; Gay et al., 2018). Since the number of chimeric reads 
was very low, many interactions were only supported by a single unique 
chimeric read. Similarly in the modified iPAR-CLIP only 18% of the chimeras 
were supported by more than a single read (Grosswendt et al., 2014). The low 
number of chimeras is unlikely to represent a comprehensive view of the 
interactions that actually occur in the cell. Recovery of only a small proportion 
of miRNA-target interactions may also account for the poor reproducibility 
between experiments.   
 
6.3.1.2 HMW RISC chimeric reads 
 
We attempted to enrich for chimeric reads by isolating GW182-bound Ago-2 
or size separated HMW RISC associated Ago-2. However, these additional 
steps resulted in reduced recovery of immunoprecipitated Ago-2, which 
significantly decreased the amount of starting material for the CLASH protocol. 
As a result, we ended up with fewer reads obtained from these samples 
compared to total Ago-2 IPs. From the GW182 IP, we recovered mostly rRNA 
and very few miRNAs and chimeric reads compared to other samples. This 
may have been RNA that was associated with GW182, or background noise 
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from the polyclonal GW182 antibody used for immunoprecipitation, despite 
attempts to reduce the background by gel purifying the band at the molecular 
weight of Ago-2. For HMW and LMW RISC Ago-2 IP, again we recovered 
fewer chimeric reads from these samples compared to total Ago-2 IP. While 
HMW and LMW RISC Ago-2 IPs had a similar proportion of miRNA reads, 
HMW Ago-2 IP contained more protein coding reads. Indeed, the number of 
protein coding reads was comparable between HMW RISC Ago-2 IP and the 
total Ago-2 IP, with essentially no reads from the LMW RISC IP, indicating that 
most of the pc mRNAs were contained in the HMW fraction. The number of 
chimeric reads was also much lower in LMW RISC compared to HMW RISC 
(~30 unique chimeras compared to ~130 in HMW RISC and ~350 in total Ago-
2 IP). This supports the hypothesis that while LMW RISC contains miRNAs, 
these are predominantly not target-bound.  
 
6.3.1.3 CLASH protocol modifications 
 
While we started with the original CLASH protocol published by Helwak et al., 
many modifications were made to the protocol to optimise it for our 
experiments. A key difference was the purification of endogenous Ago-2, 
instead of a tagged overexpressed protein to favour the recovery of biologically 
relevant targets. To make the protocol quicker and easier, instead of 
radioactive labelling of RNA, we used a 3’ adaptor conjugated to IR800-dye, 
similar to one described in ir-CLIP (Zarnegar et al., 2016). This allowed 
convenient visualisation using an Odyssey CLx scanner. We also used a kit 
by TriLink for making RNA libraries to speed up this step, enable more 
reproducibility between samples and reduce the amount of adaptor dimers in 
our datasets.  
 
In the past few years, many new publications have reported modified protocols 
with improved HITS-CLIP and CLASH datasets.  The following the steps could 
potentially be modified and significantly affect the outcome of the protocol: 
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• The first key step is cross-linking RNA to proteins. Cross-linking 
increased the number of chimeras that were recovered, even though 
some were found without cross-linking as well (Fig.6.4). Some protocols 
use chemical cross-linking instead of UV irradiation (Grosswendt et al., 
2014). Optimisation of cross-linking conditions may increase the 
amount of recovered RNA. 
• Following the cross-linking, the cells are lysed and Ago-2 is 
immunoprecipitated on magnetic beads. The beads are washed several 
times in high-salt and low-salt washes throughout the protocol. The 
washing steps are crucial since these reduce amount of non-specific 
RNA that could co-purify. However very stringent washing conditions 
could lead to a loss of real signal. The washing conditions could 
therefore potentially be further optimised for maximal recovery of Ago-
2 bound RNA.  
• The amount of RNase and length of digestion could be adjusted for 
optimal RNA end trimming to allow ligation of the two ends.  
• The yield of chimeric reads was increased in CLEAR-CLIP by 
optimising the ligation step, thus this may be crucial for recovering more 
chimeric reads (Moore et al., 2015).  
• The next key step after elution from the IP beads, is cutting the Ago-
RNA complex from the gel. In HITS-CLIP, Ago bound to mRNAs was 
suggested to be found further up in the gel compared to miRNA-bound 
Ago (Chi et al., 2009). We cut the gel around the molecular weight of 
Ago, as well as a section above it. The WB showed a clear RNA band 
at the molecular weight of Ago-2, suggesting that by cutting this band 
we enriched for Ago-bound RNAs. However, these may have been 
predominantly miRNAs which could saturate the sequencing reads, 
thus cutting a different section on the gel higher up might be better for 
enriching for chimeric reads (the same holding true when purifying the 
PCR products of the libraries prior to sequencing).   
• Many of the reads that were recovered following sequencing were 
ribosomal reads. This may be because some of the targets that are 
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being bound by Ago were also be bound to ribosomes. HMW RISC has 
been shown to co-fractionate with ribosomal proteins (Landthaler et al., 
2008). Therefore, depletion of ribosomal RNA with commercially 
available kits may help to reduce unwanted reads focusing on the 
chimeric reads.  
 
6.3.2 Non-canonical targets 
 
6.3.2.1 Binding without miRNA seed 
 
We evaluated the quality of the chimeric reads by searching for seed matches 
in the mRNA sequence. 12% of the reads contained a perfect seed match, 
showing that canonical miRNA targets could be identified with our CLASH 
protocol. 88% of the reads therefore did not contain a perfect seed match. This 
could be due to non-canonical binding not involving a perfect seed match, 
background from miRNA:mRNA pairs formed ex vivo, or issues with the 
bioinformatic analysis. For example, the seed matching site of the mRNA may 
be lost during the trimming and ligation of the chimeras, though we extended 
short pc sequences to 55 bp when looking for seed matches.  
 
The chimeric reads that did not contain a perfect seed match may have instead 
involved imperfect pairing through the seed region and/or binding through the 
3’ end of the miRNA. This type of non-canonical binding has been widely 
reported in CLASH experiments. 37% of CLASH chimeric reads from HEK 
cells had uninterrupted seed pairing, whereas for chimeric reads in C.elegans 
detected by iPAR-CLIP and CLEAR-CLIP chimeras from mouse brain, this 
proportion was approximately 30% (Helwak et al., 2013; Grosswendt et al., 
2014; Moore et al., 2015). Most chimeras however involved some level of 
binding in the seed region. Both iPAR-CLIP and CLEAR-CLIP reported that 
80% interactions involved the seed region when allowing for 1-2 mismatches 
or bulges  (Grosswendt et al., 2014; Moore et al., 2015). In contrast, 46% of 
qCLASH identified chimeric reads had no recognisable seed-pairing even 
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when allowing for 2 mismatches (Gay et al., 2018). Non-canonical interactions 
involving imperfect seed pairing were shown to be functional, however to a 
lesser extent compared to targets containing perfect seed matches (Helwak et 
al., 2013; Grosswendt et al., 2014; Moore et al., 2015). Seed interactions were 
frequently complemented by pairing through the 3’ end of the miRNA, both in 
our data and data published by others. This was shown to stabilise 
interactions, in particular those involving imperfect seed pairing (Moore et al., 
2015; Broughton et al., 2016). Furthermore, this has been suggested to add 
specificity to miRNA targeting, meaning that members of the same miRNA 
family containing the same seed could in some cases target a different set of 
mRNAs based on 3’ end pairing. Entirely seedless interactions have been 
identified for certain miRNAs as well, CLASH chimeras for miR-92a revealed 
‘seedless binding’ involving a 3’ motif, which was shown to result in weak target 
repression (Helwak et al., 2013). 
 
In CD4+ T cells, HITS-CLIP found many non-canonical sites for mi-R-155 
(Loeb, A. a. Khan, et al., 2012). 40% of the identified Ago-binding sites did not 
contain a perfect seed match for miR-155, but were instead enriched for non-
canonical sites containing a mismatch in the seed. Again these sites were 
shown to be functional, though the suppression was not as strong as for 
canonical sites. Another study examined miR-155 targets in four different 
immune cell types, including CD4+ T cells, and found cell-type specificity for 
target suppression (Hsin et al., 2018). Sites with 8mer seed complementarity 
were more likely to be suppressed in all cells, whereas those with only 6mer 
complementarity were more repressed in cells with high miR-155 expression. 
This however did not explain all the cell specific targeting. Approximately 25-
45% of miR-155 dependent sites did not have a perfect seed match, and these 
were more cell type specific. The regulation of these targets was shown to be 





6.3.2.2 Binding to the coding region of mRNA 
 
Frequent pairing to the CDS has been detected in both HITS-CLIP and CLASH 
datasets, with approximately half of the chimeric reads for miRNA:mRNA 
interactions mapping to the CDS (Loeb, A. a. Khan, et al., 2012; Helwak et al., 
2013; Moore et al., 2015; Gay et al., 2018). Similar to this, in our data nearly 
half of the chimeric reads contained an mRNA CDS. Both seed-matched and 
non-seed containing chimeric reads involved CDS binding in similar 
proportions (55% and 45%, respectively). It was previously shown that pairing 
patterns were similar across different transcript regions such as 3’UTR and 
CDS (Moore et al., 2015). In many cases binding to CDS has not been shown 
to lead to efficient target suppression (Loeb, A. A. Khan, et al., 2012; Hsin et 
al., 2018). It has been suggested that mRNAs with miRNA binding sites in both 
3’UTR and CDS were more regulated than those with a site in 3’UTR only 
(Fang and Rajewsky, 2011). miRNA binding to CDS may therefore work 
cooperatively with sites in 3’UTRs. CLASH data showed some suppressive 
function for sites in CDS, though these were weaker than sites in 3’UTR 
(Helwak et al., 2013). One study suggested that targeting the 3’UTR might be 
more efficient at causing mRNA degradation, whereas sites in CDS might lead 
to translational repression (Hausser et al., 2013). This was supported by a 
recent study that showed ‘ribosome stalling’ for transcripts containing miRNA 
binding sites in CDS (K. Zhang et al., 2018). Interestingly, this mode of 
repression was shown to require only minimal pairing through the miRNA seed 
region, and instead relied on 3’ end pairing (K. Zhang et al., 2018).   
 
Most HITS-CLIP and CLASH experiments therefore support weak but 
significant suppression for at least a proportion of targets not containing a 
perfect seed match, and a potential effect for targets in CDS. This has however 
been challenged by an independent analysis where no significant effect on 
target mRNAs containing non-canonical sites was found in a thorough analysis 
of HITS-CLIP and CLASH data (Agarwal et al., 2015). It was confirmed that 
real interactions can be formed through non-canonical binding, but it was 
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concluded that this did not cause significant repression of the target. The 
function of these non-canonical sites therefore remains to be confirmed.  
 
6.3.3 Identification of potential novel miRNA targets 
 
We identified several potential novel targets for miRNAs expressed in CD8+ T 
cells. We first looked at the miRNA with the most chimeric reads across all 
experiments: miR-142a-3p. Both strands of miR-142 were expressed, 
however the majority of chimeric reads were for the more abundant miR-142a-
3p. This miRNA has been described to regulate T cell proliferation through 
targeting of the atypical transcription factors E2f7 and E2f8, and the cell cycle 
inhibitor Cdkn1b (Sun et al., 2015; Mildner et al., 2017). Furthermore, miR-142 
KO in T cells shows dysregulation of several cell cycle associated genes (Sun 
et al., 2015; Mildner et al., 2017). We also analysed potential targets for miR-
17 and miR-92. These miRNAs are well known to target Pten 3’UTR in T cells 
(Wu et al., 2012). We did not find these previously validated targets for miR-
142, miR-17 or miR-92 from our data. This could be due to several reasons: i) 
a rapidly degraded target mRNA may not be captured ii) the time-point of 
targeting may be different, for example early in the activation instead of in 
CTLs iii) the low number of chimeric reads may not give a comprehensive 
overview of targets. For miR-142, we found some cell cycle associated targets 
from our data, notably Mki67 and Mcm6. A seed match for these miRNAs was 
found in the CDS, thus making it more uncertain whether binding leads to 
suppression of these genes. Other potentially interesting novel targets for miR-
142a-3p included Coronin and Roquin-1, both of which could be validated 
experimentally (Table 6.9).  
 
Finally, we also attempted to identify potential targets for the HMW RISC 
enriched miRNAs miR-7a an miR-210. Both these miRNAs were amongst 
those with most chimeric reads (Table 6.3). Other HMW enriched miRNAs, 
such as the let-7 family members and miR-378a miRNAs also appeared 
amongst these miRNAs, despite downregulated expression in activated T 
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cells. This supports our hypothesis that less abundant miRNAs could be 
actively suppressing their targets when in HMW RISC. Unfortunately, most of 
the targets identified for miR-7a and miR-210 had low predicted binding 
energy, making it unlikely that these are real interactions, or that the binding 
would cause target suppression. We did however identify some potential 
canonical and non-canonical targets that could be further validated (Tables 
6.12 and 6.13). 
 
The bioinformatic tools used in our study aid in short-listing miRNA:mRNA 
target pairs that are already predicted TargetScan targets or are likely to be 
true targets due to a perfect seed match or a high binding energy predicted by 
Mirza. This gives an overview of potential novel miRNA targets. However, true 
confirmation of an interaction would require experimental validation, such as 
overexpression or knock-down of a specific miRNA, and measurements of 
target suppression through reporter assays, qPCR and western blotting. Of 
interest, it has recently been suggested that miRNA targeting may be even 
more subtle than previously thought, based on the observation that individual 
variation between mice was shown to be stronger than the repressive effect of 
a miRNA on a target gene (Pinzón et al., 2017). It was concluded that this level 
of regulation would not be robust enough to affect gene function, and that 
miRNA effects may consequently be due to repression of a few dose-sensitive 
genes rather than global downregulation of all its potential targets (Pinzón et 
al., 2017; Seitz, 2017). Therefore, in addition to confirming miRNA binding to 
the target, it is important to investigate the biological effects of disrupting this 
interaction. It was however also noted that since many genes contain multiple 
miRNA binding sites, the collective effect of these may have a more notable 
effect, with such cooperativity previously described for many miRNAs 
(Grimson et al., 2007). Accurate detection of biologically important miRNA 
targets therefore remains a challenge, but CLASH-based methods have the 
potential to improve our understanding of this.   
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CHAPTER 7: Discussion 
 
7.1 The role of miRNAs and HMW RISC in T cell activation 
 
We set out to study the role of miRNAs in CD8+ T cell activation. To get a 
global understanding of miRNA function, we measured miRNA expression in 
naive and activated cells T cells, studied the formation of RISC upon T cell 
activation, analysed differential association of miRNAs with HMW and LMW 
RISC and finally attempted to identify miRNA targets using CLASH.  
 
T cell activation induces dramatic changes in the expression of miRNAs and 
RISC-associated proteins. Our results showed that miRNA expression 
changes dynamically during cell activation, in response to the strength of the 
activating signal and the cytokines influencing cell differentiation. In addition to 
this, the expression of the Ago-interacting protein GW182 increased upon 
activation leading to the formation of HMW RISC. We showed that just under 
half of Ago-2 was found in a complex with GW182, whereas the rest remained 
unbound. The GW182 associated Ago-2 in the HMW RISC  could be 
separated from Ago-2 in LMW RISC following size exclusion chromatography.  
 
When we sequenced HMW and LMW RISC associated miRNAs, we found 
many that were differentially distributed between the two complexes. Abundant 
miRNAs were mostly found in both complexes to some extent, though some 
were very strongly enriched in the HMW RISC. While many downregulated 
miRNAs were found enriched in LMW RISC, some miRNA families, such as 
the let-7 family and miR-378 family, were enriched in HMW RISC. We 
examined further the function of one specific miRNA that was enriched in HMW 
RISC, miR-7a. This miRNA was shown to be upregulated upon T cell activation 
and its inhibition caused changes in the T cell activation phenotype, with 
reduced cell proliferation and increased expression of activation markers. miR-
7 has been shown to target components of the mTOR pathway in cancer cells, 
thus it is interesting to speculate that it may also target this pathway in T cells. 
We attempted to identify miRNA targets using CLASH. Efforts to enrich for 
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chimeric reads by isolating GW182 bound or HMW RISC associated Ago-2 
were not successful compared to immunoprecipitating total Ago-2. Despite 
technical challenges, we identified several potential novel miRNA targets 
which could be  experimentally validated in the future.  
 
miRNA expression levels are commonly thought to reflect the functional 
capacity of a miRNA in a given cell context. However, despite high expression 
levels of miRNAs in naive T cells, the lack of GW182 may limit the formation 
of HMW RISC and efficient target suppression. Genetic studies of T cells 
deficient in Dicer or Ago-2 have shown that while naive cells display no 
abnormalities, activation of the cells results in aberrant differentiation and 
proliferation (Zhang and Bevan, 2010; Bronevetsky et al., 2013). This suggests 
that miRNAs may play a key role at the early stages of activation when GW182 
is first expressed. T cell activation requires rapid remodelling of the miRNA 
repertoire to support cellular changes guiding effector cell differentiation. In 
CD4+ T cells global downregulation of miRNAs and Ago proteins was 
suggested to allow fast turnover of RISC upon activation (Bronevetsky and 
Ansel, 2013; Bronevetsky et al., 2013). While we saw only slight 
downregulation of Ago upon activation, changes in RISC formation occurred 
due to increased expression of GW182. Recruitment of miRNAs to HMW RISC 
would allow activation-promoting miRNAs to be rapidly employed, while other 
miRNAs (whose targets are required for activation) may be sequestered in 
LMW RISC. We can speculate that distribution of miRNAs between these two 
complexes alongside expression changes could be an additional layer of 
regulation, particularly for less abundant miRNAs. miRNA expression did not 
directly correlate with association in HMW versus LMW RISC, though the 
tendency was for low abundance miRNAs that are downregulated upon 
activation to be present in LMW RISC. The enrichment of specific miRNAs and 
miRNA families in HMW RISC opens up the question of whether specificity 
exists in miRNA recruitment to this complex. It is not currently understood 
whether competition exists between miRNAs for binding HMW RISC, or how 
this would be regulated. While we and others (La Rocca et al., 2015) noted 
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clear significant differences in miRNA association with the two complexes, it 
remains to be proven how important these differences are for miRNA biological 
function.  
 
7.2 Future work 
 
Several open questions remain in regards to the function, composition and 
recruitment of miRNAs to HMW RISC. We identified a range of intermediate 
MW RISC complexes from activated T cells, and it would be interesting to 
determine the exact protein composition of these complexes and whether they 
represent precursors of HMW RISC or separate entities. It is possible that 
these may promote miRNA target suppression through mechanisms that do 
not involve GW182, such as repression of translational elongation, which have 
been described in other cell types (Wu, Isaji and Carthew, 2013; K. Zhang et 
al., 2018). The observation that miRNAs are differentially associated with 
HMW and LMW RISC opens up the possibility that miRNA recruitment to these 
is somehow regulated and not the same for each miRNA. More work is needed 
to understand the potential mechanisms that could underpin this. Active 
recruitment could involve miRNA modifications affecting their localisation or 
Ago-binding, whereas target availability may passively influence HMW RISC 
formation. 
 
We identified miR-7a as a miRNA that is enriched in HMW RISC and showed 
preliminary results suggesting it may regulate T cell activation. In particular, T 
cell proliferation and expression of activation markers were affected by a miR-
7a inhibitor. Further experiments are needed to understand the function of 
miR-7a in T cells in regard to its effect on the expression of transcription 
factors, cell cycle genes and effector molecules. In cancer cells, miR-7a has 
been shown to target components of the mTOR pathway, making this an 
interesting possibility to explore in T cells. Apart from miR-7a, we identified 
several other HMW RISC enriched miRNAs that have not been well 
characterised in CD8+ T cells. For example, miR-210-3p plays a role in hypoxia 
and Th17 differentiation in CD4+ T cells but has not been studied in detail in 
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CD8+ T cells (Wang et al., 2014). Furthermore, we identified several miRNAs 
that were downregulated but enriched in HMW RISC, such as the let-7 family 
and miR-378 family. It is interesting to speculate that these miRNAs may 
therefore be functional in activated T cells. La Rocca et al. also showed that 
the let-7 miRNA family is downregulated but enriched in HMW RISC in 
activated T cells, and additionally showed that this led to more efficient 
suppression of a target reporter in activated cells (La Rocca et al., 2015). The 
miR-378 family has not been reported to play a role in T cells and it would be 
interesting to understand its function in naive and activated cells.  
 
miR-7a, mR-210-3p, let-7 and miR-378 were also amongst the miRNAs with 
the most chimeric reads in CLASH data, supporting the idea that presence in 
HMW RISC translates to high rate of target association. However, for many of 
these we did not enrich for seed-matched targets and probably did not capture 
the real range of targets for these miRNAs. A poor recovery of chimeric reads 
was the main issue with the CLASH experiments and the protocol therefore 
requires further optimisation to increase the proportion of these, as discussed 
in Chapter 6. We attempted to bioinformatically validate the identified CLASH 
targets by searching for miRNA seed sites and TargetScan predicted targets, 
and by calculating binding energies for non-canonical targets with Mirza. While 
this allowed us to short-list high-confidence targets, this does not confirm the 
repression of these targets or prove the biological importance of the 
interactions. In particular the repression of non-canonical sites has been 
controversial and requires experimental validation. Target validation could be 
done globally by mRNA sequencing and/or proteomics to compare the levels 
of miRNA-targeted and non-targeted genes. For targets of individual miRNAs, 
inhibition or knock-down of the miRNA can be used to assess effects on mRNA 





7.3 Therapeutic implications 
 
Understanding miRNA function and targets in CD8+ T cells could have wide-
ranging implications for health and disease. miRNAs are important players in 
various human pathologies: their dysregulation is frequent in cancer and in 
immunological, cardiovascular and infectious diseases. Increased 
understanding of miRNA function in these disorders has led to a surge in 
interest in the development of miRNA-based therapeutics, including miRNA 
inhibitors and miRNA mimic replacements. miRNAs are appealing therapeutic 
targets in many aspects due to their ability to target many components of a 
pathway with subtle effects on the individual proteins. However, the mode of 
function of miRNAs also poses additional challenges for therapeutic 
implication. The potential to target many different genes may cause unwanted 
or unexpected effects and redundancy between different miRNAs may allow 
for members of the same miRNA family to compensate for the loss of each 
other (Li and Rana, 2014). Technically, ensuring the stability, targeted delivery 
and efficient uptake of miRNAs into different tissues is not straight-forward 
(Kaczmarek, Kowalski and Anderson, 2017). Despite these challenges, the 
miR-122 inhibitor miravirsen, the first miRNA-based drug currently in clinical 
trials, has shown great promise for the treatment of HCV infection in Phase II 
trials (Janssen et al., 2013). Since miRNAs are known to play key roles in the 
development and pathology of immune-based diseases including multiple 
sclerosis, type I diabetes and allergic diseases, these could be potential 
targets of future treatments (Luck, Muljo and Collins, 2015; Garo and 
Murugaiyan, 2016). However no approaches to target immune cells have yet 
advanced to clinical trials, with most drugs currently in pre-clinical trials aimed 
towards treating cancer or cardiovascular disease (Chakraborty et al., 2017).  
 
When developing miRNA-based drugs, it is crucial to know the exact targets 
of these miRNAs to prevent unwanted side-effects. miRNAs are frequently 
expressed by multiple cell types and may have cell-specific targets in these 
(Hsin et al., 2018). Many miRNAs are expressed by both cells of the immune 
system and by cancer cells and could have opposing roles in each. For 
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example, miR-362 has been found elevated in multiple sclerosis and type I 
diabetes patients, with expression correlating with disease severity (Du et al., 
2009; Sebastiani et al., 2011). Inhibition of miR-362 was shown to reduce Th17 
mediated pathology in the mouse model EAE, whereas overexpression 
exacerbated disease by increased targeting of Ets-1. However, miR-362 was 
also shown to play a tumour suppressive role in malignant glioma by targeting 
Nob1 (Zhou et al., 2013). Therefore, when considering targeting miR-362 for 
treating autoimmune diseases, the risk for potentially increased oncogenesis 
must be taken into account. In addition to the application of miRNA-targeting 
therapies for treating autoimmune diseases, miRNAs may have the potential 
to enhance T-cell based cancer immunotherapy. TCR engineered or chimeric 
antigen receptor (CAR) T cells hold a lot of promise for future cancer treatment. 
CD19 CAR T cell therapy has been successfully used to treat patients with B 
cell lymphoma or leukaemia. T cell therapy has however not yet been 
effectively applied for solid tumours. Key miRNAs could be targeted to 
enhance TCR sensitivity, and to improve T cell persistence and effector 
function against cancer cells (Ji, Hocker and Gattinoni, 2016; Z. Zhang et al., 
2018). Strikingly, co-transfection of CAR T cells with miR-17~92 was shown to 
improve anti-tumour responses against glioblastoma in mice with human 
xenographs (Ohno et al., 2013). Furthermore, miRNA-based therapeutics may 
be used in combination with existing strategies. Overexpression of miR-153 in 
colon cancer cells was shown to improve CAR T cell mediated killing, in 
support of combining treatments (Q. Huang et al., 2018). To start applying 
these novel therapeutic approaches to treating human disease, a deep 
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